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The humoral arm of the adaptive immune system works by producing antigen-specific antibody to clear 
pathogens from the extracellular spaces in the body. The humoral immunity requires the germinal center 
(GC) reaction to enable the formation of antibody-secreting cells and the production of antibodies that can 
bind the target antigen and trigger the appropriate immune responses. GC is a microanatomical structure 
in the B cell follicle that transiently arises from lymphocyte proliferation over the course of humoral 
immune response. While in vivo models have provided us with new insights regarding the GC reaction, 
there is a lack of ex vivo systems that can be utilized to model the GC process. Existing techniques do not 
fully recapitulate the lymphoid niche or require implantation into live animal models. It is thus 
challenging to assess the specific signals that control GC reaction, analyze the heterogeneous GC B cell 
population, and understand the decision-making process that determines GC B cell fate. 
 
In order to address these limitations, we have developed immune organoids to recapitulate key GC 
characteristics and control B cell activation in culture. We first analyzed the techniques that have been 
used to engineer B cell phenotype (Chapter 1). Inspired by the role of integrin in cell microenvironment, 
we utilized the gelatin matrix to enhance GC-like B cell expansion in culture (Chapter 2). We next 
showed that ex vivo GC-like B cells were comparable to in vivo GC B cells and could be used to study the 
GC cell cycle regulation (Chapter 3). We then used the modular immune organoid to assess the role of 
integrin ligand specificity in modulating GC-like B cell phenotype (Chapter 4). Finally, we demonstrated 
that B Cell Receptor (BCR) stimulation could induce ASC differentiation and facilitate the enrichment of 
antigen-specific GC-like B cells in the presence of a negative selection pressure (Chapter 5). 
  
Having described the works done to develop an improved B cell culture system, we concluded this 
dissertation with a reflection on the research journey and some suggestions regarding the next key steps to 
continue this project (Chapter 6). In the long term, we believe that the immune organoid platform could 
be used to obtain mechanistic insights about the adaptive immune system generation, understand the 
decision-making process in GC reaction, model lymphoid transformations that trigger certain diseases, 
and identify therapeutic agents that can interact with the immune system.   
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CHAPTER 1  
 
Introduction to Humoral Immunity and B Cell Engineering Approaches 
 
1.1. Abstract 
 
Germinal center (GC) reaction occurs during the humoral immune response generation to ensure the 
secretion of antibodies capable of binding target antigens with specificity, affinity, and capability to elicit 
the appropriate immune responses. While numerous insights regarding GC reaction have been gained 
using animal models, there are several challenges associated with in vivo systems. Here we review 
various techniques that have been demonstrated to control B cell phenotype in cell culture system, 
analyze the motivations behind each approach, describe the techniques, and discuss several considerations 
for their implementation in B cell research. These methods include soluble factors, stromal cells, synthetic 
platforms, and biomaterials integration. By classifying these techniques based on the length scale of their 
interaction with B cells, this chapter aims to summarize the key elements of ex vivo B cell studies, gain 
inspiration from relevant fields, and propose research directions. By accomplishing these goals, we hope 
that this chapter can introduce the relevance of rationally designed B cell culture platform with tunable 
signal presentation to assist with immunology research and therapeutics development. 
 
1.2. Introduction 
 
The adaptive immune system enables the body to respond against specific invading pathogens. This 
function is exerted by both cellular and humoral arms of the immune system. As opposed to the cellular 
immunity that targets infected or mutated cells, humoral immunity specifically protects the extracellular 
spaces via the secretion of immunoglobulin molecules (also referred to as antibodies) by B cells that can 
bind the surface molecules of a foreign substance with high specificity and affinity. Such binding is also 
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capable of generating the appropriate immune responses: neutralization, opsonization, or complement 
activation. In order to work properly, an antibody requires the following three key traits: specificity, 
affinity, and functionality. 
 
It is important to understand how the aforementioned three critical traits are gained by B cells during their 
development process. Specificity results from several mechanisms. Early during B cell development, 
V(D)J recombination occurs to facilitate the rearrangement of numerous gene segments and this process 
allows the generation of various immunoglobulin genes. Later during the humoral immune response, 
somatic hypermutation occurs in the form of single point mutations (along with insertions and deletions) 
to further modify the rearranged immunoglobulin genes. Upon translation, these diverse immunoglobulin 
genes can give rise to a broad range of immunoglobulin molecules capable of binding many molecular 
targets. Affinity results from the repeated rounds of Darwinian-like selection that picks high-affinity B 
cell clones. Functionality comes from class switch recombination (CSR) that controls the antibody 
effector function. Studies performed over the past decades have demonstrated that the germinal center 
(GC) reaction is responsible for inducing somatic hypermutation, selection, and CSR. This indicates the 
importance of GC in ensuring the generation of an effective humoral immunity. 
 
First reported back in 1884, GC is frequently defined as a microanatomical structure containing 
proliferating lymphocytes in the lymph node B cell follicles, appearing transiently following 
immunization, and consisting of two cellular compartments that can be distinguished with imaging 
techniques [1-3]. While the GC reaction is very complex, the prevailing view suggests that GC reaction is 
formed after naïve B cells encountering their corresponding exogenous antigens in the follicle, interacting 
with follicular T helper (Tfh) cells in the interfollicular region, start proliferating in the follicle, 
experiencing somatic hypermutation to rearrange immunoglobulin variable region genes, and then 
undergoing affinity-based selection via interaction with follicular dendritic cell (FDC) and Tfh cells [2-4]. 
The GC reaction dynamics can also be understood from the visual schematic provided to accompany this 
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chapter (Figure 1-1). The schematic can be used not only to see GC progression over time, but also the 
decision making made by GC B cells following the selection process. While there are general agreements 
regarding its constituent components and functional outcomes, numerous models have been proposed to 
describe the GC reaction dynamics [1, 3]. New insights have been generated regarding the migration 
across GC zones, the role of Tfh cells in selecting high-affinity B cell clones, and the factors that sustain 
GC reaction over time [3]. This situation indicates that GC has been known to play an important role in 
mounting an antigen-specific humoral immune response and yet GC reaction still appears as a black box 
with researchers learning new things about it all the time. 
 
The aforementioned insights pertaining to GC reaction in humoral immunity and the broader immune 
system have been generated mostly from in vivo systems with few validations using in vitro models, 
which makes sense considering the complexity of a single immune reaction that involves numerous cell 
types and signaling molecules over varying time and length scales. While the animal models have 
facilitated such fundamental discoveries, in vivo systems are faced with several inherent challenges: high 
cost, long turnaround time, and low experimental throughput. The inherent complexity of an animal 
model can also make it difficult to identify the critical building blocks necessary to recapitulate an 
immune reaction outside of animal models or even modulate it by changing the relevant design 
parameters. In contrast, there is no reliable in vitro systems that can capture such complexity because 
existing techniques have typically relied on co-culturing B cells with stromal cells on a tissue culture plate 
in the presence of certain soluble growth factors added exogenously at certain time points during the cell 
culture period. This situation has suggested the necessity of an artificial culture system that replicates the 
simplicity of in vitro approaches and reproduces the key attributes of in vivo models.  
 
We hypothesized that such goal can be achieved with a rationally designed tool to model the B cell 
development process. But we have to first understand the critical design parameters for reproducing 
humoral immune response in the test tubes. These elements can be identified from animal studies and 
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further demonstrated using in vitro approaches. We then have to figure out the bioengineering techniques 
that can modulate cell phenotype and pick the ones that can be adapted in studying B cells. Considering 
the recent proliferation of new insights regarding GC reaction, the aforementioned techniques can be used 
to further understand the factors that control GC kinetics during its initiation, maintenance, and 
termination phases. The first step toward achieving this goal is to assess what techniques have been 
shown to reasonably control B cell activation. 
 
This introduction chapter is written to answer such question by first describing what factors have been 
identified as important for B cell activation process from in vivo studies, then showcasing how such 
findings have inspired approaches to generate specific B cell phenotypes in vitro, and finally proposing 
what considerations are needed to further B cell engineering effort in the future. Due to the complexity of 
B cell development, this chapter plans on analyzing the relevant factors based on the length scale of each 
interaction. This classification will help us determine the appropriate bioengineering techniques based on 
the length scale because the physical dimension is one of the main levers in designing bioengineered 
systems. As various studies have suggested that the average murine B cell diameter is approximately 4-6 
micron with a possible increase in the range of 7-10 micron following activation, such number will be 
used a baseline for the length scale (medium) and summarize published findings using this conceptual 
framework. This chapter will also draw inspirations from other immune engineering techniques and 
biomaterials-based approaches to provide future perspectives on B cell engineering. 
 
1.3. Small-scale Approach to B Cell Engineering 
 
The small-scale approach is defined by the use of synthetic or biological molecules with a diameter 
smaller than 5 nm, thus making these particles smaller than B cells. This method typically works by 
interaction with a specific marker on the cell surface and/or triggering a particular intracellular process 
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within the cell itself. Considering the length scale of said interaction, this technique generally consists of 
adding the soluble factors exogenously into the cell culture system. 
 
1.3.1. Antigen Physical Modification 
 
B cell activation is initiated following an engagement between a specific antigen and its corresponding B 
Cell Receptor (BCR) to stimulate subsequent B cell proliferation and differentiation [5]. While the 
protocol appears to be straightforward and similar across publications, the results can vary because 
antigenic stimulation depends on the antigen characteristics that include size, molecular weight, and form 
upon entering lymphoid organs (i.e. individual particles or immune complexes) [5]. With this perspective 
on the relationship between antigen and immune response, several research studies have been focused on 
engineering the physical characteristics of an antigen to modulate the resulting immune response. 
 
Modifying the physical characteristics of an antigen can be done in several ways. Paus et al. modulated 
the strength of BCR-antigen binding by using sheep red blood cells (SRBCs) conjugates of a series of 
recombinant hen egg lysozyme (HEL) proteins that bind the corresponding BCR with varying affinities 
[6]. The resulting data suggested that lower antigen affinity resulted in normal GC reaction but impaired 
extrafollicular plasma cell response, although the latter could be improved by increasing epitope density 
and vice versa. Peptide ligands with varying affinity have also been prepared via phage display and the 
resulting data suggested that BCR affinity could modulate several BCR activation metrics [7]. Similar 
studies on epitope density have been done as exemplified by the use of virus-like particles with a varying 
surface amount of peptide D2 to increase antigen-specific IgG antibody production and the utilization of a 
fusion protein bearing varying amount of M2e epitopes to induce the generation of antibodies with greater 
antigen binding strength [8, 9]. The antigen can also be combined with particles to modulate the 
subsequent immune response. Based on the idea that BCR crosslinking is facilitated by structurally 
repetitive antigens (i.e. the multivalent display of an antigen can enhance humoral response), Moon et al. 
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designed a unique class of lipid-based nanoparticles with recombinant Plasmodium vivax 
circumsporozoite VMP001 antigens presented on the surface and also encapsulated inside it and this 
platform enhanced GC B cell number and frequency [10]. 
 
This antigen modification approach can be done to systematically investigate how the nature of an antigen 
influences the corresponding humoral immune response. Nevertheless, there are several challenges here: 
the need for animal models for investigating the immune reaction against a particular antigen, the 
requirement of genetic engineering to modify antigen affinity, and the lack of comprehensive 
understanding of the role of varying materials (and their specific modifications) toward the B cell 
activation and differentiation events. 
 
1.3.2. Viral Genes Delivery 
 
Epstein-Barr virus (EBV) has the unique capability of immortalizing B cells. In this process, EBV 
infection results in the constitutive expression of several viral genes (EBNAs and LMPs) and such gene 
expression pattern, in turn, hijacks the cellular pathways for physiological B cell activation process [11]. 
 
There are several ways to achieve B cell immortalization with EBV viral genes. The standard protocol 
generally consists of co-incubating mononuclear cells with virus suspension in culture for 3-5 weeks until 
transformed cells can be observed under phase-contrast microscopy [12]. The introduction of specific 
viral genes can also be achieved with the development of a plasmid carrying several EBV genes in E. coli 
and the introduction of this recombinant vector into primary B cells for immortalization [13]. This 
approach enables the use of defined parts of EBV genome and the potential co-delivery of additional 
genes to further modify the immortalized B cells. Despite the relatively simple process, the use of EBV to 
generate constitutively activated B cells can have several challenges: the possibility of viral particles 
being released [14], the generation of B cells with abnormal phenotypes such as lacking surface 
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immunoglobulin or inactivated immunoglobulin genes [15], and the adoption of tumor-like cell 
phenotype [11]. 
 
1.3.3. Soluble Factors 
 
Although soluble factors are generally used to supplement other stimulatory techniques and activation 
with soluble ligands have been found to be quite inefficient, it is important to recognize the ability of 
soluble biomolecules in controlling the B cell activation and/or differentiation process in vitro. Following 
engagement with the CD40 ligand, isotype switching has been known to be inducible with cytokine 
presence and controllable based on cytokine type [16, 17]. BAFF has been shown to preferentially 
promote the survival of murine B cells from the spleen, but not those from the peripheral blood or lymph 
node [18]. The use of immunoglobulin (Ig) antibody capable of crosslinking with BCR to mimic antigen-
specific interaction has also been exogenously added to activate B cells in culture, although some 
researchers have reported the importance of immobilizing IgM on a surface as soluble Ig antibody has 
less potency than its immobilized counterpart [19-21] While CD40 receptor on B cell surface can be 
targeted for activation, published works have described the importance of CD40 ligand (CD40L) to be 
membrane-bound and/or presented in trimeric format as further explained in the section on stromal cells 
below. Complicating things further, a particular stimulatory signal can also be stimulating apoptosis or 
promoting survival depending on multiple factors (i.e. signal strength) [22]. While the addition of soluble 
factors is the simplest way of modulating B cell phenotype ex vivo, it is still challenging to determine the 
right signal presentation format and understand the unclear results seen in the literature. 
 
1.4. Medium-scale Approach to B Cell Engineering 
 
This approach is defined as the engineering of B cells at the cellular level via tools that are within the 
ballpark of B cell diameter, which is assumed to be around 5 nm, and engagement with multiple cellular 
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markers on the cell surface. Ensuring signal presentation at the cellular level can present more technical 
challenges when compared to the simple addition of soluble factors because B cells have to receive 
multiple signals targeted toward several receptors and/or sustained interactions at a short distance. 
Researchers can achieve this with the use of stromal cells, artificial cells, or patterned scaffold with single 
cell patterning. 
 
1.4.1. Immune Cells 
 
Several reviews have discussed the importance of CD4+ Tfh cells in initiating the differentiation of 
activated B cells into GC B cells, controlling the resulting GC reaction, and providing survival signals [1, 
23]. These findings have arisen from the critical need for several key signals found in Tfh cells and the 
negative effects seen in GC reaction when those signals are absent. Further studies have suggested 
additional roles that include selecting high-affinity B cells via transient contacts and thus promoting the 
expansion of B cells expressing high levels of peptide bound to MHC Class II [24, 25].  
 
While most studies have utilized animal models to showcase the role of Tfh cells during GC reaction, 
some in vitro experiments have been performed to understand the specific signals that are important in 
said process. Lahvis et al. demonstrated that activated CD4+ T cells could improve the upregulation of 
PNA marker on the surface of B cells in culture via CD40-CD40L interaction and increase the expression 
of other activation markers, but the latter could only be achieved with either activated CD8+ T cells or 
cytokine combinations alone [26]. Huang et al. suggested that the cell-cell contact between activated 
CD4+ human T cells and naïve human B cells could enhance the percentage of somatic mutations in both 
IgM and IgG transcripts but such outcome could not be achieved with the soluble trimeric CD40L 
addition [27]. Zan et al. further showed that BCR crosslinking and cell-cell contact with activated CD4+ 
T Cells, which was based on CD40L and CD28 presentation, were required for in vitro somatic 
hypermutation induction [28]. Despite the important roles of Tfh cells in B cell culture, there are several 
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challenges faced by this approach: the need to obtain differentiated Tfh cells, the requirement to have 
multiple cells types in the same culture, and the lack of comprehensive understanding about the precise 
signal presentation to GC B cells. Additional signals have been found to maintain the adhesive interaction 
between T and B cells [29]. Nevertheless, more studies are needed to better understand Tfh differentiation 
protocol and characterize the resulting cells from phenotypic and functional perspectives [30-32]. 
 
From current reviews on GC reaction, FDC network has been shown to permeate throughout the GC light 
zone (LZ) compartment, retain intact antigen in the form of immune complexes for an extended period, 
generate various biological signals, and facilitate the GC selection process based on antigen affinity [1, 
33].  Kosco et al. showed that co-culturing FDCs with B cells and T cells resulted in the formation of 
large cellular aggregates and increased B cell proliferation [34]. Several studies suggested that FDCs 
containing immune complexes could mediate in vitro somatic hypermutation process [35, 36]. The 
molecular basis of such adhesion between B cells and FDCs has been shown to require ICAM-1 and 
VCAM-1 on FDCs and LFA-1 and VLA-4 on B cells [37-39]. But it can be challenging to include the 
FDC component because of the small number of FDC in the lymphoid tissues, the sensitivity of FDC 
population to stresses in vitro, and the technical complexities of protocols currently available in the 
literature [40, 41]. 
 
1.4.2. Stromal Cells 
 
Signals critical for B cell development process are mostly physically presented or secreted with precise 
spatiotemporal considerations. This concept can be illustrated by the CD40L signal, which is presented by 
Tfh cells and has been identified as a critical driver for GC induction because GC will fail to form if the 
CD40L-CD40 interaction is blocked [42, 43]. While the use of relevant immune cells can facilitate the 
introduction of relevant biological signals, such approach can be troublesome because primary immune 
cells have to be harvested prior to each experiment, these cells can be prone to apoptosis in the absence of 
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stimulatory signals, activation protocol may have to be carried out for certain ligands to be expressed, and 
signal presentation can be unstable/variable across batches. 
 
Going with the same example, a simple addition of soluble recombinant CD40L does not yield the same 
reaction efficiency because CD40L is biologically active in its trimeric form [44, 45]. CD40L, along with 
few other B cell stimulatory signals, has also been shown to require membrane-bound (instead of soluble) 
presentation to be effective in its functionality. With this concept in mind, several culture methods to 
activate and/or differentiate B cells have been developed with the use of CD40L-presenting stromal cells. 
Pound et al. utilized CD32-transfected L cells, which were in turn conjugated with CD40 monoclonal 
antibody due to the binding capability between CD32 and the Fc region of IgG antibodies, to stimulate 
DNA synthesis in cultured human GC B cells [46]. Arpin et al. implemented a combination of CD40L-
transfected L cells and several cytokines to induce the differentiation of human GC B cells into cells 
resembling either plasma cells or memory B cells [47]. Nojima et al. engineered fibroblasts to present 
CD40L and secrete BAFF for improving B cell proliferation, isotype switch, and induction of GC 
phenotype [48]. The resulting stromal cell line is called 40LB and it has been shown to mediate selective 
expansion of antigen-specific B cells by presenting antigen and Fas ligand, as CD40L-activated GC-like 
B cells are prone to Fas-dependent cell death unless the BCR is ligated [49]. While stromal cells enable 
the easy introduction of critical signals from relevant immune cells, there are several potential issues: the 
need to genetically engineer the stromal cells and the potential cross-reaction with other signals. 
 
1.4.3. Synthetic System 
 
As researchers have identified important signals in the interaction between B cells and their neighboring 
cells, several synthetic systems have been developed in order to study B cell in a more controlled 
environment with the combination of substrates or patterns and conjugated biomolecules. The culture 
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condition can be designed to recreate physiological conditions based on the known building blocks and/or 
systematically investigate the role of various design parameters.  
 
The use of patterning to ensure the placement of B cells at specific spots within an array has been 
demonstrated in several studies. As B cells are non-adherent or weakly adherent, B cell patterning 
requires the combination of microscale pattern of interest and surface-conjugated antibody targeted 
against a particular marker on B cell surface. This can be contrasted with the patterning of adherent cells 
that typically require only physical wells with treated surface or protein spots containing bioadhesive 
ligands. These two methods are not mutually exclusive, however, since the use of physical microwells can 
strengthen the anchoring of B cells to scaffold surface and prevent disturbance from various mechanical 
agitations (e.g. mixing, washing, etc.). While this approach is typically done to showcase the feasibility of 
anchoring non-adherent cells on a 2D surface and identifying a rare cell population, the resulting platform 
can be used in certain applications that have been demonstrated in other cell types. Some examples 
include identification of therapeutic molecules, analysis of single-cell behaviors, and investigate the 
spatial presentation of biologically relevant signals. 
 
Patterning can be applied in various ways that include microarray chip containing microscale cell 
chambers [50, 51], patterned polymer spots [52, 53], or a combination of both [54]. Kim et al. 
demonstrated that spatial B cell configurations could be achieved by combining patterned biotinylated 
spots with streptavidin and biotin-functionalized anti-CD44 antibody [52]. This paper interestingly noted 
the importance of maintaining antibody orientation to improve array fill rate (as compared to the surface-
adsorbed antibody with random orientations). Vasconcellos et al. showed that patterned substrates could 
bind B cells via CD44-mediated interaction (with hyaluronic acid as the top layer) or electrostatic 
interaction (with chitosan as the top layer), although the former appeared stronger as demonstrated by the 
high number of cells from chitosan group released with the introduction of soluble HA and the high 
resistance in the HA group against flow-induced detachment [55]. Another work from Kim and 
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colleagues also demonstrated the possibility of combining lymphocytes and patterned scaffold to prepare 
an array of cells for biosensing [51]. In the aforementioned paper, the detection of a certain peptide was 
conducted by having B cells to capture the peptide and present it via the peptide-MHC complex to the 
neighboring T cells. There are three interesting approaches performed in this work, namely: the 
combination of physical microwells and anti-CD44 antibody to pattern and anchor lymphocytes, the use 
of calcium-binding fluorochrome to visualize the binding between TCR on T cells and the peptide-MHC 
complex, and the ability to demonstrate dose-dependent response toward the added peptide analyte. While 
interesting, patterning has mostly been done for single-cell analysis and has yet to be used to study the 
mechanistic role of signal density. 
 
Another application of patterning is to investigate the antigen extraction process by B cells. Antigen 
extraction occurs following the encounter between B cells and APCs at some point before or during the 
GC reaction, where B cells process the antigen to be presented as peptide-MHC complex to CD40L-
presenting Tfh cells. Since this synapse formation is a transient event, it can be challenging to understand 
the molecular building blocks that regulate the said interaction. Researchers have studied the interaction 
between BCR and antigen leading to the internalization process with a synthetic platform, specifically by 
incubating B cells with antigen presented on a planar surface [56-59]. The resulting findings have 
indicated that, among other things, cellular antigen extraction machinery depends on B cell activation 
state and antigen extraction is controlled by several physical properties (e.g. membrane flexibility, antigen 
affinity, and antigen tethering strength). In addition to antigen extraction, antigen-induced B cell 
activation has also been shown to depend on the stiffness of antigen-presenting substrate as indicated by 
the greater expression of BCR and the phosphorylated form of BCR target proteins - pSyk, and pTyr [60]. 
These studies have demonstrated the role of physical environment in modulating B cell phenotypes. 
 
Single cell patterning is a fascinating technique because of the defined signal presentation targeted toward 
single B cells, the separation between individual B cells to decouple same cell interactions, and the high 
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throughput experimentation capability. Nevertheless, there are several technical challenges facing this 
method that include ensuring that relevant signals are presented, generating consistently uniform patterns 
across experiments, reducing the number of individual spots occupied by either zero or more than one 
cells, and avoiding mechanical disturbance that can easily alter the patterned cell population. 
 
1.5. Large-scale Approach to B Cell Engineering 
 
This approach is defined as the engineering of B cells with tools targeted at the level of B cell population, 
generally by encapsulating numerous B cells inside a matrix and culturing them in 3D. Such method can 
be contrasted with culturing B cells on a planar scaffold in the presence of other signals, which is covered 
in the previous section on medium-scale approach, since each spot or well is designed to target individual 
B cells. While large-scale B cell engineering is interesting, such technique is still challenging to 
implement due to the lack of scaffold characterization data. We have yet to understand how scaffold type, 
mechanics, and matrix proteins can influence B cell phenotype, activation, and differentiation. 
 
1.5.1. Antibody Production 
 
A published work from Suematsu and Watanabe showcased the formation of lymphoid organoid 
following the implantation of a sponge-like collagenous scaffold containing chemokine-producing 
lymphoid stromal cells and activated DCs into mice [61]. Looking at the organoids formed in the 
transplanted construct, the researchers demonstrated the formation of B cell zones - with proliferating 
cells and differentiated plasma cells - and T cell zones and the vascularization of this scaffold. It is 
interesting to note following transplantation and immunization in normal mice, the scaffold could be re-
transplanted in Severe combined immunodeficiency (SCID) mice and provide them with antigen-specific 
antibody production after immunization. The collagen sponge was found to have a 1 mm thickness, 
heterogeneous pore shape, and pore size ranging from 50 to 300 µm. Another work done by the same 
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group showcased that the lymphoid organoid in SCID mice could generate antibody response 4 weeks 
after transplantation, antibody-secreting cells migrated from the scaffold to the spleen of SCID mice to 
facilitate high IgG1 antibody production, and GC-like CD38+ B cells increase in frequency following the 
second round of immunization [62].  
 
1.5.2. Analyte Detection 
 
The use of a similar collagen-based matrix was shown by Banerjee et al. to facilitate the construction of 
biosensor for detecting the presence of pathogenic bacteria and/or bacterial toxin [63]. Collagen type 1 gel 
was used to encapsulate B cells for the purpose of entrapping non-adherent cells and capturing cells of 
different size because collagen pore size is tunable. After preparing the construct to have a thickness in 
the range of 30 to 50 µm when dispensed in 48- or 96-well plate, the researchers demonstrated that 
reduction in B cell viability could be detected as a function of bacteria/toxin presence, amount, and 
incubation time. While the detection described in this work was non-specific, Rider et al. have 
demonstrated that bacterial-specific detection capability could be imparted on B cells by genetically 
engineering them to express BCR specific for a particular pathogen and emit light following BCR binding 
with high speed, specificity, and sensitivity [64]. 
 
1.5.3. Cell Expansion 
 
In order to mimic the tissue niche, biomaterials have been investigated in other immune-related 
bioengineering studies. While these reports were not exclusively focused on B cells, they could elucidate 
our understanding regarding the role of microenvironment and B cell functions in the body. In one 
example, in vitro bone marrow was fabricated with inverted colloidal crystal geometry for expanding 
CD34+ hematopoietic stem cells (HSCs) with B cell differentiation [65]. This approach was fascinating 
because of the nanocomposite surface made from negatively charged silicate nanoparticles and positively 
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charged PDDA to facilitate cell adhesion, the high percentage of cells expressing B cell surface markers 
(e.g. CD40 and immunoglobulin molecules) when compared to the control plate, and the high amount of 
IgM secreted by B cell-like population in response to bacterial LPS exposure – also when compared to the 
control plate. In another study, scaffold-based CD34+ HSC expansion was successfully done with 
fibronectin-immobilized 3D polyethylene terephthalate (PET) matrix although no difference in CD19+ 
was seen among matrix protein type or when compared to the control plate [66]. 
 
1.5.4. Cell Culture Condition 
 
Changing cell culture condition represents B cell engineering at the macro level because such technique 
influences the way cells interact with their environment, specifically from the perspective of nutrient and 
gas exchanges. This concept was illustrated by Abbott et al. in activating B cells via anti-CD40 and anti-
IgM in hypoxic (1% O2) condition [67]. Inspired by the observation that hypoxic areas were observed in 
splenic GCs, the hypoxic condition was found to result in greater GL7 surface marker expression, 
accelerated class switch kinetics from IgM to IgG1 at early time points, and increased amount of 
differentiation into the CD138+ ASC phenotype. While limited studies have been done to investigate the 
role of hypoxia in B cells, published works have also suggested that oxygen availability could control 
CXCR4 expression in B cells and other cell types [68, 69]. 
 
1.6. Inspirations from Other Immune Engineering Techniques 
 
While this chapter attempts to cover important topics pertaining to B cell engineering approaches, 
additional conceptual and technical insights can be obtained from related research areas. We will look 
into published studies on early B cell development, T cell engineering, and relevant biomedical 
engineering innovations. 
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1.6.1. B Cell Generation from Stem Cells 
 
As B cells are generated from hematopoietic stem cells (HSCs) in the bone marrow, there are numerous 
protocols that have been developed to recapitulate this process in the laboratory. The approaches typically 
require the co-culture of stem cells with OP9 stromal cells in the presence of soluble recombinant factors 
that generally include FLT3 ligand (FLT3L) and other cytokines [70-75]. Following a combinatorial 
presentation of biomolecules, validation of the resulting B cells is carried out by looking at the cell 
phenotype and the response following stimulation with LPS. Interestingly, several protocols have also 
looked at the role of ligand density in controlling B cell development process. The Notch ligand Delta1 
(DL1) was shown to facilitate differentiation into the B cell lineage only at lower density and the resulting 
cell population can form CD19+ early B cell precursor after exposure to classical B cell differentiation 
protocol, while the higher density of said ligand inhibits this B cell lineage induction process [76]. The 
examples listed above show the importance of presenting biological signals via stromal cells and soluble 
factors, while ligand density can drastically control the resulting cellular response. 
 
1.6.2. T Cell Generation and Activation 
 
While this chapter has been focused mainly on B cell engineering techniques, the study of immune cell 
microenvironment and the implementation of biomaterials-based engineering techniques are more 
commonly seen in the context of T cell generation (from stem cells) and activation process. We will look 
into T cell works for conceptual insights and technical ideas. 
 
The use of DL1-presenting stromal cells to generate early T cell population in vitro has been reported in 
several publications [77-80]. The use of DL1-presenting OP9 stromal cells became widespread because of 
its simplicity in comparison to the traditional T cell generation protocols like fetal thymic organ cultures 
(FTOCs) or reaggregate thymic organ cultures (RTOCs). These approaches require the culture of 
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hematopoietic progenitor cells and thymic stromal cells as 3D cellular constructs because thymic stromal 
cells fail to maintain DL-1 expression in 2D monolayer format and therefore lose the ability to induce T 
cell differentiation in such setting [81]. Such finding suggested the importance of 3D architecture in 
facilitating T cell differentiation within the thymic microenvironment.  
 
Realization regarding the role of cell microenvironment resulted in the gradual use of biomaterials-based 
approaches in T cell generation protocols. While DL1-presenting stromal cells represent a robust way of 
forming T cells, it can be difficult to understand the role of ligand density and engineered ligand 
represents a possible approach to study this issue. The use of immobilized ligand was first demonstrated 
by Dallas et al. in two ways. First of all, DL-1 ligand density level determines whether murine Lin- Sca+ 
Kit- (LSK) cells decides to enter the T cell differentiation pathway exclusively for forming Thy1+ CD25+ 
early T cell precursors [76]. Secondly, culturing murine LSK cells with increasing density of immobilized 
DL1 showcased that the group with the highest density produced the highest number of CD44+ CD25+ 
DN2 early T cell progenitor population [82]. It is also importing to note that DL1 is immobilized because 
such presentation provides greater potency than the soluble one as reported by Varnum-Finney et al., 
further suggesting that ligand stabilization can determine its function [83]. These approaches suggest the 
importance of engineered signal and presentation style in controlling T cell differentiation events. 
 
Since 3D cell microenvironment is one focus area of biomaterials research and has been demonstrated to 
be important in the thymic microenvironment, 3D matrix utilization in T cell research has also been 
demonstrated in several publications. The focus on 3D format was also demonstrated by Marshall et al. 
with the use of a highly porous tantalum-based 3D matrix to generate CD4+ and CD8+ T cells from 
matrix-encapsulated thymus fragments encapsulated. This tantalum-based system was previously studied 
by Poznansky et al. in the form of matrix seeded with murine thymic stroma for the generation of mature 
functional CD3+ T cells from bone marrow (BM)-derived hematopoietic progenitor cells [84]. 
Combining 3D scaffold and stromal-free system, Lee et al. developed a 3D inverted colloidal crystal 
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scaffolds coated with immobilized engineered DL1 notch ligand for culturing CD34 hematopoietic 
stromal cells [85]. The data suggested that the resulting cell population maintained HSC marker CD117 
expression and exhibited T cell lineage commitment  - as indicated by the TCR alpha and CD3 
expression, although no CD4+ and/or CD8+ T cell were observed there. But we have yet to fully 
understand the mechanistic role of 3D architecture toward T cell differentiation and rational design can be 
challenging without a comprehensive understanding of the relationship between scaffold design 
parameters and T cell phenotype. 
 
In addition to the 3D scaffold, ligand-presenting beads represented another biomaterials-based technique 
for immune cell engineering. This concept was demonstrated by Lin et al. to solve the challenge of 
generating mature functional T cells in vitro specifically by co-culturing mouse embryonic stem cell (ES) 
cells or immature DP T cells with MHC Class I tetramers [86]. With the idea that T cell maturation 
requires interaction between TCR and MHC molecules, this approach was conducted and resulted in the 
generation of antigen-specific CD8+ T cells from the precursor cell population. In another work, Taqvi et 
al. added DLL4-presenting beads into ES cells being cultured with OP9 stromal cells to direct the 
differentiation toward T cell lineage as indicated by Thy1.2 cell surface marker expression [87].  
 
The beads-based approach has been further applied in the context of in vitro T cell activation. In vitro T 
cell activation and expansion has generally been carried out by stimulating the TCR complex and the co-
stimulatory molecules. The conventional approach involves the use of immobilized antibodies against 
CD3 and CD28 as demonstrated by Levine et al. with beads presenting both signals to expand polyclonal 
CD4+ T cells [88]. Immobilized signal appeared to be important because soluble anti-CD28 antibody 
does not work as well for long term T cell proliferation and this phenomenon was found to occur due to 
CD28 downregulation with soluble signal [89]. The importance of immobilized signal presentation was 
further demonstrated by Tham et al. with latex microspheres providing peptide-MHC complex (pMHC) 
in the presence of either bead-bound B7-1 and B7-2 recombinant proteins or soluble ones, as the former 
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resulted in superior cell proliferation and IL-2 secretion in contrast to the latter [90]. While activation can 
be carried out with either pMHC or anti-CD3 antibody, Oelke et al. showed that pMHC facilitated 
antigen-specific expansion while CD3 resulted in decreased antigen specificity [91]. In addition to studies 
on signal presentation format, the role of signal density has also been explored in T cell activation. Matic 
et al. observed that increased anti-CD3 antibody density alone upregulated CD69 expression, while 
greater anti-CD3 antibody density with the anti-CD28 antibody produced greater T cell expansion and IL-
2 secretion [92]. Despite the versatility of such beads-based approach, a more comprehensive niche 
recapitulation will require the reconstitution of biomimetic microarchitecture and other signals. 
 
These surface-bound activation signals can then be combined with 3D scaffold functionalized with 
important biomolecules to further engineer the system, as shown by Stephan et al. with the scaffold 
containing GFOGER collagen-mimicking peptide and stimulatory beads as T cell delivery platform for 
cancer therapy [93].  Motivated by lymphocytes known to typically move along collagen fibers, the use of 
GFOGER resulted in a greater migration velocity similar to the one seen in lymphoid organs and more 
cells migrating out in response to IP-10 inflammatory cytokine. Just like methods employed to augment T 
cell differentiation, three approaches appear to be as important for improving T cell activation in culture: 
signal immobilization, ligand density, and 3D scaffold utilization. It is possible that similar biomaterials-
based approaches can also be used in the context of B cell engineering. 
 
1.7. Conclusions and Perspectives 
 
As described here, several approaches are available to control B cell development and GC reaction in the 
cell culture system. The strategies can be very different depending on the length scale of interaction with 
B cells, ranging from the simple addition of soluble factors into the development of biomaterials-based 
scaffold presenting relevant signals. For such artificial systems, the most important considerations consist 
of whether the relevant signal is presented and if the important cellular events can be recapitulated.  
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The main challenges of developing a B cell culture system consist of determining if the generated B cells 
are functionally comparable to the ones generated in animal models, maintaining B cell viability 
throughout the culture period without triggering diseased/transformed phenotypes, and ensuring the 
ability to respond appropriately toward specific stimulatory signals. Illustrating the difficulty of 
recapitulating GC phenotype, standard ex vivo B cell stimulation protocols frequently induce lymphoid 
transformations - as indicated by the expression of genes that typically characterize ABC DLBCL [94] - 
and fail to upregulate BCL6 expression [95]. While we have learned the transcriptional program for GC 
reaction maintenance and the signals that are required to enable ASC differentiation (Figure 1-2), we have 
yet to determine if such program exists in ex vivo B cell culture models and whether they can reconstitute 
such response toward those signals. 
 
An additional challenge is to provide the relevant biological signals for controlling ex vivo GC reaction. 
Since most B cell studies are done with animal models, there is a lack of information regarding the 
microenvironmental cues needed to recapitulate the B cell activation process. This situation is 
compounded by the lack of information on the interaction between relevant matrix proteins and B cell 
phenotype in culture. While transplanted collagen-based scaffold has been reported to produce organoids 
with physiologically GC characteristics such as B cell clusters with actively proliferating B cells (Figure 
1-3), we have yet to understand if and how the scaffold drives the cell cluster formation. 
 
Despite the limited knowledge so far, there are several promising directions for B cell engineering. 
Biomaterials research has been focused toward understanding the extracellular matrix (ECM) since ECM 
has been known to modulate various cell behaviors with integrin molecules mediating cell-matrix 
interactions. Integrin ligands have also been observed to mediate the interactions between B cells and 
other immune cells as described earlier in this chapter [37-39]. ECM proteins that act as integrin ligands 
have also been found in the secondary lymphoid tissues [96, 97]. It is therefore exciting to investigate the 
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role of ECM proteins and/or integrin ligands in controlling B cell activation or other processes in the 
context of lymphoid tissue microenvironment. Natural polymers can be used to directly implement ECM 
component and one example is to utilize gelatin for cell encapsulation due to its wide use in 3D cell 
culture [98-101]. It is also possible to utilize synthetic matrix that can be functionalized with integrin 
ligands as demonstrated by Phelps et al. with the use of 4-arm maleimide-functionalized polyethylene 
glycol (PEG) and thiolated adhesive peptide [102, 103]. Despite the flexibility of such synthetic systems, 
we will have to first identify the integrin ligands that are present and relevant for B cell processes before 
presenting them in culture. We also need to investigate the role of matrix proteins, 3D microarchitecture, 
and ligand density. 
 
While biomaterials-based technologies are rarely used to study immune cells, biomaterials have been 
becoming increasingly popular in other research areas due to the ability to integrate cell culture dimension 
(2D vs. 3D) and design parameters (e.g. signal tethering, chemical gradients, and cell patterning) to 
recapitulate cell microenvironment. There are also inspirations that can be gained from biomaterials 
utilized to modulate immune activation and regulation in animal models. Material parameters (e.g. type, 
size, shape, structure, and functionalization) can also impart specific functionalities (e.g. targeting and 
controlled release) on nanoparticle-based vaccines [104, 105]. By identifying key signals and optimizing 
signal presentation format, we can design a more physiologically relevant B cell culture platform. We 
thus plan on studying ex vivo B cell development process and assessing the role of various 
microenvironment signals. This project will be done to generate a B cell culture system that replicates the 
simplicity of ex vivo approaches and reproduces the key attributes of in vivo models. We hope that a 
successful development of such technology will enable us to model the GC reaction for understanding the 
key factors that regulate GC kinetics, tracking the fate of GC B cell, and learning the decision making 
process that happens in GC. 
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1.8. Figures 
 
 
 
Figure 1-1: Schematic of GC Reaction Dynamics 
Activated B cells initiate GC formation by first undergoing massive proliferation and experiencing 
somatic hypermutation (SHM) in the dark zone compartment. Dark zone GC B cells then migrate into the 
light zone compartment to undergo the affinity-based selection process and class switching (CSR). 
During selection, GC B cells can decide to undergo apoptosis, cycle back into the dark zone, or terminally 
differentiate toward ASC or memory B cell fates. Adapted by permission from Macmillan Publishers Ltd: 
Nature Reviews Immunology [3], copyright 2015. 
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Figure 1-2: Schematic of GC Transcriptional 
Maintenance Program 
GC maintenance is enabled by BCL6 by 
transcriptionally repressing differentiation toward 
ASC pathway. BCL6 repression by CD40 and/or 
BCR stimulations will result in the initiation of 
ASC differentiation program via IRF4 and 
BLIMP1 induction. Adapted by permission from 
Macmillan Publishers Ltd: Nature Reviews 
Immunology [4], copyright 2008. 
 
 
 
 
Figure 1-3: Proliferating B Cell Clusters in Lymph Nodes and Organoids 
Comparison between mesenteric lymph nodes - as a representative secondary lymphoid organ - and the 
transplanted organoids based on the formation of B cell clusters containing proliferating B cells in the 
centers. Tissue sections were stained by double staining with B220 (purple) and BrdU (red). B220 was 
used to visualize the B cell populations. BrdU was delivered intraperitoneally at 1 hour before tissue 
harvesting and used to stain actively proliferating cells. Adapted by permission from Macmillan 
Publishers Ltd: Nature Biotechnology [61], copyright 2004. 
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CHAPTER 2  
 
Ex vivo Engineered Immune Organoids for Controlled Germinal Center Reaction 
 
2.1. Abstract 
 
Realizing the limitations of existing ex vivo B cell culture systems, we were inspired to study the role of 
lymphoid microenvironment with a focus on integrin signaling. We developed a biomaterials-based 
immune organoid to model GC reaction by integrating 40LB stromal cells and gelatin scaffold reinforced 
with silicate nanoparticle. We first determined the optimal composition for this artificial lymphoid niche 
based on mechanical properties and stromal cell characteristics. We then demonstrated the ability of our 
immune organoids to produce B cell clusters, sustain B cell number in culture, and enhance the expansion 
of GC-like B cells. We also noted the importance of RGD motif from the gelatin matrix in maintaining B 
cell number in the absence of 40LB stromal support. These results suggest the importance of capturing 
the lymphoid microenvironment in the development of an immune organoid.  
 
2.2. Introduction 
 
Following up on our goal to develop an improved ex vivo B cell culture system, we utilized a 40LB 
stromal cell line for GC phenotype induction in B cells [48]. Since 40LB stromal cells were fibroblasts 
that had been engineered to present membrane-bound CD40 ligand (CD40L) and secrete BAFF, these 
cells could represent the relevant immune cells (Tfh cells and FDCs) and be expanded easily in culture. B 
                                                      
 The content of this chapter has been published as Purwada, Alberto, Manish K. Jaiswal, Haelee Ahn, 
Takuya Nojima, Daisuke Kitamura, Akhilesh K. Gaharwar, Leandro Cerchietti, and Ankur Singh. "Ex 
vivo engineered immune organoids for controlled germinal center reactions." Biomaterials 63 (2015): 24-
34. The detailed methodology has been published as Purwada, Alberto, and Ankur Singh. "Immuno-
engineered organoids for regulating the kinetics of B-cell development and antibody production." Nature 
protocols 12, no. 1 (2017): 168-182. 
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cells activated by this method were also found to proliferate extensively, experience isotype class switch 
following soluble IL-4 cytokine addition, and exhibit the expression of relevant GC markers: GL7, Fas, 
PNA, CD38low, and BCL6. These characteristics suggest that such stromal-driven approach represents 
several improvements from conventional activation protocols and therefore warrant further study. 
 
Inspired by the stromal-driven B cell activation method, we initiated a pilot study by co-culturing 40LB 
stromal cells with primary naïve B cells in the presence of soluble IL-4 and varied stromal density that 
ranged from 20,000 to 60,000 cells per sample. Our result interestingly showed that the total number of 
CD19+ B cells were significantly reduced in culture between initial time point (day 0) and analysis time 
(day 4) with no clear difference between any of the 40LB seeding densities (Figure 2-1). From this 
finding, we used the 20,000 40LB seeding density for further comparison. With this inability to induce 
extensive cell proliferation in culture, we hypothesized that it would be important to recapitulate certain 
aspect of the lymphoid microenvironment to ensure optimal ex vivo B cell activation process. 
 
Recent studies have suggested that the ECM component of lymphoid tissues can modulate B cell 
phenotype. After learning that B cells express various integrin subunits (e.g. αv, β3, α4, and β1), Song et 
al. showed that marginal zone (MZ) and follicular (FO) B cells bind laminin α5 in an RGD-dependent 
manner and knocking out laminin α5 will result in increased apoptosis of MZ B cells based on the 
TUNEL assay readout [96]. The researchers also showcased how laminin α5 can synergize with BAFF in 
producing a high number of MZ B cells. Wang et al. then mentioned the upregulation of both αv and β3 
chains on GC B cells (vs. follicular B cells) such that this cell population can adhere strongly to 
vitronectin [97]. Interestingly, knocking out integrin β3 will result in overrepresentation in the splenic GC 
compartment. While it was not known at the moment if RGD-mediated binding to the microenvironment 
via αvβ3 integrins could improve GC B cell number in culture, cell adhesion process has been linked to 
cell survival in several cases and this motivates us to investigate this hypothesis further. 
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We took the first step in this line of reasoning by examining a genome-wide gene expression analysis 
previously published by Dominguez et al. and currently stored in the National Institute of Health (NIH) 
repository to understand the integrin gene expression level in both follicular naïve and GC B cells (Figure 
2-1) [106]. Counts per million (CPM) was used as the quantification metric because it represented the 
number of counts scaled by the number of fragments sequenced times one million such that we could 
normalize the library size in each sample. The gene expression level for integrin subunits α2, α5, and α6 
were found to be low in both B cell populations. The α4 integrin subunit, on the other hand, was highly 
expressed in total naïve B cells with 317 CPM and then reduced to 67 CPM following differentiation into 
GC B cells. While the β1 integrin subunits had an expression level of 36 CPM in naïve B cells, the value 
went up to 81 CPM in GC B cells. We then examined the expression of both αv and β3 integrin genes. 
Their values appeared to be unchanged during B cell differentiation with 22-24 CPM for αv and 48-50 for 
β3. These studies indicated that while the gene expression of α4 and β1 integrin subunits varied during 
differentiation, the gene expression of αv and β3 integrin subunits was kept constant. 
 
Despite the gene expression trend obtained by RNA sequencing, it would be important to validate such 
finding based on the expression of integrin subunits on B cell surface because there can be numerous 
post-translational modifications that occur following transcription. We determined the cell surface 
expression of integrin subunits by immunizing mice with sheep red blood cells (SRBC) such that GC 
developed over 8 days period and harvesting the spleen for flow cytometry analysis (Figure 2-3). Looking 
at the integrin subtypes on B220+ GL7+ Fas+ GC B cells, the percentage of cells expressing αv, β3, and 
β1 was found to be higher in GC B cells when compared to naïve B cells. Meanwhile, the percentage of B 
cells expressing integrin α4 was similar in both cell subsets. When we evaluated the expression level of 
these integrin subunits, we observed a similar percentage. This outcome motivated us to investigate the 
role of these integrin subunits in ex vivo GC induction. 
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2.3. Approach 
 
Hypothesizing that the B cells interact with the lymphoid microenvironment via the binding of αvβ3 
integrin subunits and such contact improves the B cell generation during ex vivo GC reaction, we co-
encapsulated primary naïve B cells and 40LB stromal cells in RGD-containing gelatin hydrogel (Figure 
2-4). The rationale for such material selection is primarily driven by the presence of RGD in gelatin. RGD 
is the peptide sequence that can be found in several ECM proteins (e.g. gelatin) that mediates cell binding 
via engagement of αvβ3 or α5β1 integrin subunits. Gelatin-based 3D cell culture system has existed for 
decades and been well characterized in numerous studies. Gelatin is typically modified (i.e. methacrylate 
functionality addition) to facilitate UV- or chemical-induced crosslinking so that gelatin remains stable 
and not liquefying at 37 °C cell culture condition [98, 107, 108]. In this approach, we initiated ionic 
crosslinking of gelatin fibers with the use of silicate nanoparticles (SiNP) that were 20-30 nm in diameter 
and ~1 nm in thickness (Figure 2-5) [99-101, 109]. With the help of ionic interaction between the charged 
surface on the surface of SiNP and the opposing charges within the gelatin molecules, the resulting 
hydrogel was found to be physically stable at 37 °C (Figure 2-6). Primary B cells were efficiently 
encapsulated in the gelatin hydrogels and stained positive for Calcein after 24 hours post-encapsulation 
(Figure 2-7). We also ensured the absence of bacterial endotoxins in the material with the use of Limulus 
Amebocyte Lysate (LAL) assay that indicated 0.01 +/- 0.001 endotoxin units (EU)/ml for SiNP and 0.04 
+/- 0.01 EU/ml for gelatin scaffold reinforced with SiNP. These values are far below the U.S. FDA 
endotoxin threshold of 0.5 EU/ml. 
 
2.4. Organoid Design Parameters 
 
In the development of biomaterials-based immune organoid, it is important to design one with similarity 
with the microarchitecture of lymphoid tissue, structural stability in culture, and capability to support both 
B cell proliferation and stromal network formation [110]. We investigated the design parameters by 
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varying gelatin and SiNP composition and then analyzing changes in hydrogel physical properties. Using 
scanning electron microscope (SEM) to evaluate the effect of material composition on hydrogel 
microarchitecture, we found that hydrogels with 2% (w/v) gelatin and 1.5% (w/v) SiNP resulted in a more 
uniformly porous structure in comparison to the one seen with gelatin only mixture and this could be 
attributed to the presence of charged SiNP surface that would prevent the ionic aggregation of gelatin 
fibers with each other (Figure 2-8). This concept was further supported by the decrease in pore size as 
gelatin concentration was raised from 2% to 4% while keeping the SiNP concentration constant at 1.5%. 
SiNP incorporation within the hydrogel was also confirmed using energy-dispersive X-ray spectroscopy 
(EDS) analysis that showed the presence of Mg and Si peaks only in gelatin hydrogels physically 
reinforced with SiNP but not in gelatin-only hydrogels (Figure 2-9). These outcomes indicated that SiNP 
was incorporated in the gelatin hydrogel and could modulate the matrix architecture. 
 
We then hypothesized that a physiologically relevant immune organoid would require a comparable 
material stiffness with the one reported for spleen as a representative secondary lymphoid organ based on 
quantification using magnetic resonance elastography [111]. With the reported spleen stiffness of 2300 
+/- 1000 Pa, we prepared hydrogels with various compositions and analyzed both storage and loss moduli 
at 37 °C cell culture condition (Figure 2-10). While gelatin alone remained in liquid phase with virtually 
zero storage and loss moduli, the addition of SiNP resulted in the formation of crosslinked gelatin 
network and the increased organoid stiffness. With 1% SiNP and 2% gelatin, there was a marginal 
increase in storage modulus to 130 +/- 40 Pa and yet the material was not physically stable as indicated by 
the lack of significant difference between storage and loss moduli. With 1.5% SiNP and 2% gelatin, the 
storage modulus increased to 1900 +/- 50 Pa and this value was seen as comparable with the previously 
reported spleen stiffness mentioned above. With 2% SiNP and 2% gelatin, the storage modulus further 
increased to 3100 +/- 410 Pa. Although the 1% SiNP and 2% gelatin composition produced a fragile 
mixture, keeping the ratio the same and doubling the concentration of each component (i.e. 2% SiNP and 
4% gelatin composition) produced a stable hydrogel as indicated by the significant difference between 
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storage and loss moduli. This finding could be attributed to the excess of non-crosslinked gelatin as made 
evident in the case of 1.5% SiNP and 4% gelatin that had a low storage modulus and no significant 
difference between the storage and loss moduli. These observations suggested that SiNP could 
successfully crosslink gelatin and facilitate the formation of stable scaffold for biological experiments. 
 
We next assessed the influence of material composition toward the 40LB stromal network formation. This 
study was carried out by staining stromal cells with CellTracker Green CMFDA Dye and encapsulating 
40,000 stromal cells per hydrogel with varying compositions (Figure 2-11). By keeping the adhesive 
ligand density the same with gelatin concentration kept constant at 2% (w/v), 40LB stromal cells 
demonstrated improved spreading with 1.5% SiNP than 2% SiNP. Increasing the adhesive ligand density 
with 4% gelatin concentration produced a marked increase in stromal cell clusters.  
 
We then examined the effect of 40LB stromal seeding density within the hydrogel made using 2% gelatin 
and 1.5% SiNP (Figure 2-12). While 20,000 cells/gel stromal seeding density resulted in small cell 
clusters, 40,000 cells/gel stromal seeding density produced a tightly connected cellular network and 
60,000 cells/gel stromal seeding density formed a dense tubular-like network. These findings indicate that 
the 2% gelatin with 1.5% SiNP composition facilitates the formation of a hydrogel network that is both 
physically stable under cell culture conditions and capable of supporting uniform stromal cell spreading.  
 
When we assessed the expression level of membrane-bound CD40L on the surface of stromal cells, we 
found that 3D encapsulation resulted in a significantly higher expression of CD40L surface marker (9500 
+/- 430 MFI) compared to the one exhibited by 2D co-culture (4600 +/- 620 MFI) following 6 days of 
culture (Figure 2-13). With these observations, we selected the 1.5% SiNP and 2% gelatin composition to 
go ahead with B cell experimentations based on physical characteristics and 40LB stromal responses. 
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2.5. B Cell Expansion 
 
After characterizing the immune organoid from both material and stromal perspectives, we moved into 
studying the proliferation of primary B cells within the immune organoid. As we expected the interaction 
between B cells and 40LB cells to depend on stromal density, we co-cultured both cell types with an 
increasing amount of stromal cells in the presence of soluble IL-4. From analyzing organoid phase 
contrast images collected as a function of time, we observed distinct regions of closely packed cells in 
hydrogels that morphologically resembled in vivo GC reactions and the morphological structure of these 
cell clusters interestingly depended stromal density (Figure 2-14).  
 
As such appearance qualitatively indicated high B cell proliferation in the organoid, we next assessed the 
number of live cells based on Calcein positive cells detected using flow cytometry and observed a 
significant increase in the number of viable cells in our 3D organoids after 4 days of culture when 
compared to the number seen with 2D co-culture systems (Figure 2-15). It is encouraging to see the 
increased number of live cells because they can only be attributable to B cells since the 40LB stromal 
cells have been previously treated with mitomycin C to prevent proliferation inside the organoid.  
 
We next quantified the number of CD19+ B cells following culture with increasing stromal density 
(Figure 2-16). We found that the use 3D system improved B cell generation as indicated by the higher 
number of B cells in 3D (3,390 +/- 295 cells) when compared to the one seen in 2D (1261 +/- 72 cells) 
and the maximum proliferation of CD19+ cells was facilitated with 40,000 stromal cells per hydrogel 
usage with the resulting cell number (5,477 +/- 477 cells) being either higher than the one seen with 
20,000 stromal cells (3,390 +/- 295 cells) or comparable to the one observed with 60,000 stromal cells. 
These findings indicate that increased CD40L density and stromal spreading could promote the 
proliferation of CD19+ B cells in culture, yet we had yet to identify the important driver behind improved 
B cell generation in the 3D system. 
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We hypothesized that the higher number of CD19+ B cells was facilitated by the pro-survival signal 
generated by the binding of RGD motifs in gelatin by integrin subunits on B cell surface. We investigated 
this idea by culturing B cells in the organoid without any stromal support and we observed a greater 
decrease in CD19+ B cells with 2D approach when compared to 3D organoid (Figure 2-17). In order to 
test the importance of the RGD motifs found in gelatin, we blocked RGD-mediated signaling with 
Cilengitide, a cyclic RGD pentapeptide that could selectively inhibit RGD binding via αvβ3 and/or α5β1 
integrin subunits (Figure 2-17) [112, 113]. Interestingly, we observed a partial but significant decrease in 
CD19+ B cells when blocked with Cilengitide. This finding confirmed the partial role of αvβ3 and/or 
α5β1 integrins in supporting B cell survival in ex vivo culture systems. At the same time, we hypothesized 
that αvβ3 signaling played a more important role in this integrin-mediated B cell survival when compared 
to α5β1 signaling due to the very low α5 integrin gene expression value seen earlier. 
 
2.6. GC Phenotype Induction 
 
In order to study GC phenotype induction inside the organoid, it is critical to figure out the relevant 
markers that can be used to distinguish the GC B cell population. We assessed the relevant GC surface 
markers by immunizing mice with SRBC and assessing GC reaction in the spleen (Figure 2-18). From the 
splenic tissue, we found that PNA+ GC clusters were formed within the B220+ B cell follicle 
compartment in the secondary lymphoid tissue. These GC clusters were also found to be positive for both 
B220 and GL7. Flow cytometry analysis of splenic B220+ B cells further indicated that the GC B cell 
population could be delineated with a double expression of GL7 and Fas surface markers.  
 
Based on this assessment regarding characteristic GC markers, we looked into GL7 surface marker 
expression on the surface of ex vivo activated B cells (Figure 2-19). We observed the significantly higher 
number of CD19+ GL7+ GC-like B cells with 20,000 40LB stromal cells in 3D organoid (57 +/- 5 fold) 
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when compared to the one seen in 2D co-culture (10-20 fold). Making comparison within the 3D 
organoid cultures, the CD19+ GL7+ response was dependent on 40LB stromal density since 40,000 40LB 
stromal cells usage produced 96 +/- fold increase that was higher than the one seen with 20,000 40LB 
stromal cells and comparable (i.e. no statistically significant difference) with 60,000 40LB stromal cells. 
The results were further confirmed by confocal imaging studies that demonstrated the co-localization of 
GL7+ B cells on 40LB stromal networks (Figure 2-20). These results emphasized the importance of 3D 
organoid in facilitating an efficient ex vivo GC reaction. We next examined the expression of Fas surface 
marker within the CD19+ GL7+ GC-like B cell population in the organoid (Figure 2-21). The data 
indicated that 3D immune organoids with 40,000 and 60,000 stromal cells demonstrated a significant 55-
fold increase in CD19+ GL7+ Fas+ GC-like B cell when compared to 3D with 20,000 stromal cells (16 
+/- 2 fold) and 2D with 20,000 stromal cells (7 +/- 1 fold). As expected with the dependence of CD40L 
on inducing GC phenotype, organoids with no stromal failed to induce the generation of GC-like B cells. 
 
2.7. Isotype Class Switch Induction 
 
In addition to surface markers upregulation, another hallmark of GC reaction is the cytokine-dependent 
isotype class switch that occurs in GC B cells to facilitate the production of immunoglobulin molecules 
with distinct effector functions [114, 115]. B cells activated with CD40L have been known to undergo 
isotype class switch in the presence of specific cytokine combinations. Recognizing that the 3D immune 
organoid induced GC phenotype, we next assessed the functional capabilities of GC-like B cells based on 
their ability to undergo class switching from IgM to IgG1 and IgE in the presence of soluble IL-4 
cytokine (Figure 2-22). Based on the flow cytometry readout, we observed a robust generation of class 
switched B cells where the number of IgG1+ B cells increased significantly from 185 +/- 14 cells on day 
0 to 7,120 +/- 612 cells on day 6 in 3D organoid with 40,000 40LB cells. This number was found to be 
comparable with the one seen in 3D organoid with 60,000 40LB cells. We then examined the level of 
membrane-bound IgE expression level and we observed a marked shift in IgE expression in 3D when 
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compared to 2D or day 0. We also observed that the significant increase in CD19+ IgE+ B cell number 
with 40,000 stromal cells (5,446 +/- 535 cells) and 60,000 stromal cells (4,441 +/- 510 cells) as compared 
to the number seen with 20,000 stromal cells (1,687 +/- 116 cells). 
 
2.8. Discussion 
 
Since very few studies have been done on engineering artificial tissues to culture primary immune cells 
and study their interactions with the cell microenvironment, this study represented an early attempt at the 
development of modular B cell follicle organoid with an ability to accelerate immune reaction via tunable 
design parameters. Here we specifically described the development of 3D immune organoid that 
morphologically and functionally resembles the GC reaction that typically occurs in the secondary 
lymphoid tissues following infection. Inspired by the mechanical and cellular compositions of the 
secondary lymphoid tissues, the organoid was designed to have comparable stiffness level and stromal 
component. From this approach, we learn how integrins are capable of mediating B cell survival in 
culture and CD40 signaling is critical for inducing GC phenotype in activated B cells.  
 
While the current study demonstrates the role of αvβ3 in maintaining B cell number in the absence of 
stromal support, we cannot rule out the role of other integrin types presented in either gelatin matrix or 
lymphoid microenvironment. Future investigations will be geared toward investigating the role of other 
integrin subunits including α5β1 and α4β1. We will also need to comprehensively characterize the 
resulting GC-like B cells to determine how they compare with in vivo GC B cells from immunized mice, 
assess the induction of other GC hallmark events, and determine the capability of ex vivo GC models to 
recapitulate mechanistic events seen in the animal models. In conclusion, this immune organoid provides 
a simple strategy for recapitulating the lymphoid microenvironment in ex vivo GC reaction protocols to 
ensure long-term cell survival. This approach can be distinguished from conventional B cell activation 
methods that require culturing B cells with other cells and soluble factors in 2D format or transplanting 
  34 
cell-seeded scaffold into live animal models. We anticipate biomaterials-based ex vivo immune organoids 
representing a new approach to study cell-matrix interactions, affinity-based clonal selection, and 
lymphoid transformation process. 
 
2.9. Materials and Methods 
 
2.9.1. GC B Cell Assessment in Mice 
 
Surface integrin expression on the surface of in vivo GC B cells was studied by first immunizing two 
C57BL/6 mice intraperitoneally at 8 weeks of age with 0.5 ml of a 2% sheep red blood cell (SRBC) 
suspension in PBS (Cocalico Biologicals) and then sacrificing the mice after 8 days post-immunization. 
Splenocyte suspension was stained with the following fluorophore-conjugated anti-mouse antibodies: 
B220 (PerCP-Cy5.5), Fas (PE-Cy7), GL7 (Alexa Fluor 647), integrin α4 (PE), integrin αv (PE), β1 
(FITC), integrin β3 (FITC), IgG2bκ isotype control (PE), IgG1κ isotype control (PE), and IgG isotype 
control (FITC). Dead cells were excluded using DAPI. GC B cells were identified as B220+ Fas+ GL7+, 
and naïve B cells were defined as B220+ Fas- GL7-. Surface integrin expression level versus isotype 
control was determined for both naïve B and GC B cells. Flow cytometry data was acquired with BD 
FACSCanto flow cytometer (BD Biosciences) and analyzed using FlowJo software package. 
 
GC formation in immunized mice was assessed by challenging C57BL/6 mice with 2% SRBC suspension 
(Cocalico Biologicals, Inc) and harvesting the spleens 10 days post-immunization for further 
examinations. We then used the spleens to examine B cell follicles for GC formation using 
immunohistochemistry (IHC), flow cytometry, and immunofluorescence (IF). For IHC assessment, 
paraffin-embedded spleen tissue sections were stained with B220 (BD Pharmingen) for B cells and 
biotinylated peanut agglutinin (PNA, Vector Laboratories) for GC B cells [116]. For flow cytometry 
analysis, splenocytes were isolated with mechanical and gradient separation methods (Fico/Lite-LM, 
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Atlanta Biologicals) and then stained for B220 for B cells and GL7 + Fas for GC B cells. For IF 
evaluation, spleen tissue sections were stained for B220 to visualize B cells throughout the lymphoid 
tissue and GL7 to define B cells exhibiting GC phenotype.  
 
2.9.2. Naïve B Cells and 40LB Stromal Cells Preparation 
 
Organoid fabrication was done by first harvesting spleens from C57BL/6 mice, purifying B cells from 
splenocytes through negative selection using EasySep Mouse B Cell Isolation Kit (Stem Cell 
Technologies) with yield ~ 90% CD19+ B cells. 40LB stromal cells expressing CD40L and secreting 
BAFF were generated as reported earlier [48] and cultured in high glucose DMEM medium (Life 
Technologies) containing 10% FBS and 1% P/S. 40LB cells were mitotically inhibited through incubation 
in medium containing 0.01 mg/ml Mitomycin C at 37 °C for 45 minutes and then rinsed twice with 10 ml 
of 1X PBS prior to encapsulation. 
 
2.9.3. Immune Organoid Fabrication 
 
Gelatin stock solution was freshly prepared by dissolving gelatin powder (Sigma Aldrich) in RPMI 1640 
medium and then sterilizing the solution with a syringe filter. Cells were suspended in warmed gelatin 
stock solution and diluted accordingly using cell culture medium. SiNP with 25-30 nm in diameter and 1 
nm in thickness were obtained from Southern Clay Products Inc., USA. The SiNP suspension was freshly 
prepared prior to the encapsulation procedure by mixing SiNP powder with deionized water and vortexing 
the resulting solution immediately before use. Organoids were fabricated in 96-well plates by first adding 
5 ml of SiNP, injecting 5 ml cell-containing gelatin solution into the initial SiNP droplet, and then mixing 
the entire hydrogel through repeated pipetting. Each organoid was cured for approximately 10 minutes 
prior to the addition of RPMI 1640 medium. The entire plate was then placed in the cell culture incubator 
for 1 hour before exchanging the cell culture medium in each well with the one containing 10 ng/ml 
  36 
murine recombinant IL-4 (Peprotech) and replacing the medium every 3 days. The IL-4 stock solution 
was reconstituted in deionized water at 0.1 mg/ml and kept as aliquots in 20 °C. 
 
2.9.4. Material Characterizations 
 
Gelatin solutions of 2% and 4% (w/v) were prepared in PBS, mixed and vortexed with aqueous 
suspensions of SiNP to obtain homogeneously crosslinked gels. Modulus measurements were done for 
strain sweep (1-10% strain) at a fixed frequency of 0.1 Hz and 37 °C temperature using a rheometer 
(Anton Paar) equipped with 50 mm flat-plate geometry and a gap of 50 mm. For scanning electron 
microscopy (SEM) imaging of various hydrogel compositions, samples were freeze-dried and sliced into 
transverse sections by razor slitting. The sections were then sputter coated with Pt/Pd to provide 
conductivity and imaged using Quanta 600 (FEI) at 20 kV equipped with energy-dispersive X-ray 
spectroscopy (EDS) detector (Oxford Instruments). The recorded EDS spectra were further analyzed by 
INCA software (Oxford Instruments) to confirm the presence of elements. For transmission electron 
microscopy (TEM) imaging of the SiNP, approximately 5 ml of SiNP in water was drop-casted onto a 
carbon-coated copper grid, air-dried, and then imaged under 200 keV voltage using JEOL JEM-2010 
instrument (Japan). Bacterial endotoxin analysis was done with the LAL assay based on the US Food and 
Drug Administration (FDA) guidelines [117].  
 
2.9.5. Cell Extraction from Organoids 
 
For enzymatic degradation, cell culture medium was aspirated from each well and the organoids were 
washed once using 1X PBS before covered with 10 U/ml collagenase solution (Worthington Biosciences) 
for overnight incubation in cell culture conditions. The collagenase solution was prepared by 
reconstituting collagenase powder in serum-free RPMI 1640 medium. The organoids were then 
mechanically digested through pipetting and combined with excess FACS buffer for collagenase 
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inactivation. FACS buffer was prepared with 1X PBS++ containing 10% FBS. The resulting cell 
suspension was filtered using a 70 mm cell strainer to remove gel debris prior to flow cytometry analysis. 
 
2.9.6. Immunofluorescence Microscopy and Flow Cytometry Analysis 
 
For flow cytometry analysis, the filtered cell suspension was stained in FACS buffer containing various 
antibody combinations with 1:1000 dilution for 45 minutes in the dark at 4 °C. The antibodies consisted 
of: FITC-, APC-, or PE-Cy7-conjugated anti-mouse anti-CD19, anti-GL7, anti-Fas, anti-CD40L, anti-
IgG1, anti-IgM, and anti-IgE (eBioscience). After staining, the cell suspension was then rinsed twice 
using FACS buffer. Flow cytometer data were acquired using BD Accuri C6 and analyzed with FlowJo 
software package. 
 
For IF assessment, immune organoids were rinsed and then incubated in FACS buffer containing 
fluorophore-conjugated antibodies and/or live cell stains for 12 hours in cell culture conditions. The 
samples were washed three times with each wash involving the aspiration of old medium and the 
incubation in fresh FACS buffer for 1 hour. Each organoid was covered with 1X PBS during imaging 
with Zeiss LSM 710 confocal microscope. 
 
2.9.7. Integrin Blocking 
 
Freshly purified B cells were incubated in FACS buffer containing cyclic RGD pentapeptide Cilengitide 
at the specified final concentrations of 10 and 50 µM for 30 minutes at 4 °C. 
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2.9.8. Statistical Analysis 
 
Statistical analysis was performed using GraphPad Prism software with statistical significance determined 
based on a p-value of less than 0.05. All studies were performed in triplicates unless otherwise noted. 
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2.11. Figures 
 
 
Figure 2-1: Ex vivo GC reaction with 2D co-
culture system 
(A) Number of CD19+ B cells in 2D culture. 
(B) Number of CD19+ IgG1+ B cells in 2D 
culture with varied IL-4 cytokine concentration 
(left) or stromal density (right). Statistical 
significance (*) was determined based on P < 
0.05. Statistical test was conducted using 
ANOVA. Values are shown as mean ± SEM (n 
= 5). 
 
 
 
Figure 2-2: Analysis of integrin gene 
expression levels in murine splenic naïve and 
GC B cells 
The values were obtained from the NIH 
repository linked to a published study by 
Dominguez et al. Statistical significance (*) 
was determined based on P < 0.05. Statistical 
test was conducted using ANOVA. Values are 
shown as mean ± SEM (n = 4). 
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Figure 2-3: Surface integrin expression in murine splenic naïve and GC B cells 
Quantitative analysis indicated the percentage of integrin-expressing cells (left) and the mean 
fluorescence intensity for each integrin subunit (right). Assessment was conducted on both B220+ naïve 
B cells and B220+ GL7+ Fas+ GC B cells from immunized mice. The cells were harvested from 
C57BL/6 mice after 8 days following intraperitoneal immunization with SRBC. Statistical significance 
(*) was determined based on P < 0.05. Statistical test was conducted using ANOVA. Values are shown as 
mean ± SEM (n = 2). 
 
 
Figure 2-4: Schematic of B cell follicle 
immune organoid fabrication 
The approach was inspired by the interaction 
between naïve B cells and signals provided by 
the neighboring cells – specifically CD40L 
presented by TFH cells and BAFF secreted 
from FDCs. In the organoid, B cells were 
encapsulated with 40LB stromal cells that 
provided both CD40L and BAFF inside RGD-
presenting 3D hydrogel matrix. 
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Figure 2-5: Overview of silicate nanoparticles 
The schematic indicating how ionic crosslinking occurred upon the mixing of silicate nanoparticles and 
liquid gelatin to facilitate the formation of stable hydrogel matrix at 37 °C (left). The TEM image of 
silicate nanoparticles displayed with 20 nm scale bar (right). 
 
 
Figure 2-6: Role of SiNP addition toward gelatin matrix stability 
The images indicated the visual comparison of organoid matrix stability in gelatin only (left) and ionically 
crosslinked gelatin (right) gels. Assessment was performed following incubation at 37 °C. The images are 
displayed with 10 mm scale bar. 
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Figure 2-7: Primary B cell viability and 
distribution in organoid 
Primary naïve CD19+ B cells were stained with 
Calcein prior to encapsulation and imaging was 
performed 24 hours after organoid fabrication 
with 500 µm scale bar. 
 
 
 
Figure 2-8: SEM analysis of gelatin matrix prepared with various compositions. 
Two gelatin concentrations (2% and 4%) were prepared and each gelatin amount was mixed with several 
silicate nanoparticle w/v concentrations (0%, 1%, 1.5%, and 2%). 
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Figure 2-9: EDS analysis of gelatin matrix with 
and without silicate nanoparticles 
Analysis was conducted to determine the presence 
of Si and Mg peaks in gelatin scaffold following 
reinforcement with silicate nanoparticles (bottom). 
Gelatin only group was used as control (top). 
 
 
 
Figure 2-10: Rheological analysis of gelatin matrix with various compositions 
Analysis was conducted on both storage and loss moduli. Two gelatin w/v concentrations (2% and 4%) 
were prepared and each gelatin amount was mixed with increasing silicate nanoparticle w/v 
concentrations (0%, 1%, 1.5%, and 2%). Statistical significance (*) was determined based on P < 0.05. 
Statistical test was conducted using ANOVA. Values are shown as mean ± SEM (n = 5). 
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Figure 2-11: Role of organoid stiffness toward 40LB stromal cell phenotype 
Fluorescence imaging was conducted on stained stromal cells encapsulated in gelatin network with 
varying gelatin and silicate nanoparticle concentrations. Images are displayed with 500 µm scale bar. 
 
 
Figure 2-12: Role of stromal seeding density toward 40LB stromal cell phenotype 
Fluorescence analysis was conducted on stained stromal cells in gelatin network seeded with increasing 
stromal cells. Images are presented with 200 µm scale bar. 
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Figure 2-13: CD40L surface expression on 40LB stromal cells in 2D and 3D culture systems 
Histogram on the left provided an overlay of CD40L expression in unstained, day 0, 2D (day 6), and 3D 
(day 6). Bar graph on the right quantified CD40L expression in mean fluorescence intensity for 40LB 
cells cultured with 2D or 3D culture system over 6 days. Statistical significance (*) was determined based 
on P < 0.05. Statistical test was conducted using ANOVA. Values are shown as mean ± SEM (n = 4). 
 
 
Figure 2-14: Image analysis of cell cluster 
formation inside immune organoid 
Phase images were taken of the hydrogels 
containing primary B cells and 40LB stromal 
cells at various seeding densities. For each 
stromal density, two images were taken of the 
same hydrogel at two time points: day 2 and 4. 
Images are presented with 500 µm scale bar. 
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Figure 2-15: Quantification of total viable 
cells in ex vivo B cell culture systems 
Analysis was done on Calcein positive cells in 
both 2D and 3D culture methods with 
increasing stromal density as a function of time. 
Statistical significance with regard to the 2D 
groups on day 4 (*) was determined based on P 
< 0.05. Statistical significance with regard to 
day 0 (ψ) was determined based on P < 0.05. 
Statistical test was conducted using ANOVA. 
Values are shown as mean ± SEM (n = 5). 
 
 
Figure 2-16: Number of CD19+ B cells in 2D 
culture and 3D organoid 
The immune organoids were prepared with 
increasing 40LB stromal density. Flow 
cytometry analysis was conducted on day 4. 
Statistical significance with regard to the 2D 
group (*) was determined based on P < 0.05. 
Statistical significance with regard to the 3D 
20K group (ψ) was determined based on P < 
0.05. Statistical test was conducted using 
ANOVA. Values are shown as mean ± SEM (n 
= 5). 
 
 
Figure 2-17: Number of CD19+ B cells in 2D 
culture and 3D organoid for integrin analysis 
The immune organoid was cultured in the 
absence or presence of Cilengitide. Cilengitide 
was administered at doses: 10 and 50 µM. 
Analysis was conducted on day 2. Statistical 
significance with regard to the 2D group (*) 
was determined based on P < 0.05. Statistical 
significance with regard to the 3D 20K group 
(ψ) was determined based on P < 0.05. 
Statistical test was conducted using ANOVA. 
Values are shown as mean ± SEM (n = 5). 
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Figure 2-18: Assessment of in vivo GC reaction. 
(A) Immunohistochemistry (IHC) analysis of B cell follicles for the presence of GC reaction based on B 
cell marker B220 and GC marker peanut agglutinin (PNA). IHC was obtained from paraffin-embedded 
murine splenic sections. (B) The left image indicated immunofluorescence (IF) analysis of B cell follicles 
for the presence of GC reaction using B cell marker B220, GC marker GL7, and nuclear stain DAPI. The 
scale bar in these images represented 50 mm. The right image showed flow cytometry analysis of B220+ 
primary B cell population from immunized C57BL6 mice with the gate indicating GL7+ Fas+ GC B cells. 
 
     
Figure 2-19: Induction of GC-like CD19+ GL7+ B cells in 2D culture and 3D organoid 
The immune organoid was prepared with increasing stromal density. (Left) Gating schematic for flow 
cytometry analysis. (Right) Quantified GC-like B cell expansion as a function of culture period. 
Statistical significance (*) was determined based on P < 0.05. Statistical test was conducted using 
ANOVA. Values are shown as mean ± SEM (n = 5). 
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Figure 2-20: Imaging 
analysis of GC-like CD19+ 
GL7+ B cells in 3D. 
Imaging was conducted with 
phase contrast and 
immunofluorescence. The 
images were taken with either 
10 or 500 µm scale bar. 
 
 
      
Figure 2-21: Induction of GC-like CD19+ GL7+ Fas+ B cells in 2D culture and 3D organoid 
The immune organoid was prepared with increasing stromal density. (Left) Gating schematic for flow 
cytometry analysis. (Right) Quantified GC-like B cell fold expansion as a function of time. Statistical 
significance (*) was determined based on P < 0.05. Statistical test was conducted using ANOVA. Values 
are shown as mean ± SEM (n = 5). 
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Figure 2-22: Generation of CD19+ IgG1+ B cells in 2D culture and 3D organoid 
The immune organoid was prepared with increasing stromal density. (Top) Gating schematic for flow 
cytometry analysis. (Bottom) Quantification of class switched B cell number as a function of time. 
Statistical significance (*) was determined based on P < 0.05. Statistical test was conducted using 
ANOVA. Values are shown as mean ± SEM (n = 5). 
  
0 2 4 6
0
2000
4000
6000
8000
10000
Days
C
D
19
+ 
Ig
G
1+
 C
el
l N
um
be
r
Class Switched B Cell Expansion
2D: 20K
3D: 20K
3D: 40K
3D: 60K *
  50 
CHAPTER 3  
 
Characterizing Immune Organoids and Studying Germinal Center Maintenance Mechanisms 
 
3.1. Abstract 
 
Understanding the importance of characterizing the gelatin-based immune organoids, we compared ex 
vivo organoid derived GC-like B cells with in vivo GC B cells from immunized mice. We demonstrated 
that our system compares well with its native counterpart based on viability, acquisition of signature GC 
transcriptome, and somatic hypermutation. We also learned that the use of biomaterials impart superior 
viability, higher proliferation, and better acquisition of GC transcriptome when compared to the results 
seen using 2D co-culture method. Since tracking GC B cells in the lymphoid tissue has been difficult due 
to their heterogeneity and constant cycling into/from the GC reaction, we showed a potential application 
of this approach in studying EZH2-dependent cell cycle regulation that enables GC B cell proliferation.  
 
3.2. Introduction 
 
The previously described immune organoids was developed with the goal of obtaining mechanistic 
insights about immune response generation, modeling lymphoid transformations that trigger certain 
diseases, and identifying biomolecules that can interact with the immune system. Complementing the 
traditional animal models, the organoid platform is expected to facilitate these studies with lower cost, 
reduced complexity, and higher experiment throughput. As primary GC B cells have been known to 
quickly undergo apoptosis following isolation, it can be challenging to functionally characterize in culture 
and such situation has prevented us from studying GC mechanistically with ex vivo techniques. 
                                                      
 This study was carried out by Wendy Béguelin, PhD, and Matt Teater from the Ari M. Melnick Lab at 
Weill Cornell medicine and the resulting manuscript has been submitted for publication.  
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Nevertheless, it is important to ensure that the B cells generated from immune organoid recapitulate the 
relevant cellular phenotype prior to conducting the aforementioned studies. In order to understand how 
the GC-like B cells from the immune organoid compare with their in vivo counterpart, we have to perform 
in-depth characterization that ranges from proliferation assay to gene expression analysis via RNA 
sequencing. Following these validation steps, we can then continue with performing mechanistic studies 
to demonstrate its utility in immunology research. 
 
Characterization can be done primarily by using several assessment metrics to compare ex vivo organoid-
derived GC like B cells and in vivo GC B cells isolated from immunized mice. From the literatures, the 
GC B cell population is typically identified by looking at several surface markers that include canonical B 
cell marker (e.g. B220 or CD19) and GC marker (e.g. GL7, Fas, and/or PNA). Further identifications are 
usually made by looking into the presence of GC-specific transcription factors (e.g. BCL6, PAX5, and/or 
EZH2). Gene expression analysis can also be done to gain a comprehensive transcriptome analysis of the 
cell, although such method tends to be used for understanding specific GC B cell subsets that are formed 
over the course of GC reaction from induction to exit and differentiation. 
 
Upon the completion of characterization and validation steps, one mechanism that can be explored is the 
rapid proliferation of GC B cells over the course of humoral immune response [118, 119] . Such area of 
research is applicable due to the enhanced GC-like B cell formation seen in the immune organoids and the 
current lack of understanding regarding what exactly mediates the GC proliferative response. Our initial 
hypothesis is that epigenetic changes drive GC proliferation by repressing the cell cycle checkpoint genes. 
Based on the scientific literatures, massive cell proliferation is possibly mediated by the silencing of cell 
cycle checkpoint genes via epigenetic mechanisms [120, 121]. In the context of GC reaction, epigenetic 
silencing of several genes is partially mediated by the Polycomb protein EZH2 with a specific expression 
only in GC B cell population [122, 123]. EZH2 has been implicated in enabling cellular proliferation in 
other cell types by repressing cyclin dependent kinase inhibitors. Interestingly, only modest reduction in 
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cell cycle was observed in stimulated Ezh2 KO primary B cells [124]. At the same time, depleting or 
inhibiting EZH2 via pharmacologic means in GC-derived lymphoma cells resulted in strong anti-
proliferative effect along with reduced repression of CDKN1A relative to other checkpoint genes [123, 
125]. Based on these observations, EZH2 appear to drive cellular proliferation during GC reaction. 
 
Nevertheless, it is challenging to test the hypothesis that EZH2 promotes GC proliferation via CDKN1A 
suppression because the resulting data has not been that clear. This situation can be attributed to the fact 
that GC reactions are very heterogeneous in mice with B cells constantly entering, cycling, and leaving. 
Such complexity is compounded with the knowledge that EZH2 amount in mice circulation will vary 
following drug administration. It will not be technically or financially feasible to optimize the process 
because hundreds of mice over years will be required. While ex vivo functional studies may provide an 
alternative way to test the aforementioned hypothesis, there is currently no reliable technique available to 
obtain purified GC B cells from Ezh2 KO mice. Based on these limitations, we will be using the organoid 
system to help determine if EZH2 alone can drive GC cell cycle via epigenetic repression of CDKN1A. 
 
3.3. Approach 
 
The biomaterials-based 3D immune organoid will be prepared as previously described by co-
encapsulating both primary naïve B cells and 40LB stromal cells in RGD-presenting gelatin matrix 
ionically crosslinked with SiNP. Based on the frequently described characteristics of GC B cells, we plan 
on characterizing the organoid-derived GC-like B cells from its proliferation, viability, surface markers, 
gene expression, and somatic hypermutation. 
 
The proposed application of our immune organoid platform is investigating the mechanics of GC reaction 
in two ways: the dependence on EZH2 and the ability of rescuing GC reaction in EZH2 null phenotype by 
knocking out Cdkn1a. The study will be carried out with the use of transgenic mice and pharmacologic 
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inhibition. In the first method, conditional Ezh2fl/fl knockout (KO) mice with Cγ1-Cre strain would be 
utilized with Ezh2 getting knocked out following post-CSR IgG1 transcription (i.e. EZH2 would be 
knocked out upon GC induction). In the second method, Ezh2 KO would be applied by GSK343 
administration since this compound had been known to inactivate EZH2 by suppressing EZH2 
methyltransferase activity.  
 
3.4. Organoid Characterization 
 
Having previously shown that immune organoids enhance GC-like B cell generation and promote the 
induction of GC-relevant markers, we further validated these observations with various biological assays. 
Similar to our previous observation, phase images showed the formation of cell clusters inside the 
hydrogel after 3 days of culture (Figure 3-1). In order to determine the composition of these cell clusters, 
IF images were obtained from hydrogels containing GFP+ B cells and the resulting data indicated that the 
cell clusters mainly consisted of primary B cells (Figure 3-1). While the formation of cell clusters brings 
to mind the morphology of a developing GC reaction, another way to define the GC phenotype is by 
looking into the expression of GC-specific surface markers in the B cell population. We then looked into 
the percentage of live B cells expressing both GL7 and Fas to measure GC induction inside the immune 
organoids (Figure 3-2). From the resulting data, the percentage of GL7+ Fas+ GC-like B cells increased 
from 20% (day 2) to 39% (day 3) and was maintained at a similar level with 38% (day 5) and 30% (day 
7). Such trend indicated a sustained GC induction in the immune organoids. 
 
Since GC phenotype is generally associated with proliferative capacity and the formation of B cells 
clusters is indicative of cell proliferation, we next analyzed cell expansion using eFluor670 proliferation 
dye with dye intensity reduction serving as a measure of cell proliferation (Figure 3-3). The resulting data 
showed that more than 80% of live GC-like B cells had proliferated after 7 days of culture and the biggest 
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increase in proliferation occurred prior to day 2 as shown by the highly reduced proliferation dye 
intensity. We can thus infer that massive cell proliferation occurred inside the immune organoids. 
Although GC B cells have been known to undergo apoptosis in culture, organoid GC-like B cells showed 
a similar rate of apoptosis to the one exhibited by GC B cells isolated from immunized animals (Figure 
3-4). The approximate apoptosis rate of 10% was obtained based on the amount of cells that appeared 
positive for Annexin V. This observation suggests that organoid-derived GC-like B cells exhibit a 
comparable viability with their in vivo counterparts. 
 
Despite the encouraging GC phenotype that includes comparable viability, the next step is to continue the 
benchmarking process by specifically looking into whether organoid-derived GC-like B cells have 
obtained the characteristic GC transcriptome. This analysis was carried out by looking into the RNA-seq 
profile of B220+ GL7+ Fas+ organoid-generated GC B cells. Principal component analysis (PCA) was 
first done to analyze the gene expression data and identify the two principal components responsible for 
the majority of variances. Using PCA space defined by in vivo GC B cells, plasma cells, and NB cells, we 
observed the acquisition of signature GC transcriptome based on the relative proximity of the day 4 
organoid GC-like B cells cluster with the in vivo GC B cells cluster (Figure 3-5). Interestingly, we also 
noted the induction of ASC differentiation with the shift of the day 6 organoid GC-like B cells cluster 
toward the plasma cells cluster. Gene ontology tree analysis further supported these GC induction and 
differentiation trends (Figure 3-6). The resulting data implied that while day 4 organoid GC-like B cells 
resembled in vivo GC B cells, day 6 cells had undergone differentiation toward PC phenotype. Gene 
expression heatmap was next utilized to look into the genes that strongly influenced each principal 
component (Figure 3-7). Since PC2 appeared to describe the GC induction program, we saw that GC 
marker genes (e.g. Aicda) were similarly upregulated in both organoid and in vivo GCB cells. With PC1 
seemed to define the ASC differentiation program, we noticed that ASC marker genes (e.g. Sdc1, Prdm1 
and Xbp1) were similarly downregulated in both organoid and in vivo GCB cells. We can therefore 
conclude that the gene expression pattern of the organoid GC-like B cells resembled that of the in vivo 
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GC B cells instead of naïve B cells or plasma cells. Using GSEA, we also learned that the GCB gene 
signature (i.e. a set of genes that are strongly correlated with GCB phenotype) was enriched in the 
organoid gene expression profile (Figure 3-8). These results suggest that ex vivo organoid-derived GC-
like B cells can represent in vivo GC B cells from the transcriptome perspective. 
 
Further supporting the transcriptome analysis, we utilized qPCR to confirm that the characteristic GC 
genes (e.g. Ezh2, Bcl6, and Aicda) were similarly upregulated in both organoid-derived GC-like B cells 
and in vivo GC B cells (Figure 3-9). In order to verify that these genes were translated into proteins, we 
conducted flow cytometry analysis on intracellular EZH2 expression and showed that EZH2 was 
expressed at a comparable level in both populations (Figure 3-10). This observation further supports the 
idea that these relevant GC genes were expressed and translated in the immune organoid system. 
 
Since ex vivo activation protocols have been known to result in B cell proliferation and induction of GC-
like surface markers (e.g. GL7 and Fas), we wanted to determine if the 3D organoid GC-like 
transcriptional profile resulted simply from the proliferative phenotype. In other words, we checked 
whether the transcriptional similarities came purely from organoid-mediated changes in the proliferation 
genes or not. We tested this argument by excluding proliferation-related genes from the RNA-seq profiles 
of organoid GC-like B cells and then repeating the PCA analysis along with naïve B cells, GC B cells, 
and plasma cells (Figure 3-11). It turned out that the exclusion of proliferation-related genes did not 
change the previously observed trend from earlier where the cluster of day 4 organoid GC-like B cells 
was located close to the one for in vivo GC B cells. 
 
One hallmark event that occurs during GC reaction is somatic hypermutation, specifically high rate of 
mutations occurring in the immunoglobulin gene variable regions. In order to determine whether somatic 
hypermutation transpired in the GC organoid system, immunoglobulin variable loci were amplified from 
naïve B cells, organoid-derived GC-like B cells, and GC B cells from primed mice (Figure 3-12). 
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Looking at four loci (JH4, Sµ, VHJ558, and Vλ1), the resulting data denoted a significant increase in 
missense mutations and indels in GC-like B cells in comparison to NB cells. Furthermore, the mutation 
profile of the ex vivo GC-like B cells appeared to be comparable to the in vivo GC B cells. These 
mutations in immunoglobulin gene variable regions further showed that the GC organoid system 
recapitulated the key aspects of a developing GC reaction. 
 
We have seen that the 3D immune organoids facilitated the generation of GC-like B cells with sustained 
GC induction, high cell proliferation, and various similarities to in vivo GC B cells (e.g. viability, 
transcriptome, and somatic hypermutation). But we have yet to determine if these outcomes were driven 
by the 40LB stromal component or the biomaterials-based niche. From assessing the proliferative 
phenotype, a greater percentage of proliferative GC-like B cells were observed with 2-3 greater amounts 
at any day (Figure 3-13). This trend demonstrated that the high cell proliferation was sustained in immune 
organoids. Cell viability assessment with Annexin V demonstrated a greater percentage of apoptotic cells 
in 2D co-culture (27%) vs. 3D organoid (11%) after day 6 in culture (Figure 3-14). This behavior was 
consistent throughout 7 days of culture and therefore indicating high cell viability in immune organoids. 
Looking into the BCL6 transcription factor expression with flow cytometry, highest BCL6 expression 
was seen in in vivo GC B cells then followed by 3D organoid GC-like B cells and finally 2D GC-like B 
cells (Figure 3-15). Naïve B cells were used as the control group since their BCL6 expression level was 
close to the background level produced by isotype control.  
 
PCA assessment on the gene expression data showed that 2D GC-like B cells were more transcriptionally 
distant than organoid GC-like B cells with regards to in vivo GC B cells (Figure 3-16). From these 
observations, gelatin scaffold reinforced by silicate nanoparticles appeared to generate GC-like B cells 
that better represent in vivo GC B cells based on the improved acquisition of signature GC transcriptome. 
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3.5. Mechanistic Investigation into EZH2 and CDKN1A 
 
Having shown that the immune organoid platform can be used to model the GC reaction, we next 
assessed the EZH2 dependency of GC-like B cell generation in the immune organoid. We also verified if 
the Ezh2 conditional KO system could be implemented in this platform for GC mechanistic studies. The 
latter was done by determining if the conditional Ezh2fl/fl Cγ1-cre Cdkn1a-/- KO phenotype observed in 
mice would be recreated by the immune organoids. In order to conduct this experiments, naïve B cells 
were isolated from four sources: Ezh2fl/fl Cγ1-cre Cdkn1a-/- (double KO), Cdkn1a-/-  (Cdkn1a KO), Ezh2fl/fl 
Cγ1-cre (Ezh2 KO), and Ezh2fl/fl (control). After encapsulating these cells in the organoid, reduction in the 
percentage of GL7+ Fas+ GC-like B cells was observed in single Ezh2 KO system but not double KO or 
single Cdkn1a KO (Figure 3-17). Interestingly, Ezh2 KO phenotype was rescued by Cdkn1a KO to 
prevent any disruption in the GC reaction. This data indicated that EZH2 promoted GC reaction in the 
organoid and conditional Ezh2 KO system was successfully applied. 
 
We next looked into the EZH2-dependent regulation of cell cycle in the immune organoids with the 
hypothesis that EZH2 suppresses CDKN1A to enable massive cell proliferation during GC reaction. 
Since the Cdkn1a gene is expected to inhibit the cell cycle transition in GC B cell from G1 to S phase, we 
looked into such transition based on the percentage of cells with newly synthesized DNA based on BrdU 
staining (Figure 3-18). The resulting data indicated that the BrdU+ cell population was reduced in Ezh2 
KO group based on flow cytometry analysis and no such effect was observed in either double KO or 
single Cdkn1a KO. While the result did not reach statistical significance possibly due to incomplete 
conditional Ezh2 KO, the lack of EZH2 expression was validated in the double KO model (Figure 3-19). 
 
Since EZH2 inactivation could also be done via pharmacologic inhibition, we exposed organoids to a 
single dose of EZH2 inhibitor after 1 day of culture and incubated the treated organoids for additional 4 
days of culture before analysis. For the treatment, we used either GSK343 (EZH2 inhibitor) or GSK669 
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(control compound). The resulting data indicated a significant reduction in the percentage of GL7+ Fas+ 
GC-like B cells following GSK343 treatment only in the Cdkn1a+/+ group (Figure 3-20). No such effect 
was seen in the same cell population from the Cdkn1a-/- group. Interestingly, we noted that GSK343 
inhibited EZH2 methyltransferase activity as indicated by the reduced trimethylation of lysine 27 residue 
of histone H3 (H3K27Me3) without altering the EZH2 expression level (Figure 3-21) in both Cdkn1a+/+ 
and Cdkn1a-/-. Cell cycle analysis indicated a significant reduction of cells in S phase as indicated by the 
BrdU+ cell population only in the Cdkn1a+/+ group following GSK343 treatment (Figure 3-22). Similar to 
the previous observation, no such effect was seen in the Cdkn1a-/- group after GSK343 exposure under the 
same protocol. These observations suggested the importance of EZH2 in mediating GC formation and 
proliferation with the latter by enabling cell cycle transition into S phase via CDKN1A repression. This 
insight also illustrates the use of immune organoids for GC mechanistic studies. 
 
3.6. Discussion 
 
Due to the lack of well-characterized artificial lymphoid tissues currently available for studying immune 
system mechanistically in culture, this study demonstrated an attempt toward characterizing our 
previously published B cell organoid platform and then functionally validating its application in the 
mechanistic investigation into GC reaction. Here we specifically analyzed the GC reaction from various 
dimensions: proliferation, viability, marker expression, transcriptome, and somatic hypermutation. From 
our understanding about GC phenotype, we demonstrated how our organoid system could model the GC 
reaction in animal models. Despite the strong similarities from various phenotypic studies (e.g. 
proliferation, viability, and marker expression), we also noticed some differences in the gene expression 
profile between GC-like B cells generated from the organoid and actual GC B cells harvested from 
immunized mice. As we have yet to understand what factors are required to increase the gene expression 
comparability, future investigations will be focused toward investigating the role of other variables such 
as antigens, specific integrins, and cytokine types.  
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We also showcased two potential applications of our technology: investigating the biological mechanisms 
behind the complex GC reaction and identifying immunomodulatory agents. While the current study was 
focused on understanding how EZH2 could facilitate GC B cell proliferation and demonstrating how 
GSK343 worked as a specific EZH2 inhibitor, we can expand this observation into studying other 
mechanisms that regulate the GC reaction and analyzing other relevant pharmacologic inhibitors (e.g. 
SYK or BTK inhibitor). We also need to utilize this approach to systematically understand the role of 
various microenvironment signals that may influence B cell development and activation. We anticipate 
that such biomaterials-based ex vivo immune organoids to be further utilized in mechanistic research 
studies and immunomodulatory drug development works. 
 
3.7. Materials and Methods 
 
3.7.1. Mouse Models 
 
Conditional Ezh2 KO mice (loxP-flanked Ezh2 allele – Ezh2fl/fl) were generously provided by Dr. 
Alexander Tarakhovsky at Rockefeller University [126]. By crossing Ezh2fl/fl with the transgenic Cγ1-cre 
strain we generated heterozygous Ezh2fl/WT mice that were then crossed to obtain Ezh2fl/fl mice. These 
mice were crossed to Cdkn1a-/- to obtain Ezh2fl/WT Cγ1-cre+ Cdkn1a-/+ heterozygous that were then further 
crossed to yield Ezh2fl/fl Cγ1-cre+ Cdkn1a-/- double KO. Control groups consisted of Ezh2fl/fl Cγ1-cre- and 
the single KOs Ezh2fl/fl Cγ1-cre+ and Cdkn1a-/- littermates. The following strains were purchased from 
The Jackson Laboratory: Cγ1-cre+ (010611), Cdkn1a-/- (003263), E2F1-/- (002785), B6129SF2/J (101045) 
and C57BL6 (000664). 
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3.7.2. GC B Cell Generation from Immunized Mice 
 
Age- and sex-matched mice were immunized intraperitoneally at 8 to 12 weeks of age with either 0.5 ml 
of a 2% SRBC suspension in PBS (Cocalico Biologicals) or 100 µg of highly substituted NP(32)-KLH ( 
Biosearch Technologies) in alum (Thermo Scientific) and sacrificed after 8-10 or 14 days, respectively. 
All procedures have been approved by the Research Animal Resource Center of the Weill Cornell 
Medicine. 
 
3.7.3. Immune Organoid Fabrication 
 
Spleens were harvested from C57BL6, B6129SF2/J, Cdkn1a-/- single KO, Ezh2fl/fl Cγ1-cre single KO, 
Ezh2fl/fl Cγ1-cre Cdkn1a-/- double KO and Ezh2fl/fl mice. Splenocytes were prepared using mechanical and 
gradient separation methods (Fico/Lite-LM, Atlanta Biologicals). B cells were purified from splenocytes 
using EasySep Mouse B Cell Isolation Kit (Stem Cell Technologies, 19854) with a yield of ~90% B220+ 
B cells. 40LB stromal cells expressing CD40L and secreting BAFF were generated as reported earlier by 
Nojima et al [48] and cultured in DMEM medium with 10% FBS and penicillin G/streptomycin. 40LB 
stromal cells were mitotically inhibited by incubation in medium containing 0.01 mg/ml Mitomycin C 
(Sigma-Aldrich, MO503) at 37 °C for 55 minutes and were rinsed twice with PBS before encapsulation. 
 
Gelatin stock solution was freshly prepared by dissolving gelatin powder (Sigma Aldrich) in RPMI 1640 
medium and sterilizing it with syringe filter. Cells were suspended in 5% gelatin stock solution and 
diluted accordingly using cell culture medium. Silicate nanoparticles (SiNP) with 25-30 nm in diameter 
and 1 nm in thickness was obtained from Southern Clay Products Inc., USA. 3% hydrogel SiNP 
suspension was freshly prepared prior to the encapsulation procedure by mixing SiNP powder with 
deionized water and vortexing the resulting solution immediately before use. Organoids were fabricated 
in 96-well plates by first adding 10 µL of 3% hydrogel SiNP, injecting 10 µL of cell-containing gelatin 
  61 
solution into the initial SiNP droplet, and then mixing the entire hydrogel through repeated pipetting. 
Each organoid contained 50,000 B cells and 80,000 40LB cells. Organoids were cured for approximately 
10 minutes and then covered with RPMI medium containing 10% FBS, penicillin G/streptomycin, and 50 
ng/ml murine recombinant IL-4 (R&D, 404-ML). The organoids were incubated at 37 °C with 5% CO2 
and the cell culture medium was replaced every 3 days. 
 
3.7.4. Flow Cytometry Analysis 
 
Cell suspensions from mouse spleens or immune organoids were stained using the following fluorophore-
conjugated anti-mouse antibodies: PE-Cy7 conjugated anti-B220, APC conjugated anti-CD38 
(eBioscience), APC conjugated anti-B220, PE and PE-Cy7 conjugated anti-Fas, FITC conjugated anti-
GL7, Alexa Fluor 488 conjugated anti-EZH2, Alexa Fluor 488 conjugated IgG1κ isotype control, V450 
conjugated anti-BrdU (BD Biosciences), Alexa Fluor 674 conjugated anti-H3K27Me3, Alexa Fluor 674 
conjugated IgG isotype control (Cell Signaling), PerCP-Cy5.5 conjugated anti-GL7 (BioLegend). DAPI 
was used for the exclusion of dead cells. 7AAD was used to determine DNA content in cell cycle 
analysis. For internal markers, cells were fixed and permeabilized with BD Cytofix/Cytoperm 
Fixation/Permeabilization Solution Kit (BD Biosciences) and further permeabilized with cold Phosflow 
Perm Buffer III (BD Biosciences). Cell proliferation was measured by first labeling B cells with the 
proliferation dye eFluor670 (eBioscience) prior to encapsulation. PE-conjugated Annexin V in Annexin V 
binding buffer (BD Biosciences) was used to identify apoptotic cells. Flow cytometry data were acquired 
using BD FACSCanto (BD Biosciences) and analyzed with FlowJo software package. 
 
3.7.5. RT-qPCR  
 
RNA was prepared using Trizol extraction (Invitrogen). cDNA was prepared using cDNA synthesis kit 
(Thermo Scientific) and detected by fast SyberGreen (Applied Biosystems) on 7900HT Fast Real-Time 
PCR System (Applied Biosystems). Gene expression was normalized to HPRT1 and the values were 
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presented relative to control with the ΔΔCT method. qPCR results were provided as fold expression with 
the standard deviation for 2 series of triplicates. 
 
3.7.6. qPCR Primers 
 
Used for Gene  Oligonucleotide (5'-3') 
 
cDNA 
 
Aicda 
Fwd CCTCCTGCTCACTGGACTTC 
Rev CAGGAGGTGAACCAGGTGAC 
Bcl6 
Fwd GCGAACCTTGATCTCCAGTC 
Rev TGACTCTCACTGCTGCTTCG 
Cdkn1a 
Fwd GTGGCCTTGTCGCTGTCT 
Rev TTTTCTCTTGCAGAAGACCAATC 
Ezh2 
Fwd ATCTGAGAAGGGACCGGTTT 
Rev GCTGCTTCCACTCTTGGTTT 
Hprt1 
Fwd  TATGCCGAGGATTTGGAAAA 
Rev AATCCAGCAGGTCAGCAAAG 
 
3.7.7. RNA-seq library preparation and Illumina sequencing processing  
 
RNA-seq libraries were constructed with TruSeq RNA Sample Prep Kit (Illumina). Libraries were 
validated using the Agilent Technologies 2100 Bioanalyzer and Quant-iT dsDNA HS Assay (Life 
Technologies) and 8-10 pM sequenced on HiSeq2000 sequencer mRNA-seq, 2 x 50. 
 
3.7.8. RNA-seq analysis 
 
RNA sequencing results were aligned to mm10 using STAR [127] and annotated to RefSeq using the R 
subread package [128]. Genes with differential expression between naïve B and GC B cells were 
identified using the EdgeR package GLM [129] with thresholds of fold-change >1.5 and p<0.01 adjusted 
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for multiple testing using Benjamini-Hochberg correction. PCA was performed on centered, log-
transformed FPKM values using the prcomp() function within R framework. Principal component genes 
were defined as those with 2 standard deviations above or below the respective mean loading factor. 
Unrooted phylogenetic tree was created using neighbor-joining tree estimation within the ape R package 
[130]. GSEA was conducted using the previously described algorithm [131]. 
 
3.7.9. Immunoglobulin Somatic Hypermutation Analysis  
 
Somatic hypermutation analysis was conducted using genomic DNA from (1) naïve B and GC B cells 
sorted from 3 immunized WT mice, (2) naïve B cells from 3 naïve WT mice used for immune organoid 
fabrication, and (3) GC B cells sorted from day 6 immune organoids. IgH and Igλ regions were amplified 
with PCR using primers that anneal to the framework region of the most abundant families of 
immunoglobulin rearrangements as previously described [132-135]. PCR products were cleaned up using 
the MinElute PCR Purification kit (QIAGEN) and then purified using the Gel Extraction Kit (QIAGEN). 
Sequencing libraries were constructed from the purified PCR product with TruSeq DNA Sample 
Preparation Kit v2 (Illumina). Each sample was tagged with a unique index and sequenced on the 
Illumina MiSeq platform producing 2x151 base-pair paired-end reads. Paired-end reads were mapped 
against the Mus musculus primary assembly GRCm38 using aligner Star 2.4.0 [127]. A pileup of the 
resulting sorted bam files was made in samtools for each targeted region and filtered using >20 quality 
score. A list of all single nucleotide polymorphisms was made using VarScan 2.3.4 on each base with 
minimum read depth of 10 reads and tabulated per targeted region into bed-files [136]. The mutation rate 
per kilobase was calculated by dividing the average missense or indels per base by the average coverage 
of sequenced read and multiplying by 1000 to obtain the rate of missense or indels per kilobase. 
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3.7.10. Immunoglobulin Somatic Hypermutation Primers  
 
Locus  Oligonucleotide (5'-3') 
JH4 
Fwd GTCAAGGAACCTCAGTCACCGTCT 
Rev CAGACCTCTCTAGACAGCAACTACC 
Sµ 
Fwd AATGGATACCTCAGTGGTTTTTAATGGTGGGTTTA 
Rev GCGGCCCGGCTCATTCCAGTTCATTACAG 
VHJ558 
Fwd CGAGCTCTCCARCACAGCCTWCATGCARCTCARC 
Rev TCTCAGCCGGCTCCCTCAGGG 
Vλ1 - Jλ1,3 
Fwd GCCATTTCCCCAGGCTGTTGTGACTCAGG 
Rev ACTCACCTAGGACAGTCAGCTTGGTTCC 
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3.9. Figures 
 
Figure 3-1: Imaging analysis of cell 
clustering in the organoid 
(Top) Phase images were taken of the immune 
organoids. Images were taken with 400 µm 
scale bar. (Bottom) IF images were obtained 
from immune organoids containing GFP+ B 
cells. These B cells were isolated from the 
spleen of GFP mice prior to encapsulation. 
Images were taken with 100 µm scale bar. 
 
A 
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Figure 3-2: GC-like B cell generation in the immune organoid 
GC induction was assessed based on GL7 and Fas double expression and measured as a function of time. 
(A) Gating schematic for flow cytometry analysis showing the initial selection of B220+ DAPI- live B 
cells and the subsequent selection of GL7+ Fas+ GC B cells within the live B cell population. (B) 
Representative flow cytometry plot indicating GC-like B cell percentage after 2, 3, 5, and 7 days in 
culture. Similar to the previously shown gating schematic, the gated area indicating organoid GC-like B 
cells was based on GL7+ Fas+ GC subset within B220+ DAPI- live B cell population. (C) Bar graph 
quantifying the average percentage of GC-like B cell subset in culture with flow cytometry analysis. 
Values are shown as mean ± SEM (n = 6). 
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Figure 3-3: GC-like B cell proliferation in the immune organoid 
Cell proliferation was measured using proliferation dye eFluor670. (A) Representative flow cytometry 
histogram for measuring the percentage of proliferating cells based on the fluorescence intensity of 
proliferation dye eFluor670 in organoid B220+ GL7+ Fas+ GC-like B cell population cultured for several 
days. (B) Bar graph quantifying the average percentage of proliferating GC-like B cells in culture with 
flow cytometry analysis. (C) Bar graph quantifying the average mean fluorescence intensity of 
proliferation dye eFluor670 in the organoid GC-like B cells. Values are shown as mean ± SEM (n = 6). 
 
      
Figure 3-4: Cell viability assessment in both in vivo GC B cells and organoid GC-like B cells 
Cell viability was measured using Annexin V. Organoid GC-like B cells that have been cultured for 5 
days and GC B cells from immunized mice were used in this experiment. Positive Annexin V staining 
was used to identify apoptotic cells. (Left) Representative flow cytometry histogram for dividing the cell 
population into live and apoptotic based on Annexin V staining. (Right) Bar graph quantifying the 
average percentage of apoptotic GC B cells based on Annexin V intensity in both cell populations with 
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flow cytometry analysis. Values are shown as mean ± SEM (n = 6 for ex vivo GC-like B cells from 
immune organoids and n = 3 for in vivo GC B cells from immunized mice). 
 
 
Figure 3-5: Principal component analysis on 
gene expression data 
Gene expression was analyzed based on 
RNAseq profile from the following cell 
populations: B220+ GL7+ Fas+ in vivo GC B 
cells from immunized mice (in vivo GCB, n = 
6), in vivo CD138+ PC (n = 6), B220+ GL7+ 
Fas+ ex vivo GC-like B cells from immune 
organoids (organoid GCB, n = 4 for day 4 and n 
= 3 for day 6), and B220+ IgD+ Fas- GL7- 
naïve B cells (NB, n = 3). The RNAseq profile 
from organoid GCB was projected into the 
principal component space defined by in vivo 
GCB, in vivo PC, and NB. 
 
 
Figure 3-6: Gene ontology tree analysis 
Unrooted phylogenetic tree analysis was conducted 
using RNAseq gene expression profile from B220+ 
GL7+ Fas+ ex vivo GC-like B cells from immune 
organoids cultured for 4 days (GC_org_d4, n=4) 
and 6 days (GC_org_d6, n=3), B220+ GL7+ Fas+ 
in vivo GC B cells from immunized mice (GC, 
n=6) and CD138+ in vivo plasma cells (PC, n=6). 
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Figure 3-7: Heat map analysis on gene expression data 
Gene expression level was represented as log2 ratio relative to either mean naïve B cells (left) or mean 
plasma cells (right). PC was defined as the principal component described in the previous PCA analysis. 
(Left) PC2 genes that explained the variances between ex vivo organoid GC-like B cells and in vivo GC B 
cells. (Right) PC1 genes that described the variances between in vivo GC B cells, ex vivo organoid GC-
like B cells, and PC. 
 
 
Figure 3-8: GC B cell signature enrichment 
analysis in organoid GC-like B cells 
Analysis was conducted to measure the 
enrichment of murine GC B cell signature 
genes. Enrichment of upregulated (n=1,799) 
and downregulated (n = 1,140) genes in day 4 
ex vivo organoid GC-like B cells was assessed 
relative to those of naïve B cells (B cells from 
day 0 prior to culture). 
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Figure 3-9: Expression of GC signature 
genes 
RT-qPCR was conducted on several mRNAs 
from ex vivo organoid GC-like B cells (n = 3) 
and in vivo GC B cells (n = 3). Gene expression 
values were shown as mean fold change mRNA 
levels ± SEM normalized to the housekeeping 
gene HPRT1 and further normalized to mean 
mRNA levels in naïve B cells. Analysis was 
conducted on four genes: Ezh2, Bcl6, Aicda, 
and Cdkn1a. Statistical significance (*, **, and 
***) was based on p < 0.05, p < 0.01, and p < 
0.001, respectively. Statistical test was 
conducted using t test. Values are shown as 
mean ± SEM  (n = 3). 
 
 
Figure 3-10: Intracellular EZH2 expression in various B cell populations 
Cells from both immune organoids and immunized mice were fixed, permeabilized, and then stained for 
EZH2. Cells were co-stained to identify B220+ GL7+ Fas+ GC B cells and B220+ IgD+ GL7- Fas- naïve 
B cells. (Left) Representative flow cytometry histogram indicating the mean fluorescence intensity of 
EZH2 in various cell populations and isotype control. (Right) Bar graph quantifying the average mean 
fluorescence intensity of EZH2 intracellular expression in various B cell populations. Values are shown 
as mean ± SEM (n = 6 for ex vivo organoid GC-like B cells from immune organoids, n = 3 for in vivo GC 
B cells from immunized mice, and n = 3 for naïve B cells). 
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Figure 3-11: Principal component analysis 
on gene expression data without 
proliferation genes 
Gene expression was analyzed based on 
RNAseq profile - excluding 941 proliferation-
related genes - from the following cell 
populations: B220+ GL7+ Fas+ in vivo GC B 
cells from immunized mice (in vivo GCB, n = 
6), in vivo CD138+ PC (n = 6), B220+ GL7+ 
Fas+ ex vivo GC-like B cells from immune 
organoids (organoid GCB, n = 4 for day 4 and n 
= 3 for day 6), and B220+ IgD+ Fas- GL7- 
naïve B cells (NB, n = 3). The RNAseq profile 
from organoid GCB was projected into the 
principal component space defined by in vivo 
GCB, in vivo PC, and NB. 
 
      
Figure 3-12: Somatic hypermutation analysis with immunoglobulin loci amplification 
Measurement of missense mutations (left) and indels (right) in both in vivo GC B cells and day 6 
organoid GC-like B cells was normalized to that of naïve B cells. Analysis was conducted on the 
following four loci: JH4, Sµ, VHJ558, and Vλ1. PCR was utilized to amplify the specified 
immunoglobulin variable loci from genomic DNA extracted from purified naïve B cells (day 0 before 
culture), ex vivo organoid GC-like B cells (day 6 in culture), in vivo GC B cells from immunized mice, 
and naïve B cells from the same mice. Sequencing libraries were constructed from the purified PCR 
products and sequenced on the Illumina MiSeq platform. The mutation rate per kilobase for each gene 
was calculated by dividing the average missense (N) or indels (O) per base by the average coverage of 
sequenced read. The average mutation rate per kilobase in GC B cells was normalized to the average in 
naïve B cells from the same cell source: immunized mice or immune organoids. Statistical significance (* 
and **) was based on p < 0.05 and p < 0.01, respectively. Statistical test was conducted using t test. 
Values are shown as mean ± SEM  (n = 3). 
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Figure 3-13: GC-like B cells proliferation in 
3D immune organoids and 2D co-culture 
systems 
Cell proliferation was measured using 
proliferation dye eFluor670. The percentage of 
proliferating cells was assessed based on the 
fluorescence intensity of proliferation dye 
eFluor670 in B220+ GL7+ Fas+ GC-like B cell 
population after being cultured for 2, 3, 5, and 7 
days. Bar graph quantifying the average 
percentage of proliferating GC-like B cells in 
both culture methods for the specified days with 
flow cytometry analysis. Values are shown as 
mean ± SEM (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-14: GC-like B cell viability in 3D immune organoids and 2D co-culture systems 
Cell viability was measured using Annexin V. GC-like B cells that have been cultured for 5 days using 
both immune organoids and 2D co-culture systems were used in this experiment. Positive Annexin V 
staining was used to identify apoptotic cells. (Left) Representative flow cytometry histogram for dividing 
the cell population into live and apoptotic based on Annexin V staining. (Right) Bar graph quantifying the 
average percentage of apoptotic GC B cells based on Annexin V intensity in both cell populations with 
flow cytometry analysis. Values are shown as mean ± SEM. 
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Figure 3-15: Intracellular BCL6 expression 
in various B cell populations 
Cells from first isolated from immune 
organoids, co-culture systems, and immunized 
mice. The cells were then fixed, permeabilized, 
and stained for BCL6. (Left) Representative 
flow cytometry histogram indicating the mean 
fluorescence intensity of BCL6 in various cell 
populations and isotype control. (Right) Bar 
graph quantifying the average mean 
fluorescence intensity of BCL6 intracellular 
expression in various B cell populations. Values 
are shown as mean ± SEM (n = 3). 
 
 
Figure 3-16: Principal component analysis of 
gene expression data 
Gene expression was analyzed based on 
RNAseq profile from the following cell 
populations: B220+ GL7+ Fas+ in vivo GC B 
cells from immunized mice (in vivo GCB, n = 
6) and B220+ GL7+ Fas+ ex vivo GC-like B 
cells from both immune organoids (organoid 
GCB, n = 4) and 2D co-culture systems (2D 
GCB, n = 4). 
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Figure 3-17: GC phenotype induction with Ezh2 and Cdkn1a KO models 
The assessment was conducted based on GL7 and Fas double expression. B cells were isolated from four 
animal models:  Ezh2fl/fl Cγ1-cre, Cdkn1a-/-, Ezh2fl/fl Cγ1-cre Cdkn1a-/-, and Ezh2fl/fl control mice (n=3 
mice per group). Immune organoids were harvested for flow cytometry analysis after 4 days in culture. 
(Left) Representative flow cytometry plots indicating GC-like B cell percentage from each genotype. The 
gated area indicating organoid GC-like B cells was based on GL7+ Fas+ GC subset within B220+ DAPI- 
live B cell population. (Right) Bar graph quantifying the average percentage of GC-like B cells from each 
genotype using flow cytometry analysis. Statistical significance (** and ***) was determined based on p 
< 0.01 and p < 0.001, respectively. Statistical test was conducted using t test. Values are shown as mean ± 
SEM (n = 9). 
 
       
Figure 3-18: Cell cycle analysis with Ezh2 and Cdkn1a KO models 
The assessment was conducted using BrdU and 7AAD. BrdU was used to assess cell cycle, while 7AAD 
was utilized to determine DNA content. Organoids were pulsed with BrdU 2 hours before harvesting. B 
cells were isolated from four animal models:  Ezh2fl/fl Cγ1-cre, Cdkn1a-/-, Ezh2fl/fl Cγ1-cre Cdkn1a-/-, and 
Ezh2fl/fl control mice (n=3 mice per group). Immune organoids were harvested for flow cytometry 
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analysis after 4 days in culture. (Left) Representative flow cytometry plots indicating the percentage of 
GC-like B cell in S phase from each genotype. The gated area indicated the B220+ DAPI- GL7+ Fas+ 
live organoid GC-like B cells that were in S phase as indicated by positive BrdU staining. (Right) Bar 
graph quantifying the average percentage of S phase GC-like B cell from each genotype using flow 
cytometry analysis. The gated area indicating organoid GC-like B cells was based on GL7+ Fas+ GC 
subset within B220+ DAPI- live B cell population. Statistical significance (** and ***) was determined 
based on p < 0.01 and p < 0.001, respectively. Statistical test was conducted using t test. Values are 
shown as mean ± SEM (n = 9). 
 
       
Figure 3-19: Conditional Ezh2 KO analysis in organoid GC-like B cell population 
Cells from immune organoids were fixed, permeabilized, and then stained for EZH2. Cells were co-
stained to identify B220+ GL7+ Fas+ GC-like B cells. B cells were isolated from four animal models:  
Ezh2fl/fl Cγ1-cre, Cdkn1a-/-, Ezh2fl/fl Cγ1-cre Cdkn1a-/-, and Ezh2fl/fl control mice (n=3 mice per group). 
Immune organoids were harvested for flow cytometry analysis after 4 days in culture. (Left) 
Representative flow cytometry histogram indicating the mean fluorescence intensity of EZH2 in various 
genotype groups and isotype control. (Right) Bar graph quantifying the average mean fluorescence 
intensity of EZH2 intracellular expression from each genotype group using flow cytometry analysis. 
Statistical significance (** and ***) was determined based on p < 0.01 and p < 0.001, respectively. 
Statistical test was conducted using t test. Values are shown as mean ± SEM (n = 9). 
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Figure 3-20: GC phenotype induction with Cdkn1a KO model and EZH2 inhibitor 
The assessment was conducted based on GL7 and Fas double expression. B cells were isolated from two 
animal models: Cdkn1a+/+ and Cdkn1a-/- (n=3 mice per group). The organoids were then treated with 
either GSK669 or GSK343. Immune organoids were harvested for flow cytometry analysis after 4 days in 
culture. (Left) Representative flow cytometry plots indicating GC-like B cell percentage from each 
genotype and treatment group. The gated area indicating organoid GC-like B cells was based on GL7+ 
Fas+ GC subset within B220+ DAPI- live B cell population. (Right) Bar graph quantifying the average 
percentage of GC-like B cells from each genotype and treatment group using flow cytometry analysis. 
Statistical significance (** and ***) was determined based on p < 0.01 and p < 0.001, respectively. 
Statistical test was conducted using t test. Values are shown as mean ± SEM (n = 9). 
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Figure 3-21: Histone methylation analysis with Cdkn1a KO model and EZH2 inhibitor 
The assessment was carried out based on the expression of H3K27Me3 that measured the trimethylation 
of lysine 27 in histone 3. Cells from immune organoids were fixed, permeabilized, and then stained for 
H3K27Me3 and EZH2. Cells were co-stained to identify B220+ GL7+ Fas+ GC-like B cells. B cells were 
isolated from two animal models: Cdkn1a+/+ and Cdkn1a-/- (n=3 mice per group). The organoids were 
then treated with either GSK669 or GSK343. Immune organoids were harvested for flow cytometry 
analysis after 4 days in culture. (Top) Representative flow cytometry histogram analysis indicating the 
fluorescence intensity of both H3K27Me3 and EZH2 from each genotype and treatment group. (Bottom) 
Bar graph quantifying the average mean fluorescence intensity of both H3K27Me3 and EZH2 from each 
genotype and treatment group using flow cytometry analysis. The gated area indicating organoid GC-like 
B cells was based on GL7+ Fas+ GC subset within B220+ DAPI- live B cell population. Statistical 
significance (** and ***) was determined based on p < 0.01 and p < 0.001, respectively. Statistical test 
was conducted using t test. Values are shown as mean ± SEM (n = 9). 
 
  
Figure 3-22: Cell cycle analysis with Cdkn1a KO and EZH2 inhibitor 
The assessment was conducted using BrdU and 7AAD. BrdU was used to assess cell cycle, while 7AAD 
was utilized to determine DNA content. Organoids were pulsed with BrdU 2 hours before harvesting. B 
cells were isolated from two animal models: Cdkn1a+/+ and Cdkn1a-/- (n=3 mice per group). The 
organoids were then treated with either GSK669 or GSK343. Immune organoids were harvested for flow 
cytometry analysis after 4 days in culture. (Left) Representative flow cytometry plots indicating the 
percentage of GC-like B cell in S phase from each genotype and treatment group. The gated area 
indicated the B220+ GL7+ Fas+ DAPI- live organoid GC-like B cells that were in S phase as indicated by 
positive BrdU staining. (Right) Bar graph quantifying the average percentage of S phase GC-like B cell 
from each genotype and treatment group using flow cytometry analysis. The gated area indicating 
organoid GC-like B cells was based on GL7+ Fas+ GC subset within B220+ DAPI- live B cell 
population. Statistical significance (** and ***) was determined based on p < 0.01 and p < 0.001, 
respectively. Statistical test was conducted using t test. Values are shown as mean ± SEM (n = 9). 
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CHAPTER 4  
 
Integrin Ligand Specificity Differentially Regulates Ex vivo B Cell Activation 
 
4.1. Abstract 
 
Having demonstrated the importance of capturing the key aspects of lymphoid tissue microenvironment, 
we realize the importance of understanding the role of specific matrix signals in modulating GC reaction. 
As we previously noted the role of RGD - αvβ3 integrin ligand - in maintaining B cell number, we 
specifically looked into integrin ligand specificity using a modular immune organoid. Our studies showed 
that while 40LB stromal cell number controls the extent of ex vivo GC reaction, integrin ligand type 
influenced GC marker induction, integrin subunits expression, and IgM BCR characteristics (e.g. 
clustering, co-localization with β3 integrin subunit, and expression level). We also noted the importance 
of early αvβ3 integrin signaling in maintaining GC-like B cell number and regulating IgM BCR level. 
These results demonstrated that integrin ligand type could influence GC-like B cell phenotype inside 
immune organoids.  
 
4.2. Introduction 
 
In the previous chapters, we have demonstrated the role of 3D immune organoid approach in mediating 
an efficient GC-like B cell expansion in culture and facilitating ex vivo mechanistic investigation into GC 
reaction. Although the artificial matrix utilized in these cases is enriched with bioadhesive ligands, we 
                                                      
 The content of this chapter has been published as Purwada, Alberto, Shivem B. Shah, Wendy Beguelin, 
Ari M. Melnick, and Ankur Singh. "Modular Immune Organoids with Integrin Ligand Specificity 
Differentially Regulate Ex Vivo B Cell Activation." ACS Biomaterials Science & Engineering 3, no. 2 
(2017): 214-225. 
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have yet to understand how these signals can directly modulate the extent of ex vivo GC reaction. In order 
to answer the question above, we first assess published studies on the role of integrin in modulating 
specific GC B cell characteristics and the overall GC reaction.  
 
Integrin ligands are typically found in the form of cell adhesion molecule or extracellular matrix. Within 
the lymphoid tissue, specific integrin ligands such as α4β1-binding vascular cell adhesion molecule 1 
(VCAM-1) are upregulated on the surface of FDCs [97]. The role of α4β1 integrin has been demonstrated 
in several publications. Although B cells co-cultured with FDCs can remain viable in culture, such 
survival-boosting effect is reduced after said integrin is blocked with neutralizing antibody [39]. It has 
been proposed that interaction between BCR, CD19, and outside-in integrin signaling promotes short-
term GC B cell survival, prevents the accumulation of pro-apoptotic and anti-proliferative proteins, and 
induces the expression of anti-apoptotic proteins[137]. In the lymphoid microenvironment, αvβ3-binding 
RGD motif is observed in ECM proteins such as vitronectin within the GC light zone [97] or laminin α5 
within the marginal zone of B cell follicles [96]. While the role of αvβ3 integrin has yet to be fully 
explored, αvβ3 integrin subunits are expressed more in activated B cells [138] and therefore GC B cells 
bind vitronectin stronger than follicular B cells [97]. From the functional perspective, β3 deficiency is 
associated with slight overrepresentation in the splenic GC compartment [97] and increased sensitivity to 
TLR stimulation [138]. These studies indicate that distinct integrin-ligand interactions can have different 
influences on the GC reaction. At the same time, multiple integrin binding types can occur simultaneously 
and further increase the complexity of dissecting individual integrin contribution toward GC induction. 
 
Despite these findings, it can be challenging to understand the role of distinct integrin-ligand interaction 
in conventional methods. Animal models are inherent complex and do not provide an easy control over 
integrin ligand density and selective presentation. Furthermore, integrin KO model can be difficult to 
generate because of altered development or embryonically lethal [138]. While ex vivo B cell stimulation 
can be achieved with stromal cells and/or soluble factors, 2D co-culture methods exclude 3D presentation 
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of bioadhesive ligands. While the main issues of imprecise control and 3D presentation could be 
addressed with biomaterials-based matrix, such innovation has been rarely implemented in B cell and GC 
studies. With these challenges illustrating the difficulty of investigating integrin function in B cell 
development, we were motivated to use biomaterials-based artificial matrix for achieving this goal. 
 
4.3. Approach 
 
Having learned the differential integrin gene and surface protein expression during B cell activation, we 
engineered a modular immune organoid using 4-arm maleimide-functionalized PEG (PEG-MAL) 
hydrogel (Figure 4-1). Such system has been demonstrated to study the role of lymphoid niche in in 
malignant B cell culture [139]. In this modular approach, one arm of the PEG-MAL molecule will be 
functionalized with thiolated adhesive peptide and the remaining arms will be crosslinked to facilitate 
hydrogel formation by adding non-degradable crosslinker dithiothreitol (DTT) and/or a degradable 
peptide crosslinker to enable stromal cell spreading. Both functionalization and crosslinking will occur 
via Michael Addition reaction. We designed our studies to functionalize one arm of the four-arm PEG 
macromers with thiolated adhesive peptides at 3.0 mM concentration to maximize adhesion sites while 
ensuring the availability of arms to mediate crosslinking reaction. We selected adhesive peptide 
concentration based on previous studies reporting that 0.025 to 3.5 mM RGD peptide support cell 
adhesion and spreading in PEG hydrogels [102]. We also ensured that only one arm was occupied per 
PEG-MAL molecule because a higher conjugation rate may prevent crosslinking or produce or a non-
crosslinking cyclization as discussed earlier by Metters and Hubbell [140]. Although we did not quantify 
the incorporation of adhesive peptides via Michael Addition reaction, Phelps et al [102] has previously 
shown 100% incorporation of thiolated RGD peptides at 1:1 or higher MAL-to-RGD molar ratios. 
 
While the biomaterials are designed to mimic ECM signals from the lymphoid microenvironment, 40LB 
stromal cells providing CD40L and BAFF are utilized to recapitulate the lymphoid cellular components. 
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Similar to our previous experiments, 40LB stromal cells were made from BALB/c 3T3 fibroblasts 
genetically engineered to present CD40L and secrete BAFF were used to reconstitute the same signals 
presented by follicular helper T cells (Tfh) cells and FDCs, respectively [48]. Since CD40L normally 
originates from Tfh cells, CD40L-presenting 40LB stromal cells recapitulate the role of Tfh in mediating 
GC reaction [141, 142]. Both 40LB stromal cells and primary naïve B cells will then be co-encapsulated 
in the functionalized hydrogel to help us study the role of integrin in GC B cell generation. 
 
We then assessed the optimal hydrogel composition by looking at 40LB stromal cell spreading since we 
have previously demonstrated the importance of stromal cell spreading in mediating an efficient ex vivo 
GC reaction [143, 144]. We first looked into matrix degradability because previous studies have shown 
that cell spreading is supported in hydrogels containing protease degradable crosslinkers [102, 145-149] 
and the cells used here - 3T3 fibroblasts [150] and B cells [151] - are known to secrete matrix 
metalloprotease 9 (MMP-9). We observed that aggregated cells were produced in hydrogels with non-
degradable crosslinker DTT resulted and such outcome suggested that DTT did not support the spreading 
of 40LB stromal cells (Figure 4-1). In contrast, superior cell spreading was observed when PEG-MAL 
was crosslinked using MMP-9 degradable VPM peptides mixed with DTT at 1:1 molar ratio. This 
combination was selected because hydrogels crosslinked with 100% VPM was quickly degraded in 
culture due to matrix remodeling by 40LB cells (data not shown). We hence continued with the 1:1 VPM-
to-DTT molar ratio in the subsequent experiments. 
 
We next studied the effect of adhesive ligand density toward 40LB stromal cell spreading by 
functionalizing the PEG macromers with RGD peptide at concentrations ranging from 0.003 to 3 mM 
(Figure 4-1). The resulting data indicated the appearance of 40LB spread network at 3 mM ligand density 
but no such phenotype was observed at 0.003 – 0.3 mM ligand concentration range. We also studied the 
role of integrin ligand specificity toward stromal phenotype (Figure 4-1). 40LB cells appeared to spread 
uniformly with well-formed actin fibers in both REDV and RGD groups. A similar CD40L expression 
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level was observed in 40LB stromal cells grown with both integrin ligand types with a slightly higher 
level seen in RGD organoids. We thus used the following adhesive ligand type and concentrations: RGD 
(1.5 and 3.0 mM), REDV (1.5 and 3.0 mM), and RGD + REDV (1.5 mM for each peptide type).  
 
4.4. Integrin Ligand Composition and B Cell Activation 
 
We hypothesized that integrin ligand specificity will modulate GC-like B cell phenotype induction. To 
test this hypothesis, primary CD19+ naïve B cells were isolated from mice spleen and then co-cultured 
with 40LB cells within the 3D organoid in the presence of IL-4. Previous studies have shown the role of 
IL-4 during early interaction between B and Tfh cells to facilitate GC formation [152].  We did not 
observe any significant difference in CD19+ B cell number across integrin ligand types and densities after 
4 days of culture (Figure 4-2). Since GC B cells express the GL7 surface marker [153-156], we also 
examined GL7 surface expression to assess GC-like phenotype induction (Figure 4-2). Our data indicated 
a significantly higher percentage of GL7+ GC-like B cells in REDV organoids versus the one seen in 
RGD organoids. Within each integrin ligand type, changing ligand density by 2 fold from 1.5 to 3 mM 
did not change the GL7+ percentage. This observation indicates that integrin ligand type can modulate the 
induction of GL7 surface marker in GC-like B cells. 
 
Because Fas is a highly characterized member of the pro-apoptotic receptor family and Fas expression is 
upregulated on GC B cells relative to naïve B cells [157], we next evaluated Fas surface expression to 
further analyze GC-like phenotype induction (Figure 4-2). From the functional perspective, Fas-mediated 
GC B cell selection has been shown to be essential in the steady state maintenance of both T and B cells 
[158]. We did not observe any difference in the percentage of GL7+ Fas+ GC-like B cells between 
integrin ligand types at 1.5 mM concentration. But we observed a significant increase in the percentage of 
GL7+ Fas+ GC-like B cells with REDV at 3 mM ligand density (Figure 4-2). We did not see such effect 
with RGD at the same dose. Since multiple integrin ligands can be present in the lymphoid 
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microenvironment, we next determined the effect of combined RGD and REDV ligand presentation using 
RGD + REDV organoids with 1.5 mM ligand density for each peptide. We observed the same percentage 
of GL7+ Fas+ GC-like B cells as observed with 1.5 mM RGD and REDV organoids.  These outcomes 
further suggest the ability of integrin ligand type in controlling GC marker induction. 
 
Based on these results and our previous work on immune organoids with RGD-presenting scaffold [143], 
we proposed that αvβ3 stimulation with RGD drives GC induction better than 2D co-culture and yet α4β1 
further improves the activation process. Since combined RGD and REDV ligand presentation did not 
enhance GC formation more than RGD only, we hypothesized that αvβ3 integrin has a dominating effect 
over other integrin types. This conclusion is supported by a previous study observing an increased 
contribution by integrin β3-deficient B cells in GC reactions and thus suggesting the regulatory function 
of integrin β3 in GC B cells [97].  
 
In order to ensure that GC-like phenotype induction was driven primarily by CD40L presentation instead 
of biomaterial immunogenicity, we encapsulated B cells in the presence or absence of CD40L-presenting 
40LB stromal cells (Figure 4-2). While we observed a very low number of B cells and essentially zero 
GC-like B cell number with no 40LB cells, we noticed a significantly higher number of both B cells and 
GL7+ Fas+ GC-like B cells with 40LB cell availability. This outcome indicated the importance of CD40L 
in maintaining B cell number and facilitating GC-like phenotype induction. We also noted the importance 
of stromal density because the number of both B cells and GC-like B cells was higher with 40,000 40LB 
stromal cells (vs. 20,000 40LB stromal cells). These results indicated that B cell number and GC-like B 
cell expansion primarily depended on the amount of CD40L in the organoids. 
 
4.5. Integrin Ligand Composition and B Cell Integrin Expression 
 
With integrin ligand specificity affecting GC phenotype, we hypothesized that the presence of a specific 
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integrin ligand could alter the expression of relevant integrin subunits. We then quantified the expression 
level of several integrin subunits (α4, β1, αv, and β3) on B cell surface (Figure 4-3). From measuring the 
integrin subunit expression level with median fluorescence intensity (MFI), we found integrin α4 level to 
be significantly higher in REDV-functionalized organoids than RGD-functionalized organoids at both 1.5 
and 3 mM ligand density (Figure 4-3). A two-fold increase in ligand density from 1.5 mM to 3 mM did 
not change integrin α4 expression level. We then presented a combination of RGD and REDV integrin 
ligands with 1.5 mM ligand density for each peptide. The resulting data indicated that the integrin α4 
expression level in RGD+REDV organoids was similar to the one exhibited by 1.5 mM RGD organoids 
and significantly lower than that in 1.5 mM REDV organoids. While higher integrin α4 expression was 
detected in REDV organoids (vs. RGD organoids), a dominating effect of RGD could be seen during 
simultaneous RGD and REDV ligand presentation. This situation could reflect the situation where both 
ligands are available in the light zone compartments in GC [97, 159]. 
 
Unlike integrin α4, integrin β1 appeared to have two peaks representing low and high surface expression 
levels (Figure 4-3). Integrin β1lo expression pattern in GL7+ GC-like B cells was similar to integrin α4 
expression pattern by being significantly higher in REDV organoids (vs. RGD organoids). Furthermore, 
integrin β1lo expression in RGD+REDV organoids was comparable to the one in RGD organoids and this 
outcome further suggested the dominant role of RGD-mediated αvβ3 signaling in GC-like B cells. While 
such trend was also apparent in GL7- NB-like B cells, the expression level in each peptide type was lower 
than the one exhibited by GL7+ GC-like B cells. Our analysis suggested that only 10% of the cells 
exhibited integrin β1hi expression and an opposite trend than β1lo was observed in both B cell subsets with 
a significantly higher expression level in RGD organoids (vs. REDV organoids). There was also no 
difference in expression level across both B cell populations. Focusing on integrin β1lo due to its presence 
in the majority of B cells in our immune organoids, we could infer its dependence on integrin ligand 
specificity and B cell activation state. 
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We next determined the expression levels of integrin αv and β3 subunits (Figure 4-3). Our data 
demonstrated a higher expression level for both integrins in REDV organoids (vs. RGD organoids). The 
expression levels of both integrin αv and β3 subunits were significantly lower in GL7- NB-like B cells 
when compared to those produced by GL7+ GC-like B cells. Similar to β1lo, both αv and β3 appeared to 
be dependent on integrin ligand type and B cell activation state. Such result was indicative of our earlier 
surface integrin expression in Chapter 1, where the expression level for these three subunits (αv, β3, and 
β1) were more upregulated in GC B cells (vs. naïve B cells). 
 
While integrin ligand has been presented continuously throughout 4 days of culture, we wanted to 
determine the temporal importance of integrin signaling. We then assessed the dependency of GL7 
surface marker emergence on the timing of αvβ3 integrin stimulation with Cilengitide addition at various 
time points following encapsulation. While we noticed a significant reduction in the number of GL7+ 
GC-like B cells (vs. untreated control) when the αvβ3 integrin-ligand interaction was blocked at t = 0, no 
such effect as seen with Cilengitide addition at later time points (1, 4, 12 h). These observations indicated 
that early αvβ3 integrin activation was critical for GC-like induction. Although a similar inhibitory effect 
was observed in GL7- NB-like B cells, this cell population proliferated significantly more than GC-like B 
cells in RGD organoids when Cilengitide was added at >1 hour post encapsulation. 
 
The decreased GC-like B cell generation could also be explained by the possible role of Cilengitide in 
inhibiting 40LB stromal cells adhesion to bioadhesive ligands. Since the spreading of 40LB stromal cells 
is important for ex vivo GC reaction [143], we studied the effect of Cilengitide addition in REDV 
organoids (Figure 4-4). While no reduction of GC-like B cell generation was observed, we observed an 
increase in GL7+ GC-like B cell number in REDV organoids when αvβ3 was blocked at 1 hour post-
fabrication. This outcome suggests the availability of αvβ3 stimulation under non-RGD growth conditions 
and further raises the possibility of αvβ3 regulatory role in GC-like B cells. 
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In order to test our assertion regarding integrin β3 expression in both RGD and non-RGD conditions, we 
performed confocal imaging and observed integrin β3 clustering in both groups (Figure 4-5). This 
observation suggested the importance of integrin β3 in GC-like B cell formation. The lack of clustering in 
2D condition further suggested the relevance of 3D matrix to study the role of integrin in GC reaction. 
 
4.6. Integrin Ligand Composition and Surface IgM BCR Characteristics 
 
We then explored IgM BCR signaling in GC-like B cells since BCR stimulation facilitated B cells 
activation prior to entry into GC and affinity-based selection in the light zone compartment [160]. While 
BCR signaling has been shown to promote the selective survival or expansion of GC-like B cells during 
the selection process, we have yet to fully understand the mechanism behind BCR-mediated signaling in 
enabling selection. It is possible that BCR on GC-like B cells produced a stronger or more sustained 
downstream signaling than the one seen in NB-like B cells. We were also interested in studying the 
interaction between integrin and BCR during GC reaction. We hypothesized that selective integrin ligand 
presentation will differentially alter BCR pattern and expression. 
 
We first looked into the temporal dependence of integrin signaling toward BCR expression by inhibiting 
RGD-mediated αvβ3 integrin stimulation via Cilengitide addition at various time points following 
encapsulation (Figure 4-6). The resulting data indicated a significant increase in the surface expression 
level of IgM BCR in GL7+ GC-like B cells (vs. untreated control) after immediate blocking with 
Cilengitide post encapsulation. But such effect was not seen with Cilengitide addition at later time points 
(1, 4, or 12 hours) did not. Cilengitide addition had no effect on GL7+ GC-like B cells in REDV-
presenting organoids. We next assessed the effect of blocking αvβ3 on IgM BCR when only REDV was 
present in the hydrogels (Figure 4-6). While such inhibition produced no effect on IgM BCR surface 
expression in GL7+ GC-like B cells, increased IgM BCR level was detected in GL7- NB-like B cells with 
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later Cilengitide addition. Since the timing of integrin stimulation controlled surface IgM BCR 
expression, we further hypothesized that integrin ligand type could control other BCR characteristics. 
 
In order to determine if integrin ligand specificity could modulate IgM BCR clustering and localization, 
confocal imaging was conducted to assess IgM BCR and integrin β3 subunit on the surface of CD19+ B 
cells (Figure 4-7). The resulting data demonstrated the formation of BCR clusters that co-localized with 
integrin β3 spots in REDV-functionalized hydrogels. On contrary, uniformly diffused IgM BCR with 
clustered integrin β3 was detected in RGD-functionalized hydrogels. When we looked into both RDG 
scrambled peptide and 2D co-culture control groups, IgM BCR also appeared to be uniformly diffused 
and yet no β3 integrin signal was found on the surface of B cells. 
 
We next determined whether integrin ligand type could alter surface IgM BCR expression level. Because 
we were also interested in understanding the role of cytokines in the presence of specific integrin ligands, 
we cultured immune organoids with an increasing IL-4 dose from 10 to 1000 ng/ml (Figure 4-8). While B 
cell number was not dependent on integrin ligand type or IL-4 cytokine amount, the percentage of IgM+ 
B cells was significantly higher in REDV organoids than the one in RGD organoids. Surface IgM BCR 
expression level was also significantly higher in REDV-functionalized organoids than in RGD-
functionalized organoids and this trend was consistent at any IL-4 dose. These data suggest that integrin 
ligand specificity could modulate surface IgM BCR expression level in the immune organoids. 
 
Since IL-4 cytokine addition during CD40 stimulation has been implicated in class switching from IgM to 
IgG1, we next assessed whether IL-4 concentration and integrin ligand specificity could modulate the 
generation of class-switched IgG1+ B cells (Figure 4-9). Unlike IgM BCR, the percentage of B cells 
expressing surface IgG1 appeared to be dependent on IL-4 concentration and the highest percentage was 
reached with 1000 ng/ml concentration of IL-4 in REDV organoids. No significant difference across 
peptide groups at lower IL-4 doses. In order to verify whether the observed differences were specific to 
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integrin ligands, we prepared hydrogel functionalized with 3mM RDG scrambled peptide. No difference 
was seen in the percentage of CD19+ IgG1+ B cells with RDG versus RGD at 1,000 ng/ml IL-4 cytokine 
concentration. Since the percentage of IgG1+ B cells in RDG group was lower than the one in REDV 
group, the high IgG1+ B cell percentage seen earlier appeared to be specific to REDV-functionalized 
immune organoids. It is important to note that CD40L was available through the 40LB cells in all 
conditions such that we observed the similar response between RGD and RDG groups. We also did not 
see any change in IgG1 expression level across peptide types. These data suggested that a higher dose of 
IL-4 cytokine led to an improved generation of IgG1+ B cells in the presence of REDV peptide. Future 
studies will be done to determine whether IgG1+ B cells originate from B cells with downregulated 
surface IgM and if the generation of IgG1+ B cell is indicative of class switching. 
 
In order to verify whether class switching into IgG1 isotype occurred in the immune organoids, we 
utilized Ezh2fl/fl Cγ1-cre transgenic mouse model (Figure 4-10). In this approach, Ezh2 excision will occur 
following the expression of Cre recombinase. Since Cre will be expressed following the transcription of 
Cγ1 and class switching with IL-4 is characterized by the replacement of Cµ with Cγ1, Ezh2 knockdown 
can serve as an indirect measure of class switching. We observed a significant decrease in the percentage 
of EZH2+ B cells in the KO group (vs. WT group). We also noted a significantly lower EZH2 expression 
in EZH2+ B cell population from the KO group (vs. WT group). These EZH2 reduction data suggested 
the occurrence of class switching into IgG1 isotype in our system. 
 
4.7. Discussion 
 
Although we have yet to fully understand the role of integrin ligands with regards to GC formation and 
BCR activation, more studies are being done to understand the role of integrin signaling during GC 
reaction. Several ex vivo studies have been focusing on the integrin-dependent adhesion between GC B 
cells and FDCs [34, 37]. A previously published study utilized in vivo models to show that distinct 
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integrin ligand presentations differentially modulate the GC reaction [97]. While some in vivo studies 
showed that the removal of a single pair of integrin subunits (e.g. α4β1) or integrin ligands did not greatly 
influence B cell entry into GC reaction, α4 integrin subunit deficiency has been shown to compromise B 
cell participation in GC response [97].  Considering the oversimplified 2D systems and the complexity of 
in vivo models, we utilized biomaterials-based modular immune organoids to study the role of specific 
integrin ligand presentation during GC formation. Based on previously published data on integrin ligands 
present in the GC compartment of lymphoid tissue, we chose to focus on both α4β1 and αvβ3 integrin 
subunits. In order to study the effect of stimulating a specific pair of integrin subunits, we functionalized 
the immune organoids with adhesive ligands specific for α4β1 and/or αvβ3 integrin subunits by 
functionalizing with REDV and/or RGD peptides, respectively. 
 
While we have yet to look into other GC-associated hallmark events (e.g. somatic hypermutation and 
selection), this current study demonstrated the role of integrin ligand specificity in engineering GC-like 
phenotype and BCR characteristics. We discovered that an improved GL7+ GC-like phenotype induction 
in REDV organoids when compared to the effect seen in RGD organoids. GC phenotype induction in 
RGD+REDV organoids was similar to the one seen in RGD organoids, suggesting the dominant and/or 
regulatory role of αvβ3 integrin in the lymphoid tissue. Unlike the RDG scrambled peptide and 2D co-
culture control groups, both RGD and REDV organoids clustered β3 integrin on the surface of B cells. 
 
This work also showed that surface IgM BCR could cluster and co-localize with β3 integrin subunit 
depending on the available adhesive ligand. Further investigations are required to determine the 
regulatory roles of αvβ3 integrins. We believe that the ability to control ex vivo GC reaction from several 
design parameters will provide us with a better understanding of B cell differentiation, enable the 
generation of high-affinity antigen-specific cells in culture and accelerate therapeutics development. 
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4.8. Materials and Methods 
 
4.8.1. Polymers, peptides, and compounds 
 
Four-arm PEG-MAL with 20 kDa molecular weight was purchased from Laysan Bio, Inc. (Arab, AL) 
with >90% purity. Integrin αvβ3-binding RGD peptide [145, 161, 162] (GRGDSPC, 96% purity), integrin 
α4β1-binding REDV peptide [163] (GREDVGC, 96% purity), and MMP-9 degradable VPM peptide 
(GCRDVPMSMRGGDRCG) were purchased from AAPPTec, LLC (Louisville, KY) with above 90% 
purity. Integrin αvβ3 inhibitor Cilengitide (a cyclic RGD) was purchased from Selleck Chemicals. 
Mitomycin C was purchased from Santa Cruz Biotechnology. Murine recombinant IL-4 was purchased 
from Peprotech (Rocky Hill, NJ). 
 
4.8.2. Cells 
 
Spleens were harvested from female C57BL/6 mice that were aged 10-16 weeks and purchased from the 
Jackson Laboratory (Bar Harbor, ME). Naïve B cells were isolated from digested spleen via negative 
selection through the EasySep Mouse B Cell Isolation Kit, purchased from Stem Cell Technologies 
(Vancouver, Canada). 40LB stromal cells were generated from NIH/3T3 fibroblasts genetically 
engineered to express membrane-bound CD40L and secrete B cell activating factor (BAFF) as previously 
described by us [143] and Nojima et al. [48]. 40LB stromal cells were cultured with high glucose DMEM 
medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) with all 
components bought from Thermo Fisher Scientific (Waltham, MA). All procedures were approved by 
Cornell University's Institutional Animal Care and Use Committee. 
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4.8.3. Antibodies 
 
Fluorophore-conjugated anti-mouse antibodies used for flow cytometry consist of anti-CD19 
(eBioscience, PE-Cy7, eBio1D3), anti-IgM (eBioscience, FITC, eB121-15F9), anti-IgG1 (eBioscience, 
APC, M1-14D12), anti-integrin αv (eBioscience, PE, RMV-7), anti-integrin β3 (eBioscience, FITC, 
2C9.G3), anti-integrin α4 (eBioscience, PE, R1-2), anti-integrin β1 (eBioscience, FITC, eBioHMb1-1), 
anti-GL7 (eBioscience, FITC and APC, GL-7), and anti-Fas (BD, APC, Jo2). Antibodies used for 
confocal microscopy included anti-mouse anti-integrin β3 (eBioscience, purified, armenian hamster, 
2C9.G3), anti-mouse anti-CD19 (eBioscience, purified, Rat, eBio1D3), anti-IgM (Abcam, purified, 
Rabbit, II/41), anti-armenian secondary antibody (Abcam, Alexa Fluor 488, Goat), anti-rat secondary 
antibody (Abcam, Alexa Fluor 594, goat), and anti-rabbit secondary antibody (Thermo Fisher Scientific, 
Alexa Fluor 633, goat). 
  
4.8.4. Immune organoid fabrication 
 
Synthetic hydrogel organoids with 7.5% (w/v) macromer concentration were fabricated using PEG-MAL 
and thiolated crosslinkers. PEG-MAL macromers were initially functionalized with thiolated bioadhesive 
peptides RGD or REDV with 4:1 macromer-to-peptide molar ratio. MMP-9 degradable VPM peptide and 
non-degradable DTT thiolated crosslinkers were combined at a 50:50 molar ratio and 4:1.5 macromer-to-
crosslinker molar ratio. All components were diluted using PBS++ solution with pH 7.4 and 1% HEPES. 
Naïve B cells with 40LB stromal cells were prepared and suspended in the crosslinker solution prior to 
cell encapsulation. After 5 µL of PEG-MAL macromer was placed in the middle of a well of a non-
treated 96 well plate, 5 µL of cell-containing crosslinker solution was injected into the initial droplet and 
mixed by pipetting up and down 5 times. Hydrogel droplets were prepared and cured for 15 min at 37° C 
inside cell culture incubator for complete crosslinking. Fresh RPMI 1640 medium supplemented with 
10% FBS, 1% P/S, and 10 ng/ml IL-4 was then added to the organoid culture. 
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4.8.5. Confocal microscopy imaging 
 
For imaging studies, synthetic hydrogel organoids were prepared as described above using uncoated 
glass-bottom (no. 1.5 coverslip and 20 mm glass diameter) 35mm dish from MatTek Corporation. On day 
4 post-encapsulation, the organoids were fixed with 4% paraformaldehyde, rinsed with PBS++, incubated 
with blocking buffer, stained with primary antibodies overnight, stained with secondary antibodies for 4 
hours, and then immediately imaged using Zeiss LSM 710 confocal microscope. Blocking buffer was 
prepared using PBS++ containing 20% goat serum. Staining was performed with flow buffer containing 
antibodies (1:500 dilution). Washing was done using PBS solution. 
 
4.8.6. Flow cytometry analysis 
 
After 4 days of culture, cells were harvested from the hydrogel organoids by enzymatic degradation for 1 
hour using a 125 U/ml collagenase-1 from Worthington Biochemical (Lakewood, NJ), dissolved in 
serum-free RPMI medium. Cells were then collected by passing the cell suspension through a 70 µm cell 
strainer (BD Falcon). Cells were re-suspended in flow buffer containing antibodies (1:500 dilution) and 
washed two times with the flow buffer solution. Flow buffer solution was prepared using PBS++ 
containing 2% (v/v) FBS and 5 mM EDTA. Flow cytometry data was acquired with Accuri C6 (BD 
Biosciences) and analyzed with FlowJo software package. 
 
4.8.7. Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism software with significance based on a p-value of 
less than 0.05. All studies were performed with five technical triplicates unless otherwise noted. 
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4.10. Figures 
 
Figure 4-1: Modular immune organoids with degradable crosslinker and bioadhesive ligand 
(A) Schematic representing PEG-MAL organoids modified with integrin-specific adhesive ligands and 
cross-linked with a mixture of MMP-9 degradable and non-degradable cross-linkers. (B,C) Phase image 
assessment of 40LB stromal cells in hydrogels with differing matrix degradability (B) and varying RGD 
peptide density (C). Matrix degradability study was performed at 3 mM RGD ligand density and ligand 
density study was conducted at 1:1 VPM +DTT cross-linking ratio. All images show 20× magnifications 
using a Nikon TE2000 microscope. (D) Stromal cells cultured in 3D immune organoids functionalized 
with integrin α4β1-binding REDV peptide and integrin αvβ3-binding RGD peptide. Cells were stained 
with phalloidin (actin) and DAPI (nucleus, false colored here for improved representation). Scale 20 µm. 
(E) Surface expression levels of CD40L in 40LB cells cultured for 4 days in RGD- or REDV-
functionalized immune organoids. 
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Figure 4-2: Integrin ligand specificity and stromal density on B cell activation 
(A) Gating schematic for the analysis of CD19+ GL7+ Fas+ GC-like B cells. (B-D) The number of 
CD19+ (B), CD19+ GL7+ (C), and CD19+ GL7+ Fas+ (D) cells in RGD and/or REDV-functionalized 
immune organoids. (E-F) The number of CD19+ (E) and CD19+ GL7+ cells as a function of 40LB 
seeding density in 3 mM RGD-functionalized immune organoids. Three stromal densities were used: 0, 
20,000, and 40,000 cells per organoid. Statistical significance (*) with regard to RGD organoid group (n 
= 5) was determined based on p < 0.05. Statistical test was conducted using ANOVA. Values are shown 
as mean ± SEM (n = 5). 
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Figure 4-3: Integrin subunit expression profile in activated B cells 
(A) Histogram representing the expression profile of α4 and β1 integrin subunits. (B) The MFI of α4 
integrin when cultured with specific integrin ligand type and density. (C,D) The MFI of β1 integrin in the 
subset of B cells expressing β1lo (C) and β1hi (D). (E,F) The MFI of αv integrin (E) and β3 integrin (F) on 
B cells when cultured in 3D organoids with specific integrin ligand type and density. Analysis was 
performed after 4 days of differentiation. Statistical significance (*) was determined based on p < 0.05. 
Statistical test was conducted using ANOVA. Values are shown as mean ± SEM (n = 5). 
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Figure 4-4: Temporal control of integrin ligand presentation on B cell activation 
Relative percentage of CD19+ GL7+ GC-like (left) and CD19+ GL7- non-GC-like B cells (right) 
following the addition of integrin αvβ3-inhibiting Cilengitide at indicated time points. Statistical 
significance (*) with regard to negative control group was determined based on p < 0.05. Statistical test 
was conducted using ANOVA. Values are shown as mean ± SEM (n = 5). 
 
 
Figure 4-5: Integrin β3 expression and clustering 
(Left) 3D reconstructed confocal images of REDV-functionalized organoid (left) and RGD-functionalized 
organoid (middle), and 2D co-culture system (bottom). (Right) A representative z-section from each 
culture condition is displayed to indicate localization of CD19 and integrin β3. Scale bar = 2 µm. 
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Figure 4-6: Temporal dependency of integrin−ligand interaction on IgM BCR expression 
IgM BCR expression was quantified for both CD19+ GL7+ GC-like (left) and CD19+ GL7− non-GC-like 
(right) B cells following culture in hydrogel functionalized with either REDV (red) or RGD (blue) in the 
presence of Cilengitide added at various time points in culture. IgM BCR expression was normalized to 
the one on B cells cultured in immune organoids functionalized with the corresponding integrin ligand 
and no Cilengitide treatment (negative control, NC, group). Statistical significance (*) with regard to 
negative control group was determined based on p < 0.05. Statistical test was conducted using ANOVA. 
Values are shown as mean ± SEM (n = 5). 
 
 
Figure 4-7: IgM BCR clustering and co-
localization with integrin β3 subunit 
Confocal z-sections of day 4 B cells cultured in 3D 
immune organoids functionalized with a specific 
peptide (REDV, RGD, or RDG scrambled peptide) 
or 2D co-culture control. Staining was done to 
indicate the localization of IgM BCR and integrin 
β3 subunit on the surface of CD19+ B cells with 
scale bar of 2 µm. 
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Figure 4-8: IgM BCR surface expression in 3D immune organoids and IL-4 concentration 
(A) Gating schematic for the analysis of IgM+ cells inside the organoid. (B-D) Quantitative analysis of 
CD19+ cell number (B), CD19+ IgM+ cell percentage (C), and IgM BCR MFI expression in CD19+ cells 
(D) following culture with increasing amounts of soluble recombinant IL-4 from 10 to 1000 ng/ml added 
into the organoid culture media. Statistical significance (*) with regard to RGD organoid group was 
determined based on p < 0.05. Statistical test was conducted using ANOVA. Values are shown as mean ± 
SEM (n = 5). 
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Figure 4-9: IgG1 BCR surface expression and IL-4 concentration 
(A) Analysis of IgG1+ CD19+ B cell percentage in REDV- or RGD-functionalized immune organoids 
with increasing IL-4 cytokine concentration. (B) Assessment of IgG1+ CD19+ B cell percentage in 
immune organoids functionalized with either RGD or scrambled RDG peptide. (C) Quantification of 
IgG1 BCR MFI expression in CD19+ B cells (right). Statistical significance (*) with regard to RGD 
organoid group was determined based on p < 0.05. Statistical test was conducted using ANOVA. Values 
are shown as mean ± SEM (n = 5). 
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Figure 4-10: Class switch assessment with Ezh2 KO mouse model 
The assessment of class switching based on Cre-mediated Ezh2 knockdown following Cγ1 transcription 
based on (A) the percentage of B cells with intracellular EZH2 expression and (B) the EZH2 intracellular 
expression level in EZH2+ B cell population. Statistical significance (*) with regard to WT group was 
determined based on p < 0.05. Statistical test was conducted using t test. Values are shown as mean ± 
SEM (n = 6).  
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CHAPTER 5  
 
Integrin Ligand and BCR Crosslinking Modulate Ex Vivo GC-like B Cell Phenotype 
 
5.1. Abstract 
 
Upon learning that integrin ligand specificity could modulate surface IgM BCR clustering and expression 
level, we studied if such effect would result in altered response toward BCR crosslinking. We learned that 
integrin ligand type determined responsiveness toward BCR stimulation in terms of GC reaction 
maintenance, ASC differentiation program, and phosphorylation of BCR target molecules. We also 
showed that BCR activation could produce resistance toward Fas-mediated apoptosis and this concept 
could be extended to enrich antigen-specific B cells from a mixed B cell population. Enrichment was 
assessed from the absolute number and relative percentage of antigen-specific GC-like B cells subset. 
Interestingly, integrin ligand specificity appeared to determine the percentage increase in antigen-specific 
GC-like B cells and the number of cells with fully bound BCR post-enrichment. These results suggested 
the importance of both integrin and BCR to control GC-like B cell phenotype inside immune organoids. 
 
5.2. Introduction 
 
In the previous chapter, we have demonstrated the ability of 3D immune organoid to induce the formation 
of GC-like B cells and the role of integrin ligand specificity in controlling the B cell activation process 
[164]. While we observed that integrin ligand type could modulate surface IgM BCR expression level and 
clustering, it is still unclear whether such change translates to any altered signaling pathway following 
BCR crosslinking. We also have yet to know if it is possible to control the phenotype of ex vivo GC-like 
B cells after the activation process. In order to answer these questions, we have to first functionalize 3D 
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immune organoid with a specific integrin ligand and then induce BCR crosslinking in culture prior to 
analyzing the resulting GC-like B cell phenotype. 
 
BCR crosslinking is defined as the binding of antigen by its corresponding BCR and this process typically 
occurs at two time points: early before GC induction and later during the selection process within GC LZ 
compartment. In the first phase, soluble antigen binding activates naïve B cells within the follicle and the 
activated B cells will migrate toward the interfollicular region for interaction with the corresponding 
antigen-specific Tfh cells [3]. Primarily driven by CD40-signaling, this cell-cell binding will initiate GC 
formation in the secondary lymphoid tissue. Over the course of GC reaction, two cellular compartments 
will develop and they can be distinguished based on their appearances under the microscope into DZ and 
LZ. While DZ tends to be associated with proliferating GC B cells, LZ generally consists of activated GC 
B cells that are undergoing key GC events (e.g. CSR, selection, and differentiation). LZ is also the site 
where the second phase of BCR crosslinking occurs with the ligand being FDC-bound antigen binding 
and this process will mediate the selection of high-affinity antigen-specific B cells. While researchers are 
still trying to understand the selection process, several mechanisms may occur in parallel. It has been 
proposed that a higher BCR affinity results in increased antigen uptake and greater density of peptide-
MHC complex on the surface of GC B cells, which in turn helps the high-affinity GC B cell clone to 
compete for survival signal from Tfh cells [1]. It has also been proposed that activated B cells without 
BCR signaling will be sensitive to Fas-induced apoptosis following FasL presentation by activated helper 
T cells [165]. These results suggest that BCR primarily functions by binding antigen and facilitating the 
selection process during the GC reaction. 
 
Nevertheless, there are still numerous open questions regarding the role of BCR in GC reaction. This can 
be illustrated by the recent finding that BCR signaling is suppressed in proliferating GC B cells and such 
inhibition appears to be necessary for GC maintenance [160]. Without the ex vivo capability of 
modulating BCR signaling and reconstituting the GC B cell selection process, it can be difficult to 
  102 
understand how BCR functions during GC reaction and what role it plays in modulating GC B cell 
phenotype. Such situation is compounded by the fact that GC B cell population is both rare and 
heterogeneous. With these challenges illustrating the need for a functional GC model, we improved our 
immune organoids with BCR crosslinking to initiate ex vivo ASC differentiation and selection.  
 
5.3. Approach 
 
Similar to our previously published modular immune organoid platform [164], we utilized 4-arm PEG-
MAL hydrogel in this study. The PEG-MAL macromer was first functionalized with thiolated integrin 
ligand peptide and then crosslinked to facilitate hydrogel formation using both non-degradable crosslinker 
DTT and dithiol protease-cleavable peptide crosslinker. The adhesive peptide molar concentration was 
adjusted to be 3.0 mM such that one arm of the PEG-MAL macromer would be functionalized with the 
integrin ligand peptide. From the cellular perspective, the organoid contained both primary murine naïve 
B cells and 40LB stromal cells. 40LB cells were derived from fibroblasts genetically engineered to 
present CD40L and secrete BAFF for facilitating B cell activation and inducing ex vivo GC-like B cell 
generation [48, 49, 143]. This stromal-driven approach allows the reconstitution of relevant signals. B 
cells were freshly isolated prior to each experiment while 40LB is maintained in culture. The immune 
organoids were prepared by encapsulating cells in the crosslinker mixture, placing each functionalized 
macromer droplet in several individual wells of a 96-well plate, mixing them with cell-containing 
crosslinker mixture to induce hydrogel polymerization, and finally curing the droplets at 37 °C for 15 
minutes before adding cell culture medium. 
 
For inducing BCR crosslinking in the organoid, we added soluble anti-IgM antibody into the cell culture 
medium immediately after encapsulation. Several studies have shown the use of anti-IgM antibody as 
antigen mimic to stimulate BCR signaling in B cells [20, 21, 166]. This approach was selected as we 
started with primary naïve B cells with heterogonous BCR that were isolated from WT mice and the use 
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of anti-IgM antibody will facilitate a consistent BCR stimulation across the entire B cell population. 
While the use of soluble anti-IgM antibody represents a simple but proven way to stimulate BCR on GC-
like B cells, it is important to reproduce the binding between a specific antigen and its corresponding 
BCR will be important to better model the selection process. 
 
In order to test the hypothesis that GC B cells with BCR stimulation are resistant toward Fas-induced 
apoptosis, Fas stimulation was conducted in a similar manner by adding soluble anti-Fas antibody into the 
cell culture medium. This approach was picked for several reasons. Some works have demonstrated that 
soluble anti-Fas antibody can induce Fas-induced cytotoxicity in certain cells [167, 168]. The technique 
was relatively simple because anti-Fas antibody can be added in soluble form. While FasL can produce a 
more consistent response across a broader range of cell types, FasL requires immobilization or 
oligomerization for its pro-apoptotic function [169, 170]. It is thus more challenging to use FasL since 
FasL has to be immobilized via matrix conjugation or membrane-bound presentation.  
 
For studying antigen-specific GC-like B cell enrichment, we utilized primary B cells isolated from B1-8hi 
mice. This mouse model was generated with gene targeting to introduce B1-8 variable region (VH) 
containing point mutations that conferred higher 4-hydroxy-3-nitrophenyl (NP) affinity into the 
immunoglobulin heavy chain (IgH) locus [171]. Such system can facilitate the specific binding of NP 
hapten because B1-8 heavy chain paired with λ1 light chain can bind NP with an affinity of 5 x 105 M-1 
and the additional point mutations will further increase the affinity to 5 x 106 M-1. It has also been shown 
that the heavy chain has a dominant role in determining affinity and light chain mutations have little 
influence toward affinity [160]. Soluble NP hapten was therefore used as the model antigen to target NP-
specific B cells throughout the selection experiments. 
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5.4. GC Marker Downregulation with BCR Crosslinking 
 
We first hypothesized that BCR crosslinking will reduce GC phenotype with a greater effect seen in 
REDV-functionalized hydrogel due to the previous data indicating increased clustering and greater 
expression level of surface IgM BCR. In order to test this hypothesis, modular immune organoids 
incorporating REDV or RGD peptide were prepared and then cultured with increasing concentration of 
soluble anti-IgM antibody. Assessment of GC phenotype was conducted by analyzing the expression 
level of two intracellular GC markers - BCL6 and EZH2 - in CD19+ GL7+ GC-like B cells. 
 
BCL6 transcription factor regulates GC B cell development primarily by suppressing the transcription of 
ASC differentiation genes and this marker is only expressed in GC B cells [4]. BCL6 has also been shown 
to facilitate GC B cell proliferation in various ways including the suppression of apoptotic and cell cycle 
arrest responses. The importance of BCL6 toward GC reaction is further supported by the lack of GC 
formation in BCL6-deficient mice. Our hypothesis on BCL6 downregulation with anti-IgM antibody 
originated from the report that BCR stimulation targets BCL6 for rapid degradation [172]. We first 
looked into BCL6 expression level and observed that the 0 - 2.5 µg/ml soluble anti-IgM antibody 
concentration range resulted in a significantly higher BCL6 expression level in REDV organoids when 
compared to the one seen in RGD organoids (Figure 5-1). While a significant reduction in BCL6 level 
could already be seen at 0.5 and 2.5 µg/ml doses in REDV organoids, a similar effect was only seen at 2.5 
µg/ml dose in RGD organoids. At 5 µg/ml dose, BCL6 expression was lowered to the same level in both 
organoid types. Looking into the change in expression level after normalization based on BCL6 level in 0 
µg/ml dose group, a greater reduction in every dose could be seen with REDV organoids. These 
observations indicated that the use of REDV-functionalized organoid resulted in greater BCL6 induction 
during ex vivo GC reaction and increased responsiveness toward BCR stimulation. 
 
  105 
In addition to BCL6, EZH2 is another relevant GC marker. EZH2 is specifically expressed in GC B cells 
and primarily works by epigenetically silencing differentiation genes [125]. EZH2 is critical for the GC 
reaction because GC hyperplasia could be observed with mutant Ezh2 and GC reaction failed to form in 
Ezh2 KO mice. We then studied the change in EZH2 expression after BCR stimulation and noticed a 
significant reduction in the percentage of EZH2+ GC-like B cells with 5.0 µg/ml anti-IgM antibody dose 
in both organoid types (Figure 5-2). Without BCR stimulation, a greater EZH2+ population was seen in 
REDV group than RGD group. While the percentage of EZH2+ cells was similar at 5 µg/ml dose across 
integrin types, a greater drop occurred in REDV group when compared to that in RGD group.  
 
Since EZH2 works by catalyzing the methylation of lysine 27 residue of histone 3 (H3K27), we further 
validated this EZH2+ percentage reduction by looking into the percentage of B cells with trimethylated 
histone H3 lysine 27 (H3K27Me3) and observed a slight but significant decline in H3K27Me3+ B cells. 
Looking into EZH2 expression level in EZH2+ GC-like B cells, we observed a similar trend with greater 
expression level in REDV group and decline to the same level following the addition of 5 µg/ml soluble 
IgM antibody (Figure 5-3). Assessing the change in expression level after normalization based on the 
EZH2 level in EZH2+ cells with 0 µg/ml anti-IgM antibody, a greater reduction could be seen in REDV-
functionalized organoid. Similar to the BCL6 data, these observations demonstrated both improved EZH2 
induction during ex vivo GC reaction and greater sensitivity toward BCR stimulation in REDV group. 
 
5.5. ASC Marker Upregulation with BCR Crosslinking 
 
Upon observing the reduced expression of intracellular GC markers (BCL6 and EZH2) upon BCR 
stimulation and realizing that these markers function by suppressing GC B cell differentiation, we next 
hypothesized that BCR crosslinking could improve the expression of relevant differentiation genes. In 
order to test this hypothesis, modular immune organoids functionalized with REDV or RGD peptide were 
  106 
prepared and then exposed to the soluble anti-IgM antibody at varying doses. Assessment of ASC 
differentiation was done based on the expression level of intracellular IRF4 in organoid-derived B cells. 
 
IRF4 is a transcription factor that regulates GC B cell terminal differentiation toward the ASC fate, occurs 
later during the GC process, and suppresses BCL6 for terminating the GC reaction [4]. We developed our 
hypothesis regarding IRF4 upregulation with BCR stimulation after learning the role of BCR signaling in 
inducing IRF4 expression in B cells [173]. Our data demonstrated the increase in IRF4 expression 
following the addition of soluble anti-IgM antibody into the immune organoids (Figure 5-4). While a 
statistically significant increase in IRF4 level was observed at 0.5 – 5 µg/ml doses in REDV group, such 
significance was only noticed at 2.5 – 5 µg/ml in RGD group. A greater IRF4 expression was seen at each 
dose in REDV groups when compared to the one in RGD group. Looking at the change in expression 
level after normalization based on the level in 0 µg/ml dose group, a greater increase in IRF4 could be 
seen with REDV group when contrasted to the one seen in RGD group. These observations suggested that 
while BCR crosslinking facilitates IRF4 induction in both REDV and RGD immune organoids, a greater 
responsiveness toward BCR stimulation was seen in REDV group. 
 
Since IRF4 has been proposed to act either upstream or parallel with BLIMP1 and BLIMP1 is known to 
facilitate GC B cell differentiation toward the ASC pathway, we followed up our IRF4 observation by 
looking into the expression level of intracellular BLIMP1 in organoid-derived B cells (Figure 5-5). Our 
data indicated that 5 µg/ml anti-IgM antibody addition produced a significant increase in BLIMP1 
expression. As CD138 is a well-known ASC marker that gets upregulated throughout the terminal 
differentiation following GC exit, we also assessed CD138 surface expression level (Figure 5-5). We saw 
that CD138 was significantly increased following 5 µg/ml anti-IgM antibody addition. These trends 
suggested that BCR stimulation indeed facilitates the ASC differentiation program in B cells. 
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While the aforementioned differentiation markers are highly upregulated in ASCs, they are also expressed 
by a subset of LZ GC B cells [4]. Under the assumption that these ASC markers are generated upon BCR 
stimulation, LZ GC B cells may demonstrate a more differentiated phenotype because of the interaction 
between BCR and FDC-bound antigen in the LZ compartment. Since LZ B cells can be characterized 
with CD83 [174], we hypothesized that organoid-derived B cells may share a similar set of surface 
markers following BCR stimulation and looked into the CD83 expression on B cell surface. Our data 
demonstrated a small but significant increase in the percentage of CD83+ B cells following anti-IgM 
antibody addition and the majority of B cells were CD83+ in the immune organoids (Figure 5-6). 
Analysis on the CD83 expression level on the surface of CD83+ B cells also indicated a significant 
increase following BCR crosslinking. This data interestingly suggested that CD83+ phenotype, which 
was indicative of LZ phenotype, could be induced upon the addition of soluble anti-IgM antibody. 
 
Although CD83 function is still unclear, CD83 has been proposed to help stabilize MHC Class II 
(MHCII) expression during its constant turnover throughout the GC reaction and therefore Cd83 KO mice 
have been shown to have a reduced GC B cell population with MHCIIhi [175]. Another study also showed 
that knocking out Cd83 resulted in a defective MHCII upregulation after B cell stimulation [176]. We 
hypothesized that BCR-induced CD83 upregulation would increase MHCII surface level and we then 
assessed MHCII expression on the surface of organoid-derived B cells after BCR stimulation in culture. 
Analyzing the expression of MHCII subclass I-A and I-E in B cells isolated from C57BL/6J mice, our 
data showed a significant increase in MHCII expression with 5 µg/ml anti-IgM antibody dose (Figure 
5-7). Looking into the relative expression level after normalization to the expression in 0 µg/ml dose, we 
saw a 40% increase in MHCII surface expression and such trend further supported the functional aspect 
of CD83 upregulation seen earlier upon BCR stimulation. 
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5.6. Phosphorylation of BCR Target Proteins 
 
While we have observed changes in GC-like B cell phenotype following BCR stimulation and differential 
responses across integrin ligand groups, we have yet to determine if BCR crosslinking effects are 
mediated by the phosphorylation of BCR target proteins and whether such process is dependent on 
integrin ligand specificity. BCR stimulation can be assessed by analyzing a set of proteins that are known 
to undergo phosphorylation. These target proteins are located downstream of BCR signal transduction 
component and their phosphorylation can be measured upon BCR crosslinking. While there are many 
target proteins, we looked into three representative members: pSYK, pBTK, and pERK. Upon antigen 
binding, SRC family kinases are activated quickly prior to the phosphorylation of both SYK and BTK 
[177]. ERK phosphorylation occurs downstream of SYK activation [160] and therefore can be induced 
following BCR stimulation [178].  
 
Our data showed a significant increase in the amount of pBTK in REDV group with 5 µg/ml anti-IgM 
antibody addition (Figure 5-8). Analysis on the normalized expression level indicated that pBTK amount 
almost doubled after BCR stimulation in REDV group. In contrast, no significant increase in pBTK could 
be seen in RGD group. Analysis of the phosphorylation of pSYK (Figure 5-9) and pERK1/2 (Figure 5-10) 
also demonstrated a significant increase in both phosphorylated proteins after BCR crosslinking in REDV 
group. Similar to the previous data, no significant increase in both phosphorylated proteins could be 
detected in RGD group. These observations suggested a more sustained BCR signaling throughout 4 days 
of culture in REDV organoids when contrasted to the one seen in the RGD group. This data further 
suggested the increased BCR responsiveness in REDV-functionalized organoid. 
 
 
 
 
  109 
5.7. Enrichment of Antigen-specific GC-like B Cells 
 
Having demonstrated the role of BCR in inducing ASC differentiation program, the next step is to 
determine its importance during the selection process. Fas-dependent elimination of specific B cell clones 
has been proposed based on the observed elimination of B cells that have desensitized BCR when co-
cultured with helper T cells and such process can be prevented with Fas deficiency on B cell surface 
[165]. This process may be explained by the observation that CD40L-stimulated B cells become 
extremely sensitive to Fas-mediated apoptosis and BCR crosslinking will induce resistance to Fas [166]. 
Since our modular immune organoid platform contained CD40L-presenting 40LB stromal cells and 
demonstrated Fas upregulation during ex vivo GC reaction, we hypothesized that Fas-mediated selection 
could be modeled with Fas-mediated apoptosis occurring only in GC-like B cells without BCR 
stimulation. Our data indicated a significant reduction in the number of CD19+ GL7+ GC-like B cells 
with 5 µg/ml anti-Fas antibody addition and yet no such effect was seen in the presence of 5 µg/ml anti-
IgM antibody (Figure 5-11). This observation demonstrated the sensitivity of GC-like B cells toward Fas-
dependent cytotoxicity and BCR crosslinking conferred resistance against Fas stimulation. 
 
We further hypothesized that such approach could be applied to selectively enrich a particular GC B cell 
clone with antigen-bound GC B cells being resistant toward Fas-induced apoptosis. In order to test this 
concept, we used the B1-8hi mouse model to obtain primary B cells containing a high number of NP-
specific B cells. In the B1-8hi mouse model, gene targeting was used to introduce pre-recombined VHDJH 
genes into the mouse immunoglobulin heavy chain locus [171] and the resulting B1-8 heavy chain can 
bind NP hapten upon pairing with the Igλ light chain [179]. An additional mutation of Trp to Leu was 
introduced at codon 33 of the B1-8 heavy chain to increase the NP binding affinity by a factor of 10 
[171]. We then developed a gating schematic to separate non-specific and NP-specific GC-like B cells for 
the enrichment study with antigen specificity identified based on positive staining by fluorophore-
conjugated NP and/or anti-NP antibody (Figure 5-12). Such approach enabled us to identify NP-specific 
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B cells with free BCR and/or NP-bound BCR. We first examined the NP antigen dose required to obtain a 
high number of NP-bound GC-like B cells and this experiment was carried out by increasing the amount 
of soluble NP antigen in the cell culture medium. Our data showed that 3332 nM NP dose produced a 
significantly higher NP-bound GC-like B cells and lower doses produced no detectable NP-bound 
population at all (Figure 5-13). The data also showed that while NP-bound population increased 
significantly, the percentage of NP-specific GC-like B cells was not altered by high dose NP addition. 
 
Having shown the ability to generate NP-bound GC B cell population in the organoid, we next tried to 
selectively enrich NP-specific population with Fas stimulation using 5 µg/ml anti-Fas antibody. Fas 
stimulation appeared to significantly decrease the number of non-specific CD19+ GL7+ GC-like B cells 
and increase the number of NP-specific CD19+ GL7+ B cells (Figure 5-14). From analyzing the GC-like 
B cell composition, Fas stimulation appeared to significantly decrease the percentage of non-specific 
CD19+ GL7+ GC-like B cells and increase the percentage of NP-specific CD19+ GL7+ GC-like B cells. 
Such outcome suggested the enrichment of antigen-specific GC-like B cells in the immune organoids. 
 
We next studied if integrin ligand specificity could modulate this enrichment process because we 
observed an improved BCR responsiveness with REDV-functionalized hydrogels. The final NP-specific 
GC-like B cell percentage appeared to be similar in both peptide groups following soluble NP antigen 
presentation and Fas stimulation (Figure 5-15). But further analysis of the GC-like B cells post-
enrichment suggested a greater increase in NP-specific GC-like B cell population in REDV group during 
selection and a different composition of NP-specific GC-like B cells (Figure 5-16). We specifically 
observed a significantly higher percentage of fully bound GC-like B cells in REDV-functionalized 
immune organoids when compared to the one in RGD group (Figure 5-17). This trend was followed by a 
significantly greater percentage of partially bound GC-like B cells in RGD organoids than the one in 
REDV organoids. This observation implied the integrin ligand dependency of this ex vivo selection. 
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5.8. Discussion 
 
This chapter describes how BCR crosslinking can modulate the phenotype of GC-like B cells in our 
modular immune organoids by reducing GC markers and inducing ASC differentiation markers. While 
similar trends could be observed in both immune organoid types, greater GC phenotype induction and 
improved responsiveness toward BCR stimulation were seen in REDV-functionalized organoids. Because 
BCR activation produced GC-like B cell phenotype resembling the one seen in the GC compartment 
associated with both differentiation and selection, we attempted to reconstitute the selection process with 
Fas-based negative pressure. Our enrichment method increased antigen-specific GC-like B cell 
percentage with soluble antigen addition and Fas stimulation. This approach also showed a higher 
increase in both NP-specific GC-like B cells and the percentage of fully bound GC-like B cell in REDV-
functionalized immune organoids. These observations suggested that 3D modular immune organoids 
could control over GC phenotype and enrich a particular antigen-specific GC B cell clone. 
 
In this study, we have provided important design parameters for controlling the phenotype of ex vivo GC-
like B cells and reconstituting two hallmark GC events. Further investigations are required to understand 
whether introducing a particular stimulation at a specific time point can differentially alter GC-like B cell 
phenotype. We also need to understand how the extracellular cues can be presented to induce antibody 
secretion and generate long-lived ASCs. The introduction of additional cell types will be important to 
increase the complexity of our immune organoids and understand cell-cell interactions that occur within 
secondary lymphoid tissues. We anticipate that the ability to fully control immune reactions ex vivo will 
provide us with the ability to reconstitute the important elements of humoral immune response generation 
for rapid antibody development and improved understanding of B cell generation. 
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5.9. Materials and Methods 
 
5.9.1. Compounds 
 
Four-arm PEG-MAL with 20 kDa molecular weight was purchased from Laysan Bio (Arab, AL) with 
>90% purity. Integrin αvβ3-binding RGD peptide [145, 161, 162] (GRGDSPC, >90% purity), integrin 
α4β1-binding REDV peptide [163] (GREDVGC, >90% purity), and MMP-9 degradable VPM peptide 
(GCRDVPMSMRGGDRCG, >90% purity) were purchased from AAPPTec (Louisville, KY). 
 
5.9.2. Cells 
 
For experiments involving WT B cells, spleens were harvested from female C57BL/6 mice (Stock #: 
000664) aged 10-18 weeks from the Jackson Laboratory (Bar Harbor, ME). For experiments utilizing 
antigen-specific B cells, spleens were obtained from male B1-8hi mice (Stock #: 007594) aged 10-12 
weeks from the Jackson Laboratory (Bar Harbor, ME). Splenocyte suspension was obtained by 
mechanical digestion. Naïve B cells were isolated from splenocyte with EasySep Mouse B Cell Isolation 
Kit from Stem Cell Technologies (Vancouver, Canada). 40LB cells were generated from NIH/3T3 
fibroblasts genetically engineered to express CD40L and secrete BAFF as previously described [48, 143]. 
40LB cells were cultured with high glucose DMEM medium containing 10% FBS and 1% P/S with all 
components bought from Thermo Fisher Scientific (Waltham, MA). 40LB cells were mitotically inhibited 
prior to encapsulation with Mitomycin C from Santa Cruz Biotechnology (Dallas, TX). All procedures 
were approved by Cornell University's Institutional Animal Care and Use Committee. 
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5.9.3. Antibodies 
 
Anti-mouse antibodies used for flow cytometry included anti-CD19 (eBioscience, PE-Cy7, eBio1D3), 
anti-GL7 (eBioscience, Alexa Fluor 488, GL-7), anti-BCL6 (eBioscience, PE, BCL-DWN), EZH2 
(eBioscience, eFluor 660, AC22), anti-H3K27Me3 (Cell Signaling Technology, Alexa Fluor 488, 
C36B11), anti-IRF4 (eBioscience, PE, 3E4), anti-BLIMP1 (BD Pharmingen, Alexa Fluor 647, 5E7), anti-
CD138 (Thermo Fisher, APC, 300506), anti-CD83 (eBioscience, eFluor 660, Michel-17), anti-MHC 
Class II (BD Pharmingen, I-A/I-E, PE, 2G9), anti-p-Btk (eBioscience, Tyr551, PE, M4G3LN), anti-p-Syk 
(eBioscience, Tyr348, APC, moch1ct), and anti-p-Erk1/2 (eBioscience, Thr202/Tyr204, PerCP-eFluor 
710, MILAN8R). NP-specific GC-like B cells assessment was carried out with fluorophore-conjugated 
NP (PE, Biosearch Technologies) to target free NP-specific BCR and anti-mouse anti-NP antibody 
(Alexa Fluor 647, Novus Biologicals, B1-8) to target BCR-bound NP. 
 
5.9.4. Soluble Factors 
 
Murine recombinant IL-4 was purchased from Peprotech (Rocky Hill, NJ). BCR activation was 
performed with the anti-mouse anti-IgM antibody (eBioscience, II/41). Fas stimulation was achieved with 
the anti-mouse anti-Fas antibody (BD Pharmingen, Jo2). NP antigen was introduced with soluble NP(17)-
OVA (Biosearch Technologies, 17 NP-to-OVA conjugation/molar ratio). These soluble factors were 
mixed with cell culture medium and added into the organoid immediately following encapsulation. 
  
5.9.5. Immune organoid fabrication 
 
Synthetic immune organoids containing 7.5% PEG-MAL were fabricated using PEG-MAL macromer, 
adhesive peptides, and crosslinkers. PEG-MAL macromers were initially functionalized with thiolated 
adhesive peptides RGD or REDV with 4:1 MAL-to-peptide molar ratio for 30 minutes at 37 °C. MMP-9 
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degradable VPM peptide and non-degradable DTT crosslinkers were combined at a 50:50 VPM-to-DTT 
molar ratio and 4:1.5 MAL-to-crosslinker molar ratio. All components were diluted using PBS++ solution 
with pH 7.4 and 1% HEPES. Naïve B cells and 40LB stromal cells were suspended in the crosslinker 
solution prior to cell encapsulation. After 5 µL of PEG-MAL macromer solution was placed in the middle 
of a well of a non-treated 96 well plate, 5 µL of cell-containing crosslinker solution was injected into the 
droplet and mixed by pipetting 5 times. Hydrogel droplets were prepared and cured for 15 min at 37° C 
for complete crosslinking. Fresh RPMI 1640 medium supplemented with 10% FBS, 1% P/S, and 10 
ng/ml IL-4 was then added to each organoid. 
 
5.9.6. Flow cytometry analysis 
 
Cells were harvested from the organoids after 4 days of culture with enzymatic degradation for 1 hour 
using a 125 U/ml Collagenase Type 1 (Worthington Biochemical) dissolved in serum-free RPMI 
medium. Cells suspension was then filtered to remove gel debris using MultiScreen Mesh Filter Plates 
with 96 Well Receiver Plate (EMD Millipore). Cells were re-suspended in FACS buffer containing 
antibodies (1:500 dilution), incubated on ice in the dark for 45 minutes, and then re-suspended in FACS 
buffer. Intracellular marker staining was performed with one-step protocol for intracellular (nuclear) 
proteins using eBioscience Foxp3 / Transcription Factor Staining Buffer Set. Phosphorylation signaling 
protein staining was conducted with two-step protocol for fixation/methanol using eBioscience 
Intracellular Fixation and Permeabilization Buffer Set. FACS buffer was prepared using PBS++ 
containing 2% (v/v) FBS and 5 mM EDTA. Flow cytometry data were acquired using Accuri C6 Flow 
Cytometer (BD Biosciences) and analyzed with FlowJo software package. 
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5.9.7. Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism software with significance based on a p-value of 
less than 0.05. All studies were performed with five technical triplicates unless otherwise noted. 
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5.11. Figures 
A B 
  
 
Figure 5-1: BCL6 intracellular expression in 3D immune organoids and BCR crosslinking 
BCL6 (A) intracellular MFI expression level and (B) percent change in expression level normalized to 0 
µg/ml dose group in CD19+ GL7+ GC-like B cells was assessed for both RGD- and REDV-
functionalized immune organoids with varying amount of soluble anti-IgM antibody added to induce 
BCR crosslinking. Statistical significance (*) with regard to 0 µg/ml dose group was based on p < 0.05. 
Red statistical significance sign indicates comparison with the corresponding dose group from another 
peptide (RGD). Values are shown as mean ± SEM (n = 6). 
 
A B 
  
 
Figure 5-2: EZH2 assessment in 3D immune organoids and BCR crosslinking 
(A) Percentage of EZH2+ GC-like B cells in both RGD- and REDV-functionalized immune organoids 
with varying amount of soluble IgM antibody added to induce BCR crosslinking. (B) Percentage of 
H3K27Me3+ B cells with 0 or 5 µg/ml anti-IgM antibody. Statistical significance (*) with regard to 0 
µg/ml dose group was based on p < 0.05. Red statistical significance sign indicates comparison with the 
corresponding dose group from another peptide (RGD). Values are shown as mean ± SEM (n = 6). 
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Figure 5-3: EZH2 intracellular expression in 3D immune organoids and BCR crosslinking 
EZH2 (A) intracellular MFI expression level and (B) percent change in expression level normalized to 0 
µg/ml dose group in CD19+ GL7+ EZH2+ GC-like B cells was assessed for both RGD- and REDV-
functionalized immune organoids with varying amount of soluble anti-IgM antibody added to induce 
BCR crosslinking. Statistical significance (*) with regard to 0 µg/ml dose group was based on p < 0.05. 
Red statistical significance sign indicates comparison with the corresponding dose group from another 
peptide (RGD). Values are shown as mean ± SEM (n = 6). 
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Figure 5-4: IRF4 intracellular expression in 3D immune organoids and BCR crosslinking 
IRF4 (A) intracellular MFI expression level and (B) percent change in expression level normalized to 0 
µg/ml dose group in CD19+ B cells was assessed for both RGD- and REDV-functionalized immune 
organoids with varying amount of soluble anti-IgM antibody added to induce BCR crosslinking. 
Statistical significance (*) with regard to 0 µg/ml dose group was based on p < 0.05. Red statistical 
significance sign indicates comparison with the corresponding dose group from another peptide (RGD). 
Values are shown as mean ± SEM (n = 6). 
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Figure 5-5: ASC marker expression in 3D immune organoids and BCR crosslinking 
(A) BLIMP1 intracellular MFI expression level with varying amount of soluble IgM antibody added to 
induce BCR crosslinking. (B) CD138 surface MFI expression level with 0 or 5 µg/ml anti-IgM antibody. 
Statistical significance (*) with regard to 0 µg/ml dose group was based on p < 0.05. Values are shown as 
mean ± SEM (n = 6 for A and n = 7 for B). 
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Figure 5-6: CD83 expression in 3D immune organoids and BCR crosslinking 
(A) Percentage of CD83+ B cells and (B) CD83 surface MFI expression level in CD83+ B cells with 
varying amount of soluble anti-IgM antibody added to induce BCR crosslinking. Statistical significance 
(*) with regard to 0 µg/ml dose group was based on p < 0.05. Values are shown as mean ± SEM (n = 6). 
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Figure 5-7: MHC Class II surface expression in 3D immune organoids and BCR crosslinking 
MHC Class II (A) surface MFI expression level and (B) percent change in expression level normalized to 
0 µg/ml dose group in CD19+ B cells with varying amount of soluble anti-IgM antibody added to induce 
BCR crosslinking. Statistical significance (*) with regard to 0 µg/ml dose group was determined on p < 
0.05. Values are shown as mean ± SEM (n = 6). 
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Figure 5-8: pBTK intracellular expression in 3D immune organoids and BCR crosslinking 
pBTK (A) intracellular MFI expression level and (B) percent change in expression level normalized to 0 
µg/ml dose group in CD19+ B cells was assessed for both RGD- and REDV-functionalized immune 
organoids with varying amount of soluble anti-IgM antibody added to induce BCR crosslinking. 
Statistical significance (*) with regard to 0 µg/ml dose group was determined on p < 0.05. Values are 
shown as mean ± SEM (n = 5). 
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Figure 5-9: pSYK intracellular expression in 3D immune organoids and BCR crosslinking 
pSYK (A) intracellular MFI expression level and (B) percent change in expression level normalized to 0 
µg/ml dose group in CD19+ B cells was assessed for both RGD- and REDV-functionalized immune 
organoids with varying amount of soluble anti-IgM antibody added to induce BCR crosslinking. 
Statistical significance (*) with regard to 0 µg/ml dose group was determined on p < 0.05. Values are 
shown as mean ± SEM (n = 5). 
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Figure 5-10: pERK1/2 intracellular expression in 3D immune organoids and BCR crosslinking 
pERK1/2 (A) intracellular MFI expression level and (B) percent change in expression level normalized to 
0 µg/ml dose group in CD19+ B cells was assessed for both RGD- and REDV-functionalized immune 
organoids with varying amount of soluble anti-IgM antibody added to induce BCR crosslinking. 
Statistical significance (*) with regard to 0 µg/ml dose group was determined on p < 0.05. Values are 
shown as mean ± SEM (n = 5). 
 
0
200
400
600
800
1000
M
ed
ia
n 
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (M
FI
)
pSYK
*
ns
RGD
+
0 µg/ml
IgM Ab
RGD
+
5 µg/ml
IgM Ab
REDV
+
0 µg/ml
IgM Ab
REDV
+
5 µg/ml
IgM Ab
0
25
50
75
100
125
150
Ex
pr
es
si
on
 L
ev
el
 (%
)
(N
or
m
al
iz
ed
 to
 0
 µ
g/
m
l D
os
e 
G
ro
up
)
pSYK
*
ns
RGD
+
0 µg/ml
IgM Ab
RGD
+
5 µg/ml
IgM Ab
REDV
+
0 µg/ml
IgM Ab
REDV
+
5 µg/ml
IgM Ab
0
200
400
600
800
1000
M
ed
ia
n 
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (M
FI
)
pERK1/2
*
ns
RGD
+
0 µg/ml
IgM Ab
RGD
+
5 µg/ml
IgM Ab
REDV
+
0 µg/ml
IgM Ab
REDV
+
5 µg/ml
IgM Ab
0
25
50
75
100
125
150
Ex
pr
es
si
on
 L
ev
el
 (%
)
(N
or
m
al
iz
ed
 to
 0
 µ
g/
m
l D
os
e 
G
ro
up
)
pERK1/2
*
ns
RGD
+
0 µg/ml
IgM Ab
RGD
+
5 µg/ml
IgM Ab
REDV
+
0 µg/ml
IgM Ab
REDV
+
5 µg/ml
IgM Ab
  121 
 
 
 
Figure 5-11: Relative GC-like B cell number with BCR crosslinking and Fas stimulation 
Analysis was conducted on GC-like B cells in the presence of 5 µg/ml anti-IgM antibody with or without 
5 µg/ml soluble Fas antibody. Statistical significance (*) with regard to 0 µg/ml dose group was 
determined on p < 0.05. Values are shown as mean ± SEM (n = 7). 
 
 
 
Figure 5-12: Gating schematic for antigen-specific GC-like B cell analysis 
Gating schematic was prepared to analyze NP-specific and non-specific GC-like B cells. Gate was 
prepared based on the binding of fluorophore-conjugated NP and/or antibody against NP (left). Gating 
approach was demonstrated for GC-like B cells left unstained or stained with both fluorophore-
conjugated NP and antibody against NP (right). 
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Figure 5-13: Antigen-bound GC-like B cell percentage with soluble NP antigen addition 
(A) Quantification of NP-bound CD19+ GL7+ GC-like B cells with varying amount of soluble NP 
antigen. (B) Visualization of CD19+ GL7+ GC-like B cell composition at both 0 and 3332 nM soluble 
NP antigen dose. Statistical significance (*) with regard to 0 nM dose group was determined on p < 0.05. 
Values are shown as mean ± SEM (n = 7). 
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Figure 5-14: GC-like B cells with soluble NP addition and/or Fas stimulation 
GC-like B cell analysis in (A) absolute number and (B) relative composition percentage in the presence of 
soluble NP antigen with or without soluble Fas antibody. Analysis was conducted on both antigen-
specific (NP+) and non-specific (NP-) groups. Statistical significance (*) with regard to 0 µg/ml anti-Fas 
antibody dose group was determined on p < 0.05. Values are shown as mean ± SEM (n = 7). 
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Figure 5-15: Simplified GC-like B cell composition with soluble NP antigen and Fas stimulation 
GC-like B cell composition in (A) RGD- and (B) REDV-functionalized immune organoids in the 
presence of soluble NP antigen with or without soluble anti-Fas antibody. Analysis was done on antigen-
specific (blue) and non-specific (yellow) GC-like B cells. Values are shown as mean ± SEM (n = 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-16: Detailed GC-like B cell composition with soluble NP antigen and Fas stimulation 
Detailed GC-like B cell composition in (A) RGD- and (B) REDV-functionalized immune organoids in 
the presence of soluble NP antigen with or without soluble anti-Fas antibody. Analysis was done on 
partially bound (grey), fully bound (blue), unbound (red), and non-specific (yellow) GC-like B cells. 
Values are shown as mean ± SEM (n = 7). 
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Figure 5-17: Quantification of GC-like B cell subtype with soluble NP antigen and Fas stimulation 
Quantified GC-like B cell subsets in RGD- and REDV-functionalized immune organoids in the presence 
of soluble NP antigen with or without soluble anti-Fas antibody. Analysis was conducted on partially 
bound (Ag+ Ab+), unbound (Ag+ Ab-), fully bound (Ag- Ab+), and non-specific (Ag- Ab-) groups. 
Statistical significance (*) with regard to the same subtype and another peptide (RGD) was determined on 
p < 0.05. Values are shown as mean ± SEM (n = 7). 
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CHAPTER 6  
 
Research Discussion 
 
6.1. Summary 
 
We were initially motivated to develop an improved B cell culture system because existing ex vivo 
approaches have yet to capture the key aspects of lymphoid tissue microenvironment and/or be capable of 
functioning without live animal models. We expected that such approach could be used to model the GC 
reaction in order to better understand the signals that control GC induction, maintenance, and exit. In the 
long term, we hoped that the resulting technology could facilitate rapid ex vivo generation of antigen-
specific antibodies. Such ability would greatly benefit studies on adaptive immune response generation, 
lymphoid transformation and therapeutic agents that can interact with the immune system. 
 
With these goals in mind, we have developed the immune organoid technology and assessed the 
important design parameters. This assertion can be illustrated by highlighting several results that have 
been previously described in this dissertation. We first showed the ability of engineered immune 
organoids to improve GC induction in culture as indicated by the sustained B cell number and the 
enhanced expansion of GC-like B cells (Chapter 2). Our data indicated that the presence of RGD – the 
ligand for αvβ3 integrin subunits – was partially responsible for maintaining B cell number in culture. 
From further characterization on the immune organoids, we revealed that the organoid-derived GC-like B 
cells were comparable to in vivo GC B cells in terms of viability, acquisition of signature GC 
transcriptome, and somatic hypermutation (Chapter 3). Furthermore, the use of biomaterials-based 
scaffold provided better viability, proliferation, and representative GC transcriptome when compared to 
the conventional 2D co-culture system. In order to understand the role of integrin signaling, we utilized a 
modular immune organoid and showed that integrin ligand type could modulate GC-like B cell phenotype 
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(Chapter 4). We found that integrin ligand specificity could influence surface BCR clustering and 
expression on GC-like B cells. We then assessed the role of BCR stimulation in the presence of various 
integrin ligands toward GC-like B cell maintenance, differentiation, and selection (Chapter 5). We 
observed that BCR signaling could initiate the ASC differentiation program and facilitate the enrichment 
of antigen-specific GC-like B cells in the presence of Fas negative selection pressure. Summarizing these 
key points, we have shown our ability to expand GC reaction in culture using immune organoids, provide 
a comparable GC model relative to the in vivo counterpart, study the role of signals from the lymphoid 
microenvironment, and engineer specific GC processes in the immune organoids. 
 
These results suggest that we are not only capable of inducing GC reaction to produce GC-like B cells but 
also controlling the phenotype of this cell population. The control could be illustrated by the enhanced 
generation of GC-like B cells in culture, the improved acquisition of key GC markers, the shift toward 
ASC differentiation program, and the enrichment of antigen-specific GC-like B cells. The potential 
application of this approach was also demonstrated in studying the EZH2-dependent mechanism of cell 
cycle regulation during GC reaction. Being able to produce these outcomes mean that we are indeed 
progressing toward an improved B cell culture system that can better model GC reaction. At the same 
time, it is important to reflect on our journey to gain insights about improving this system in the future. 
 
In addition to highlighting the key findings above, this chapter is also meant to provide a reflection on the 
experience handling this project and a future outlook regarding the key next steps that can be done. By 
describing the approaches that work well and the steps that could have been taken in the past, we hope 
that the readers can learn important lessons about successfully completing a research project and avoiding 
pitfalls throughout the process. By providing a perspective about how this technology platform may 
evolve in the future, we wish that the readers could gain inspiration about potential research directions 
and improvements to the existing system. 
 
  127 
6.2. Reflection 
 
Throughout this project, several approaches have worked well in ensuring the completion of key 
milestones and the constant development of our B cell culture system. These recommended procedures 
could be distilled into three concrete steps: testing the main hypothesis, analyzing system sensitivity, and 
tracking changes throughout the proposed mechanism. We will describe the definition of each step and a 
short example of its implementation during this project. 
 
First of all, developing a simple approach to quickly test the key hypothesis. Before we develop a 
sophisticated technology, we need to ensure that the underlying argument makes sense. We hypothesized 
that BCR stimulation in GC-like B cells would make them resistant to Fas-mediated apoptosis and 
therefore antigen-binding antigen-specific GC-like B cells could be enriched using this method. 
Nevertheless, we were using WT B cells and it was unclear how we can stimulate BCR signaling 
uniformly across B cells due to their heterogeneous BCR. We also learned that FasL is commonly used 
and yet it has to be immobilized for inducing an efficient Fas-mediated apoptosis. In order to quickly test 
the hypothesis before obtaining the antigen-specific transgenic mice and optimizing FasL conjugation 
into the organoid matrix, we first utilized an antibody against IgM to initiate BCR crosslinking and then 
introduced an antibody against Fas to trigger cytolytic activity. With the result showing that BCR 
stimulation maintained cell number following Fas signaling, we could quickly demonstrate the validity of 
our preliminary hypothesis and go forward with the antigen-specific system using B1-8hi mouse model.  
 
Secondly, systematically assessing the system sensitivity. We have to realize that the optimal dose for any 
particular stimulatory signal will be different depending on the system. In order to induce BCR 
crosslinking in the immune organoids using WT B cells, we utilized a soluble antibody against IgM and 
yet we found varying protocols for BCR stimulation in the literature. Since most works are done in 2D 
and the culture conditions can be very different, we used the published doses to prepare a guideline for 
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titrating the doses ourselves. For every experiment assessing the role of BCR stimulation, we always used 
4 dose groups (including the negative control) to understand the dose response relationship and determine 
where the optimal response occurs.  
 
Thirdly, running parallel experiments to validate multiple sub-hypotheses. Since any particular 
stimulation can result in several downstream effects, it is important to assess each factor from multiple 
outcomes. When we were analyzing how BCR signaling works in the modular immune organoid system, 
we conducted experiments to assess GC maintenance, ASC differentiation, BCR signaling, and Fas 
resistance. By being able to track changes across these metrics, we could increase our confidence that 
BCR stimulation was working in accordance with the proposed mechanism and using such knowledge as 
a benchmark before studying other variables (e.g. time points, specific antigens, presentation format, etc.) 
 
At the same time, looking into past experiments has brought the realization that several things could have 
been done better. These proposed improvements could again be summarized with three concrete steps: 
balancing characterization and progression, thinking about the so what, and understanding the proper 
validation method. We will describe the definition of each step along with its relevance to this project. 
 
First of all, it is important to ensure a good balance between characterizing the system and progressing 
with the next experiment. Throughout this project, we constantly asked ourselves how long we should 
spend our time understanding the system before going into our next aim. Since research proposal is often 
defined by three specific aims, we frequently want to quickly complete our current aim and move forward 
with the next aim. When we were trying to develop an immune organoid system for modeling GC 
reaction, we initially hoped that showing the presence of GC-like B cells would be enough and we could 
move toward generating antibody in culture. But then we realized the importance of assessing the 
presence/absence of each GC hallmark event, understanding the role of each design parameter, crafting a 
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strategy to induce differentiation toward ASC fate, and preparing a method to enrich antigen-specific cells 
such that antigen-specific antibodies could be produced in the future. 
 
Secondly, we have to constantly think about the relevance of our result (i.e. the so what). Upon 
completing the study of integrin ligand specificity, it was unclear what was the next step for us. Such 
situation could be explained by the intense focus placed on running the previously planned experiments, 
analyzing the data, and writing the manuscript for submission. It would also be important to carefully 
think about the next study to be done. At the same time, having a good idea about the relevance of your 
current study would make it easier to plan the next ones. Realizing that integrin ligand specificity mostly 
modulated surface BCR on GC-like B cells and BCR stimulation could allow us to achieve our other 
goals (e.g. ASC terminal differentiation and antigen-based selection), we next studied how our immune 
organoids respond to BCR crosslinking in culture. 
 
Thirdly, it is critical to understand the best way to validate your hypothesis. When we started with 
initiating GC reaction ex vivo using the immune organoid, we thought that validation was simply based on 
B cell number and expression of GC surface markers (e.g. GL7 and Fas). Our assumption originated from 
reading several papers on B cell activation and noticing that expansion of GL7+ Fas+ B cells was the 
main metric used in most of them. From further research and correspondence with our medical school 
collaborators, we learned the importance of supporting the earlier observations with sequencing data. The 
resulting information could notify us about things like gene expression profile and somatic 
hypermutation. Gene expression analysis would be important because the presence of signature GC 
transcriptome represents the gold standard for GC B cell identification, while somatic hypermutation 
signifies a GC-specific functional event. Conducting these studies to validate ex vivo GC reaction is truly 
important to demonstrate the comparability of our immune organoids with their in vivo counterparts. 
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6.3. Future Outlook 
 
Having spent a large part of this dissertation discussing the observations made from past experiments, it is 
time to start considering the next steps of this project. While we have made great strides in achieving our 
initial goals, we realize that there is still room for further learning and improvements. From numerous 
discussions with my research advisor and lab colleagues, the next key steps could be distilled into four 
potential studies: understanding biomaterials-based signals, investigating the mechanism of integrin 
signaling, assessing the role of signal presentation format in selection efficiency, and studying antibody 
production in culture. For each study, we will discuss both the rationale and the expectations. 
 
Studying the role of biomaterials-based signals will be important because we have shown the importance 
of gelatin matrix reinforced by silicate nanoparticles in not only improving GC-like B cell viability and 
proliferation but also ensuring the acquisition of signature GC transcriptome. But we have yet to fully 
understand how these outcomes were generated in terms of the specific signals and pathways. We thus 
need to learn what signals are being produced by the matrix and how they work in the immune organoids. 
Considering that GC-like B cells cluster next to in vivo GC B cells in the PCA space, we can also 
investigate what signal and/or pathway has to be added to bring the two cell clusters closer together. 
 
While integrin signaling has been well studied in other cells and systems, we are just starting to appreciate 
the role of integrin in B cell activation and differentiation. We are thus still lacking a complete picture 
about how integrin activation works in GC B cells throughout GC reaction. While we observed integrin 
co-localization with BCR, we have yet to know how such process happens. We then need to determine 
the signaling pathways that occur following the binding of integrin ligand and develop a mechanistic 
understanding of integrin signaling during humoral immune response generation. 
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We need to understand the role of signal presentation format because we have been using soluble antigen 
and/or activating antibodies and yet some signals are found to be membrane-bound in the lymphoid tissue 
microenvironment. The literature has also indicated that presenting a signal in soluble form (vs. 
immobilized or membrane-bound) can either produce an opposite effect or modulate its potency. Signals 
such as FasL have also been known to require aggregation for improved function. As we are trying to 
improve the efficiency of our antigen-specific GC-like B cell enrichment process, we have to consider the 
importance of signal presentation format inside the modular immune organoids. 
 
Since our long-term goal is to produce antigen-specific class-switched antibody in culture, we have to 
optimize the protocol for inducing terminal differentiation of GC-like B cells toward ASC fate and 
ensuring rapid antibody secretion from the differentiated cells. Our results indicate the induction of CSR 
upon IL-4 addition, but we need to optimize the process to produce an efficient class switching. While we 
have shown the induction of ASC differentiation program, we still need to ensure that the cells are turned 
into long-lived plasma cells instead of short-lived plasmablasts. We also need to confirm that antigen-
specific class-switched antibodies are secreted at a sustained level over time in culture. 
 
Having described the potential studies that can be done to bring our technology platform closer to our 
initial goal, we hope that the rationales provided will inspire the readers to continue the work for 
improving the immune organoids. While there is a still a long journey ahead, we believe that the 
reflection provided earlier in this chapter and the future outlook described above will the readers to 
achieve the goals of designing a fully functional B cell culture system. Reaching such objective will 
enable us to better model GC reaction and help fellow researchers answer open questions in GC research. 
From the translational standpoint, we believe that this capability will accelerate the development of 
antibody-based therapies and other therapeutic agents that interact with the immune system.  
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